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 ABSTRACT 
Pluripotent stem cells can be obtained from embryonic stage or generated by in vitro 
reprogramming of terminally differentiated somatic cells. Such reprogrammed cells 
possess similar developmental potential as embryonic stem (ES) cells and therefore 
are an indispensible source of diverse cell types, including cardiomyocytes (CMs), for 
basic research. CMs derived from ES cells and reprogrammed cells can provide 
possibilities for study of development, differentiation processes, stem cell malignancy 
and genetic diseases in vitro. Such studies can allow for development of novel 
compounds for drug discovery and toxicity testing which might help to develop more 
efficient and safer drugs  
The present thesis is based on analyzing the impact of switching the cell fate on the 
differentiated state of reprogrammed cells using cardiomyocytes as a model. Detailed 
structural molecular and functional characterization of CMs derived from ES cells and 
reprogrammed cells like fusion hybrid (FH) cells and induced pluripotent stem (iPS) 
cells was performed. 
Somatic cells (spleenocytes and bone marrow cells) were fused with ES cells to 
generate FH cells. The formed hybrid cells were morphologically similar to 
pluripotent ES cells and retained a tetraploid genome through many passages. 
Spontaneous differentiation led to formation of embryoid bodies (EBs) with 
appearance of beating areas representing differentiation to cardiac lineage. The EBs 
derived from FH cells also retained tetraploid genome and expressed major 
histocompatibility (MHC) class I molecules of both fusing partners. FH derived CM 
expressed typical cardiac structural proteins and intact β-adrenergic and muscarinic 
signaling receptors. Atrial, ventricular and pacemaker cardiac subtypes could be 
found in FH-CMs. Thus, CMs derived from tetraploid FH cells appear to be 
structurally and functionally intact. 
Ongoing research proved iPS cell technology to be more robust reprogramming 
strategy. In order to obtain homogenous population of CMs for further studies an iPS 
cell line TiB7.4 was genetically manipulated to allow for antibiotic-based purification 
of cardiomyocytes after spontaneous differentiation. We generated highly purified 
CMs from transgenic murine iPS and ES cell lines expressing puromycin N-
  
acetyltransferase and EGFP under the control of α-myosin heavy chain promoter. iPS 
and ES cells differentiated into CMs at comparable efficiencies yielding highly 
purified CMs after drug selection. Purified iPS- and ES-CMs exhibited 
indistinguishable structural properties, similarly responded to pharmacological agents, 
expressed functional voltage-gated sodium, calcium and potassium channels and 
possessed comparable current densities. Global transcriptional profile and gene 
ontology signature of transgenic iPS-CMs were very similar to that of ES-CMs but 
clearly distinct from fibroblasts that were used to generate iPS cells and differentiated 
cells in iPS or ES cell-derived embryoid bodies. After puromycin selection, iPS-CMs 
did not contain any residual pluripotent cells nor formed teratoma in immunodeficient 
mice. 
Therefore, cell fate switching brought about by reprogramming does not affect the 
structural, molecular and functional characteristics of cardiac derivatives of the 
reprogrammed cells. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 ZUSAMMENFASSUNG 
Pluripotente Stammzellen können aus Embryonen gewonnen oder durch 
Reprogrammierung vollständig differenzierter somatischer Zellen in vitro generiert 
werden. Diese reprogrammierten Zellen besitzen ein ähnliches 
Differenzierungspotential wie embryonale Stammzellen (ES) und sind somit eine 
vielversprechende Quelle unterschiedlicher Zelltypen, wie Kardiomyozyten (KM), für 
die Grundlagenforschung. Die aus ES Zellen und reprogrammierten Zellen 
differenzierte KM, ermöglichen Untersuchungen von Entwicklungsprozessen, 
Mechanismen genetischer Krankheiten des Herzens, Entwicklung neuer Medikamente 
und Bestimmung ihrer Toxizität. 
Die hier vorliegende Arbeit basiert auf der Analyse des Einflusses von 
Zellschicksalsänderungen auf den differenzierten Zustand von reprogrammierten 
Zellen.  
Dabei wurde eine detaillierte strukturelle, molekulare und funktionale 
Charakterisierung der KM durchgeführt, die aus ES Zellen und reprogrammierten 
Zellen, wie Fusionshybrodoma (FH) Zellen und induzierten pluripotenten (iPS) 
Zellen, gewonnen wurden. 
Die FH Zellen wurden durch Fusion somatischer Zellen der Milz oder des 
Knochenmarks mit ES Zellen generiert. Die erhaltenen Hybridzellen waren 
morphologisch pluripotent, aber behielten ein tetraploides Genom über mehrere 
Passagen. Spontane Differenzierung dieser Zellen führte zur Formation von 
`embryoid bodies’  (EB), welche schlagende Areale und somit die Differenzierung zur 
kardialen Linie aufwiesen. Die EB der FH Zellen behielten ebenfalls ein tetraploides 
Genom und exprimierten MHC Klasse I Moleküle beider Fusionspartner. 
Kardiomyozyten aus FH Zellen zeigten typische kardiale Strukturproteine auf und 
exprimierten intakte β-adrenerge und muskarine Signalwege. Obwohl die KM von 
tetraploiden FH Zellen generiert wurden, waren sie strukturell und funktionell normal. 
Die gegenwärtige Forschung bewies, dass die iPS-Technologie die robustere 
Reprogrammierungsstrategie ist. Um KM besser zu analysieren, wurde eine transgene 
iPS Zelllinie generiert, welche Puromyzin-N-Acetyltransferase und EGFP unter der 
Kontrolle des Promoters für die schwere Kette des α-Myosin Gens exprimiert. Diese 
  
Zelllinie ermöglichte die Aufreinigung einer homogenen Population der KM und 
somit die Analyse ihrer physiologischer und transkriptioneller Eigenschaften unter 
kontrollierten Bedingungen. Transgene iPS- und ES-Zellen differenzierten zu KM mit 
einer vergleichbaren Effizienz und lieferten nach Antibiotikaselektion hoch reine KM. 
Gereinigte iPS- und ES-KM zeigten ähnliche strukturelle Eigenschaften, expremierten 
funktionelle spannungskontrollierte Natrium-, Kalzium- und Kaliumkanäle und 
besaßen eine vergleichbare elektrische Stromdichte. Globale Transkriptionsprofile 
und Genontologiesignaturen transgener iPS- und von ES-KM waren auch 
vergleichbar und unterschieden sich deutlich von den Fibroblasten, welche zur 
Generierung der iPS Zellen verwendet wurden. Nach Puromyzinselektion enthielten 
die iPS-KM weder verbliebene pluripotente Stammzellen noch bildeten sie Teratome 
in immundefizienten Mäusen. 
Somit beeinflusst die Veränderung des Zellschicksals mittels Reporgrammierung 
weder die strukturellen noch molekularen oder funktionellen Charkateristika der von 
ihnen abgeleiteten kardialen Zellen. 
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1 INTRODUCTION 
Development of a new organism begins with fertilization of an oocyte by the sperm 
leading to the formation of single cell called zygote. The zygote undergoes several 
rounds of cleavage to form a ball of cells called morula. Each cell in morula is called 
blastomere. The characteristic of the zygote and blastomere is a state of totipotency 
which marks their ability to give rise to all the different cells of an adult organism 
including the extra-embryonic membranes. The cells of the morula undergo more 
divisions to form a blastocyst, a hollow ball of cells in which the outer cells become 
trophoblast and develop into placenta. Some cells trapped in the interior of the 
blastocyst, termed the inner cell mass (ICM); generate the epiblast and the hyphoblast. 
The epiblast and hyphoblast will form the embryo and the yolk sac, respectively. The 
cells of the ICM are termed pluripotent as they are able to form each of the three germ 
layers; the endoderm, the ectoderm and the mesoderm. These germ layers form 
distinct lineages of terminally differentiated post-mitotic cells, which contribute to 
specific organ function. As a fertilized egg develops into an adult organism, 
specialized cells are formed by a one-way process, and they become increasingly, and 
normally irreversibly, committed to their fate.  
1.1  Pluripotent stem cells 
Pluripotency is the potential of stem cells to give rise to any cell of the embryo 
proper. The study of pluripotent stem cells began with the study of teratocarcinomas 
(Evans and Kaufman 1981), which contain a haphazard array of almost any somatic 
cell type found in the developing embryo. The stem cells of these tumours are 
embryonal carcinoma (EC) cells, which express characteristics including a 
developmental potential similar to those of the ICM of the early embryo (Na et al. 
2010). Mouse Embryonic stem (ES) cells were first  pluripotent cells derived from the 
ICM of mouse blastocyst-stage embryos (Evans and Kaufman 1981). Human ES 
(hES) cells were isolated from the ICM of human blastocysts, generated by  in vitro 
fertilization (IVF)-produced embryos that were no longer designated for clinical use, 
and donated by individuals after informed consent (Thomson et al. 1998).The 
importance of ES cells to modern biology and medicine derives from two unique 
distinguishing characteristics. First, they have the ability to be maintained in an 
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undifferentiated state (self renewal) indefinitely in culture. Second, they are 
pluripotent, possessing the capacity to generate every cell type in the body (Fig.1). 
The pluripotent nature of mouse ES cells was formally demonstrated by their ability 
to contribute to all tissues of adult mice, including the germ-line, following their 
injection into host blastocyst (Bradley et al. 1984). ES cells are of great interest for 
both basic science and medicine. Studies on ES cells can provide information about 
the complex events that occur during embryonic development by identifying how 
undifferentiated stem cells become the differentiated cells that form the tissues and 
organs. ES cells provide opportunities for basic research on developmental gene 
regulation through functional genomics, signaling, molecular mechanisms of disease, 
drug screening and toxicological testing. As gene modulation techniques, including 
gene targeting, are well established in ES cells, it is relatively easy to identify a role of 
a specific gene in the development of a cell lineage (Keller et al. 1993).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Pluripotent stem cells, isolated from the ICM in the blastocyst, have the ability 
to give rise to all types of cells in the human body, but not the placenta and other 
supporting tissues. www.innovitaresearch.org/news/res/04121501_01.jpg  
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1.2  Developmental potential of pluripotent stem cells  
In addition to their developmental potential in vivo, ES cells display a remarkable 
capacity to form differentiated cell types in vitro (Keller 1995; Smith 2001).Studies 
during the past 20 years have led to the development of appropriate culture conditions 
and protocols for the generation of a broad spectrum of lineages. Because of their 
ability to give rise to multiple lineages, ES cells open exciting new opportunities to 
model embryonic development in vitro for studying the events regulating the earliest 
stages of lineage induction and specification. Comparable studies are difficult in the 
mouse embryo and impossible in the human embryo.  
When injected into immuno-compromised animals, pluripotent cells form teratomas 
composed of multiple differentiated tissues in all three germ layers: ectoderm, 
mesoderm, and endoderm including the germ line of chimeric animals.  Tetraploid 
complementation assay test is the most stringent test for the pluripotency of ES cells. 
In this test a tetraploid embryo, incapable of developing beyond blastocyst stage, is 
fused with diploid ES cells. The resulting embryo develops normally wherein the 
fetus is exclusively derived from ES cells and the extra embryonic tissues develop 
exclusively from tetraploid embryo. In addition to these the in vivo tests, ES cells are 
able to differentiate into multiple cell types in vitro. When removed from the factors 
that maintain them as stem cells, ES cells will differentiate and, under appropriate 
conditions, generate progeny consisting of derivatives of the three embryonic germ 
layers: mesoderm, endoderm, and ectoderm ES cells can be differentiated in the form 
of three-dimensional aggregates, known as embryoid bodies (EBs), containing various 
cell types like cardiac myocytes, neuronal cells, erythrocytes, melanocytes, and others 
(Doetschman et al. 1985; Yamane et al. 1999; Lee et al. 2000).  
The mouse ES cell differentiation system can be regarded as an unlimited source of 
cells and tissues for a broad spectrum of research. To date, mouse ES cells have been 
successfully differentiated into hematopoietic precursors (Potocnik et al. 1997), CMs 
(Yamashita et al. 2000), neural precursors (Nakano et al. 1996; Brustle et al. 1997; 
Garrington et al. 2000), insulin-producing cells (Klug et al. 1996), and mast cells 
(Tsai et al. 2000) and have been transplanted successfully into recipient animals. In 
Introduction 
- - 17 - - 
vitro differentiation of ES cells has been used in basic science to study gene 
expression during development of specific cell types.  
Studies of pluripotent mouse ES cells have led to in vitro models of cardiomyocyte 
differentiation. Much of what we know about the differentiation of pluripotent ES 
cells to CMs in vitro has been learned from studies with mouse ES cells. 
Morphological, electrophysiological, and molecular techniques indicate that the in 
vitro differentiation process recapitulates the developmental pattern of early 
cardiogenesis, and genetic studies have shown how signaling molecules, transcription 
factors, ECM components, and calcium-handling proteins affect this process. 
Genomic studies, coupled with in vitro differentiation, have also led to the 
identification of developmentally regulated genes (gene trapping) and to the 
identification of differentiation-responsive genes.  
The potential use of ES cells for research is challenged by ethical considerations and 
more so due to imposition of strict regulations. Although ES cells are regarded as a 
‘gold standard’ for pluripotency, there is a need for alternate sources of pluripotent 
cells which can be easily accessible and possess the same developmental potential as 
ES cells.  
1.3 Nuclear reprogramming  
Embryonic development is a unidirectional process characterized by constant loss of 
developmental potential with progress in time. Cells progress from totipotency to 
pluripotency, multipotency and then finally commit to differentiated cell fates. 
Genomic content of totipotent zygote is identical to that of its pluripotent progeny and 
terminally differentiated somatic cells. This content remains unchanged throughout 
development. Thus the difference in developmental potential of these cell types is 
imposed by a cell specific transcriptional state that is ultimately dependent on 
epigenetic changes of genome. The cell fate of a defined specialized cell type can be 
reversed, returning the cell to an embryonic state. Reprogramming is a term used to 
describe the process that reverts nuclear gene expression of fully differentiated 
somatic cells to a pluripotent state. This process is of interest for three reasons. 
Understanding of reprogramming process can help us to understand how cell 
differentiation and specialized gene expression are normally maintained. Nuclear 
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reprogramming enables the culture of lines of cells from diseased tissues, and hence 
allows us to analyze the nature of the disease and to screen for therapeutic drugs. It 
can open several new opportunities of in vitro disease models to help in understanding 
disease mechanisms thus leading to devising new strategies for treatment.  Nuclear 
reprogramming could represent a first major step in cell-replacement therapy, 
providing replacement of heart, pancreas, or other types of cells from the skin of the 
same individual.  
1.4 Strategies of nuclear reprogramming 
 
1.4.1 Reprogramming by somatic cell nuclear transfer (SCNT) 
Nuclear reprogramming is initiated when a nucleus from a differentiated somatic cell 
is transplanted into an enucleated oocyte leading to the generation of a live offspring, 
which is a genetically identical clone of the original somatic cell. Such nuclear-
transfer experiments, also known as cloning, have shown definitively that all of the 
genes required to create an entire organism are present in the nucleus of the 
specialized cell and can be activated on exposure to reprogramming factors present in 
the oocyte. Briggs and King (Briggs and King 1952) first succeeded in producing 
normal swimming tadpoles of Rana  pipiens by transplanting the nuclei of embryo 
(blastula) cells into enucleated eggs. Similar experiments were carried out with 
enucleated eggs of Xenopus laevis (Gurdon and Uehlinger 1966), which were 
transplanted with the nuclei of intestinal epithelium of feeding tadpoles to obtain 
entirely normal and fertile male and female frogs. The major conclusion from these 
and subsequent findings was that development imposes reversible epigenetic rather 
than irreversible genetic changes on the genome during cellular differentiation. The 
first successful cloning of a higher animal using SCNT was demonstrated by the 
cloning of normal adult sheep (Dolly) by transplanting the nuclei of cultured 
mammary gland cells derived from an adult sheep to enucleated sheep eggs (Wilmut 
et al. 1997). Cloning experiments have been successfully performed with different 
kinds of terminally differentiated cells, such as T lymphocytes (Hochedlinger and 
Jaenisch 2002) post-mitotic olfactory neurons (Eggan et al. 2004), natural killer T 
cells (Inoue et al. 2005), peripheral blood granulocytes, and  malignant melanoma 
(Hochedlinger, 2004). In addition to sheep and mice, a wide range of species have 
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now been successfully cloned using SCNT, ranging from domesticated animals such 
as dogs and goats, and their hybrids such as mules, to wild animals such as African 
wildcats and wolves (Gomez et al. 2004). Extinct animals could also be successfully 
cloned by transplantation of nuclei from frozen cells into enucleated oocytes a decade 
after tissue freezing (Wakayama et al. 2008). However, most cloned animals with 
apparently normal gross anatomy can have numerous abnormalities. Common 
abnormalities include aberrant gene expression in embryos, telomere elongation, 
obesity in adults, impaired immune systems and, often, increased cancer susceptibility 
and premature death (Gomez et al. 2004) 
SCNT ES cells have been derived from an immunodeficient mouse and then used in 
vitro to correct the original genetic defect by homologous recombination. 
Subsequently, the repaired SCNT ES cells were differentiated into hematopoietic 
stem cells and transplanted back to the immunodeficient donor mouse to restore 
lymphopoiesis (Rideout et al. 2002). Although no human SCNT ES cell lines have 
been created yet, the successful recent generation of SCNT ES cell lines in primates 
(Byrne et al. 2007) suggests that therapeutic cloning in humans may be feasible in the 
future. Fig. 2 shows the process of the derivation of ES cells from a blastocyst derived 
from oocyte which has received nucleus from somatic cell. 
To increase the frequency of cloned animals various technical modifications have 
been tested in mice, including attempts at chemically activating oocytes to make them 
more responsive, changing the time of enucleation, inhibiting cytokinesis and using 
cell fusion instead of nuclear injection, but these alterations have led to only modest 
results of  1-3% increase (Thuan et al. 2010). 
 
Figure 2. Schematic representation of the technique of somatic cell nuclear transfer 
(SCNT). Yamanaka and Blau; Nature 465, 704–712. 
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The need for a large number of donated human oocytes, ethical concerns and 
extremely low cloning efficiency by SCNT in mammals render this approach 
impractical. Nuclear transfers between different strains or subspecies are just as 
successful as those within a species; however, eggs produced by transfers between 
very different species such as human, mouse, cow, or pig generally die before the 32-
cell stage (Tecirlioglu et al. 2006). So far, there is no confirmed evidence that 
proliferating ES cells can be obtained from such distant combinations, including 
human nuclei in monkey cytoplasm. 
1.4.2 Reprogramming by fusion of somatic cells 
Cell fusion involves fusing two or more cell types to form a single entity. The 
possibility that two different cell types can fuse, known as heterotypic fusion, and 
form a somatic cell hybrid was initially suggested back in 1965 (Harris and Watkins 
1965). The hybrid cells were called ‘heterokaryons’. Cell-cell fusion between 
pluripotent teratocarcinoma and differentiated thymocyte cells resulted in hybrid cells 
maintaining the potential for unlimited self renewal and differentiation into a variety 
of cell types. The authors had hypothesized that the teratocarcinoma might lose 
pluripotency by fusion with differentiated somatic cells, but instead, the hybrid cells 
obtained pluripotency and resembled EC cell morphology without expressing a tissue 
specific gene such as Thy (Miller and Ruddle 1976; Miller and Ruddle 1977). 
Following this initial study, many studies have shown that various somatic cells can 
be reprogrammed by fusing with pluripotent stem cells like ES, EG, or EC cells 
(Matveeva et al. 1998; Tada et al. 2001; Flasza et al. 2003; Cowan et al. 2005).Cell 
fusion also was suggested as a mechanism for somatic cell plasticity. Phenotype and 
potency of somatic cells (bone marrow cells and brain cell) were changed by 
spontaneous cell fusion with ES cells after co-culture with ES cells (Terada et al., 
2002, Ying et al., 2002). The hybrid cells that showed over-diploid DNA content 
expressed pluripotency related genes and could differentiate into all three embryonic 
germ layer in vivo and in vitro. 
EC cells are another source of pluripotent cells that can reprogram somatic cells by 
fusion. Since EC cells share many of the key pluripotent characteristics with ES 
therefore EC cells can provide a readily amenable alternative source for 
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reprogramming (Do et al., 2009a; Flasza et al., 2003; Mise et al., 1996). Moreover, 
mouse EC cells can reprogram human somatic cells into pluripotent state, indicating 
that reprogramming factors can cross-act through another species (Flasza et al., 2003). 
The fusion hybrid cells present pluripotential characteristics, such as inactivation of 
tissue-specific genes, reactivation of pluripotency related genes, differentiation 
potential to all three germ layers, and a specific epigenetic state corresponding to the 
pluripotent cells (Do et al., 2006). The differentiated state of somatic cells could also 
be altered by fusion with another type of somatic cell, suggesting that cellular factors 
between the two different types of cells dynamically interact and might be responsible 
for the plasticity and re-establishment of new characteristics. However, the fusion 
hybrid cells are not identical to the pluripotent fusion partner cells. 
When somatic cells acquire pluripotency through cell-cell fusion with pluripotent 
stem cells, the reprogrammed hybrid cells express pluripotency-related genes but did 
not express tissue-specific genes. The ‘memory’ of somatic cells is almost like a 
dogma considered to be erased by fusion with pluripotent cells during fusion-induced 
pluripotential reprogramming. Fusion-induced reprogramming was thought to be a 
unidirectional process resulting in an ES cell phenotype without other viable cell 
states (Silva et al., 2006). But Do et al in 2009 demonstrated that pluripotent stem 
cells also could acquire some characteristics of differentiated cells indicating that the 
reprogramming direction in pluripotent hybrid cells is not solely unidirectional, and 
some genes could be reprogrammed opposite to that of the pluripotent fusion partner 
(Do et al. 2009). 
Under differentiation-inducing conditions, fusion hybrid cells exhibit similar 
differentiation potential of their pluripotent fusion partner, and are not preferentially 
committed to the lineage of the somatic cells that had been fused with the pluripotent 
cells. Inability for neural differentiation of the F9- neural stem cells (NSC) fusion 
hybrid cells demonstrated that NSCs lose their memory and adopt the similar 
differentiation potential of F9 cells. Therefore, the differentiation potential of fusion 
hybrid cells is contingent on the type of pluripotent fusion partner cells, and the 
resulting hybrid cells have the same potential as the pluripotent fusion partner cells. 
Pluripotent cells reprogram somatic cells and may induce erasure of somatic cell 
memory by fusion.  
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Figure 3. Schematic representation of reprogramming brought about fusion of somatic 
cells with ES cells leading to formation of fusion hybrids. Yamanaka and Blau; Nature 
465,704-712. 
 
Major disadvantage of this approach of reprogramming is that it leads to tetraploid 
cells or aneuploid cells (Fig. 3). Variable chromosome number ranging from 40-85 
was observed in hybrids between mouse spleenocytes and murine ES cells due to 
extensive loss or gain of individual chromosomes. This indicates that spontaneous 
segregation leading to diploid genome in the hybrid is not achieved (Matveeva et al. 
1998).  
Experiments into cell fusion mediated by PEG have provided important information 
about the molecules and pathways that have been implicated in the regulation of 
reprogramming. Specifically, it has been seen that over-expression of the embryonic 
factor Nanog in ES cells, or Sall4 in mouse embryonic fibroblasts (MEFs), can 
increase the number of reprogrammed somatic cells after fusion (Wong et al. 2008; 
Silva et al. 2009). On the other hand, the periodic activation of the Wnt/β-catenin 
signaling pathway in ES cells and the activation of Akt signaling remarkably enhance 
cell-fusion-mediated reprogramming (Lluis, 2008; Nakamura, 2008). Interestingly, in 
ES cells over-expression of Nanog, and at the same time activation of the Wnt/β-
catenin pathway, can enhance the reprogramming efficiency of somatic cells even 
further after fusion (Lluis and Cosma 2009).The method of cell fusion might be 
regarded superior to SCNT, as it is technically less challenging and does not require 
the use of oocytes and pre-implantation embryos.  
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Fusion hybrid cells can be used to study gene expression, basics of cell division, and 
transformation of normal cells to malignant cells, obtain viral replication, 
chromosome or gene mapping, production of monoclonal antibodies and as a tool for 
investigating the mechanism of cellular plasticity. 
1.4.3 Nuclear reprogramming by cell extracts  
In this technique of reprogramming, the plasma membrane of an adult cell to be 
reprogrammed is reversibly permeabilized with the bacterial toxin Streptolysin O. 
Permeabilized cells are then incubated with a nuclear and cytoplasmic extract derived 
from another type of cell. After transient exposure to extract, cells are resealed and 
cultured (Fig. 4). During incubation, factors in the cell extract required for 
reprogramming diffuse into permeabilized cells and activate genes that are typically 
expressed in cells from which the extract has been prepared. This principle has been 
used to reprogram kidney epithelial 293T cells to express T lymphocyte or neuronal 
markers by incubating them with an extract prepared from T cells or neuronal 
precursor cells, respectively (Hakelien et al. 2002). However, although reprogrammed 
fibroblasts expressed T cell specific surface markers, such as CD3, CD4, CD8, CD45 
and T cell receptor (TCR) αβ chains, and a T cell specific function, the 
reprogramming of the 293T cells into T cells was not complete, as the reprogrammed 
cells did not express a pure T cell specific phenotype and the expression profile of 
many genes did not match that of T cells. In addition to human 293T cells, the cell 
extract based reprogramming approach was also applied to other mammalian cells 
such as human adipose tissue stem cells, which adopted cardiomyocyte properties 
following transient exposure to rat cardiomyocyte extract (Gaustad et al. 2004). 
 
Figure 4: Reprogramming by cell extracts. Yamanaka and Blau; Nature 465. 704-712. 
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At present it is unclear if complete and stable reprogramming to a pluripotent state 
can be achieved with crude cell extracts and if reprogramming efficiencies would be 
different with different types of cells. However, this method is very attractive because 
cell extract derived factors are presumably not permanently active in target cells but 
turn over at kinetics corresponding to their half lives. This approach may prove useful 
for dissecting the molecular machinery involved in reprogramming using biochemical 
methods (Hansis et al. 2004). 
1.4.4 Reprogramming by transcription-factor transduction 
Successful reprogramming of somatic cells by fusion with ES cells indicates that ES 
cells have factors that induce pluripotency. It seemed likely that these pluripotency-
inducing factors also play important roles in the maintenance of pluripotency. Based 
on this hypothesis, Yamanaka and Takahashi devised an elegant screen for factors 
within a pool of 24 pluripotency-associated candidate genes and tested for their ability 
to induce pluripotency and activate a dormant drug resistant allele integrated into the 
ES cell-specific Fbx15 locus. The combination of 24 factors, when co-expressed from 
retroviral vectors in mouse fibroblasts, indeed activated Fbx15 and induced the 
formation of drug-resistant colonies with characteristic ES cell morphology 
(Takahashi and Yamanaka, 2006). Successive rounds of elimination of individual 
factors then led to the identification of the minimally required core set of four genes, 
comprising Klf4, Sox2, c-Myc, and Oct4.  
Retrovirus-mediated introduction of four transcription factors (Oct-3/4, Sox2, c-Myc, 
and Klf4) into mouse embryonic or adult fibroblasts and selection for the expression 
of Fbx15, a target of Oct-3/4 and Sox2, resulted in the generation of induced 
pluripotent stem (iPS) cells, which are similar to ES cells in morphology, 
proliferation, and teratoma formation (Takahashi and Yamanaka 2006) (Fig. 5). The 
selected iPS cells are, however, significantly different from ES cells in gene 
expression and DNA methylation patterns. When transplanted into blastocysts, these 
iPS cells only give rise to chimeric embryos, but not adult or germ line competent 
chimeras. These data indicate that reprogramming in Fbx15-selected iPS cells is 
incomplete. These “first-generation” iPS cells therefore appeared to be only partially 
reprogrammed.  
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Although both Fbx15 and Nanog are targets of Oct-3/4 and Sox2, the former is 
dispensable for pluripotency, while the latter plays crucial roles. By selecting for the 
reactivation of the essential pluripotency genes Nanog or Oct4 instead of Fbx15, iPS 
cells were generated that molecularly and functionally more closely resembled ES 
cells (Maherali et al. 2007; Okita et al. 2007; Wernig et al. 2007). Nanog-selected iPS 
cells showed reactivation of a somatically silenced X chromosome and underwent 
random X-inactivation upon differentiation (Maherali et al. 2007). These data 
demonstrated that full reprogramming can be achieved by expression of the four 
factors and using an appropriate selection procedure.  
iPS cells have also been derived from a number of different species-including humans 
(Takahashi et al. 2007; Yu et al. 2007; Park et al. 2008; Li et al. 2009), and rhesus 
monkeys (Liu et al. 2008) by expression of the four Yamanaka factors demonstrating 
that fundamental features of the transcriptional network governing pluripotency 
remain conserved during evolution. Similarly, iPS cells have been derived from other 
somatic cell populations, such as keratinocytes (Maherali et al. 2007; Aasen et al. 
2008), neural progenitor cells (Eminli et al. 2008), stomach and liver cells (Aoi et al. 
2008) and melanocytes (Utikal et al. 2009), as well as from genetically labeled 
pancreatic β cells (Stadtfeld et al. 2008) and terminally differentiated lymphocytes 
(Hanna et al. 2008; Eminli et al. 2009), further underscoring the universality of 
induced pluripotency. 
 
 
 
 
 
 
 
 
 
Figure 5. Induction of pluripotency in adult cells by retroviral transduction of 
transcription factors. Yamanaka and Blau; Nature 465, 704–712. 
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The unique properties of ES and iPS cells also provide for practical approaches in 
pharmaceutical toxicology and pharmacogenomics. In particular, hepato-toxicity and 
cardiotoxicity are two principal causes of drug failure during preclinical testing, while 
the variability in individual responses to potential therapeutic agents is also a major 
problem in effective drug development (Rubin 2008). The advantage of iPS cell 
technology is that it allows for the first time the generation of a library of cell lines 
that may to a substantial extent represent the genetic and potentially epigenetic 
variation of a broad spectrum of the population. The use of this tool in high-
throughput screening assays could allow better prediction of the toxicology caused by 
and therapeutic responses induced by newly developed dugs and offer insight into the 
underlying mechanisms. The net result of this approach would substantially decrease 
the risk and cost associated with early-stage clinical trials and could lead toward a 
more personalized approach in drug administration. 
iPS cell derivation is ethically and legally less problematic and technically more 
feasible than SCNT. In order to use iPS cells as efficient research tools suitable 
techniques of factor delivery and efficient identification of faithfully reprogrammed 
cells are crucial.  
1.5  Advancement of methods for iPS cell generation 
 
1.5.1 Factor delivery into target cells 
A number of different approaches have been devised to shuttle reprogramming factors 
into somatic cells, which can affect the efficiency of reprogramming and the quality 
of resultant iPS cells. The first studies on iPS cells used constitutively active retroviral 
vectors that stably integrated into the host cell genome to introduce c-Myc, Klf4, Oct4, 
and Sox2 (Takahashi and Yamanaka 2006; Wernig et al. 2007; Wilber et al. 2007). 
While retroviral transgenes are usually silenced toward the end of reprogramming 
(Stadtfeld et al. 2008),  this process is often incomplete, resulting in partially 
reprogrammed cell lines that continue to depend on exogenous factor expression and 
fail to activate the corresponding endogenous genes. In addition, residual activity or 
reactivation of viral transgenes in iPS cell-derived somatic cells can interfere with 
their developmental potential and frequently leads to the formation of tumors in 
chimeric animals (Okita et al. 2007). When constitutively active lentiviral vectors are 
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used to produce iPS cells, which are even less efficiently silenced in pluripotent cells 
than retroviral vectors, it can lead to differentiation block (Brambrink et al. 2008; 
Sommer et al. 2010). The use of inducible lentiviral vectors, whose expression can be 
controlled by the inert drug doxycycline, diminishes the risk of continued transgene 
expression and allows for the selection of fully reprogrammed iPS cells, since cells 
that depend on exogenous factor expression readily stop proliferating upon 
doxycycline withdrawal (Brambrink et al. 2008; Stadtfeld et al. 2008). Lentiviral 
vectors are also more efficient than retroviral vectors at infecting different somatic 
cell types and can be used to express polycistronic cassettes encoding all four 
reprogramming factors, thus increasing reprogramming efficiency ((Carey et al. 2009; 
Sommer et al. 2009; Sommer et al. 2010). Inducible vector systems have been 
employed to generate so-called “secondary” reprogramming systems, which do not 
rely on direct factor delivery into target cells. These systems entail differentiating 
“primary” iPS cell clones, generated with doxycycline-inducible lentiviral vectors or 
transposons, into genetically homogeneous somatic cells using either in vitro 
differentiation (for human cells) (Hockemeyer et al. 2008) or blastocyst injection (for 
mice) (Wernig et al. 2007; Woltjen et al. 2009). These somatic cells are then cultured 
in doxycycline-containing media, thus triggering the formation of “secondary” iPS 
cells at efficiencies that depend on the specific cell type used but are generally several 
orders of magnitude higher than the efficiencies obtained after primary infection. 
Secondary systems therefore (1) allow for the reprogramming of large quantities of 
genetically homogeneous cells for biochemical studies and cells that are difficult to 
culture or transduce, and (2) facilitate the comparison of genetically matched iPS cells 
derived from different somatic cell types. The recent development of 
“reprogrammable” mouse strains, which contain a single inducible polycistronic 
transgene in a defined genomic position enables the breeding of animals into desired 
mutant backgrounds for mechanistic studies (Carey et al. 2009).  
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1.5.2 Integration-free iPS cells 
Potentially harmful effects of leaky transgene expression and insertional mutagenesis 
can be overcome by producing transgene free iPS cells. Techniques to generate 
integration-free iPS cells can be subdivided into three categories (Fig. 6):  
(a) Non integrating viruses. Human fibroblasts have also been reprogrammed into 
iPS cells with adenoviral vectors (Zhou and Freed 2009) and Sendai virus (Fusaki et 
al. 2009), as well as with polycistronic minicircle vectors (Jia et al. 2010) and self-
replicating selectable episomes (Yu et al. 2011), albeit the latter system required the 
simultaneous over-expression of additional factors, including another potent oncogene 
(Oct4, Sox2, c-Myc, and Klf4, together with Nanog, Lin28, and SV40 large T antigen). 
Reprogramming efficiencies with current non-integrating methods are several orders 
of magnitude lower (~0.001%) than those achieved with integrating vectors (0.1%–
1%); most likely because factor expression is not maintained for a sufficient length of 
time to allow complete epigenetic remodeling. 
(b) Integrating vectors that can be excised: Several laboratories have developed 
integration-dependent gene delivery vectors with incorporated loxP sites that can be 
subsequently excised from the host genome by transient expression of Cre 
recombinase (Kaji et al. 2009; Soldner et al. 2009). This approach enables the 
efficient generation of iPS cells from different cell types. The use of polycistronic 
vectors have especially shown to be very useful (Chang et al. 2009; Sommer et al. 
2009; Sommer et al. 2010). Transgene-free iPS cells can also be generated with 
piggyBac transposons, mobile genetic elements that can be introduced into and 
removed from the host genome by transient expression of transposase (Woltjen et al. 
2009; Yusa et al. 2009). It remains unclear if transposase expression can induce 
nonspecific genomic alterations in iPS cells (Stadtfeld and Hochedlinger 2009).   
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Figure 6. Different approaches to generate iPS cells. Modified from Lowry and Plath, 
Nature Biotechnology 26, 1246 - 1248 (2008). 
(c) non nucleic acid reprogrammers: iPS cells have been derived from both mouse 
and human fibroblasts by delivering the reprogramming factors as purified 
recombinant proteins (Zhou and Freed 2009) or as whole-cell extracts isolated from 
either ES cells (Cho et al. 2010) or EK293 cells genetically engineered to stably 
express reprogramming factors fused with 9 arginine and myc tag (Kim et al. 2009). 
While the use of purified proteins represents an attractive approach for the generation 
of transgene-free iPS cells, its efficiency is extremely low and requires chemical 
compounds that promote reprogramming. Small molecules  were utilized that could 
significantly increase reprogramming efficiencies in the context of Oct4, Klf4, Sox2, 
and c-Myc over expression ((Desponts and Ding 2010). Notably, some of these 
molecules can also replace individual reprogramming factors, raising the possibility 
of deriving iPS cells solely with chemicals. Chemical substitution of a reprogramming 
factor is, in most cases, associated with a significant decrease in the number of iPS 
cells clones generated, indicating that no single chemical compound is able to entirely 
replace the function of a transcription factor. Another potential caveat of chemical 
reprogramming approaches is the introduction of genetic or epigenetic abnormalities 
into resultant iPS cells, especially since many of the reported compounds are potent 
modulators of DNA and chromatin modifications. 
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 A more efficient and safer way of producing integration-free iPS cells may be the 
introduction of modified RNA molecules encoding for the reprogramming factors into 
somatic cells, which has been validated recently (Warren et al. 2010).These authors 
have demonstrated a simple, non-integrating strategy for reprogramming cell fate 
based on administration of synthetic mRNA modified to overcome innate antiviral 
responses. The modified RNA induced pluripotent cells thus obtained were termed as 
RiPSC. 
In earlier reprogramming strategies, microRNAs (miRNAs) were used  to promote the 
transcription factor-mediated reprogramming process but recently two independent 
groups have derived human and mouse iPS cells by adding miRNAs, in the absence 
of any additional protein factors (Anokye-Danso et al. 2011) shows that expression of 
a single primary miRNA transcript, the miR-302/367 cluster, is in rapidly and 
efficiently reprograms mouse and human somatic cells to an iPS cell state without a 
requirement for exogenous transcription factors. The resulting iPS cells exhibit gene 
expression and functional properties characteristic of fully reprogrammed pluripotent 
cells. Approximately 10% of fibroblasts form iPS cell colonies, an improvement in 
efficiency of >100-fold compared with OSKM. Moreover, the appearance of iPS cell 
colonies and the activation of pluripotency markers occur sooner. Miyoshi et al also 
demonstrated the possibility of reprogramming human and murine fibroblasts by 
transfection of a combination of mature double-stranded microRNAs (miRNAs) mir-
200c plus mir-302 s and mir-369 s family miRNAs(Miyoshi et al. 2011).  
The unique properties of ES and iPS cells also provide for practical approaches in 
pharmaceutical toxicology and pharmacogenomics. In particular, hepatotoxicity and 
cardiotoxicity are two principal causes of drug failure during preclinical testing, while 
the variability in individual responses to potential therapeutic agents is also a major 
problem in effective drug development. The advantage of iPS cell technology is that it 
allows for the first time the generation of a library of cell lines that may, to a 
substantial extent, represent the genetic and potentially epigenetic variation of a broad 
spectrum of the population. The use of this tool in high-throughput screening assays 
could allow better prediction of the toxicology caused by and therapeutic responses 
induced by newly developed dugs and offer insight into the underlying mechanisms. 
The net result of this approach would substantially decrease the risk and cost 
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associated with early-stage clinical trials and could lead toward a more personalized 
approach in drug administration. 
1.5.3 Identification of iPS cell colonies 
A technical roadblock to efficient iPS cell derivation is the inability to distinguish 
successfully reprogrammed clones from partially reprogrammed or simply 
transformed colonies. The reactivation of endogenous pluripotency-associated genes 
such as Fbx15 (Takahashi and Yamanaka 2006)), Nanog or Oct4 (Maherali et al. 
2007; Okita et al. 2007; Wernig et al. 2007), linked to drug selection cassettes has 
been successfully employed for this purpose. As mentioned above, Fbx15 selection 
generates partially reprogrammed cells, likely because activation of this gene occurs 
early in the reprogramming process when the majority of cells are not yet fully 
reprogrammed (Stadtfeld et al. 2008). High quality iPS cells can be derived from 
unmodified somatic cells without drug selection or fluorescent reporters by simply 
using morphological criteria (Blelloch et al. 2007; Maherali et al. 2007; Meissner et 
al. 2007), although this approach requires careful characterization of the resultant cell 
lines. A more stringent approach to identify fully reprogrammed human iPS cells 
without the use of drug selection combines the detection of surface markers with that 
of “indicator retroviruses” expressing fluorescent proteins, which become silenced 
upon acquisition of pluripotency (Chan et al. 2009). For human iPS cells, expression 
of surface markers such as TRA-1-81 has been shown to enrich for reprogrammed 
cells (Lowry et al. 2008).  
It has been demonstrated recently with human ES cells, that G418 resistance driven 
by the undifferentiated transcription factor1 (UTF1) promoter plus enhancer elements 
is very efficient to enrich the fraction of pluripotent cells within ES cell cultures (Tan 
et al. 2007). UTF1 is expressed in EC cells, ES cells and cells of the germ line but 
absent in adult tissues (Okuda et al. 1998). The UTF1 promoter consists of a short 
TATA less region and a downstream enhancer at the 3-prime end of the coding 
sequence (Okuda et al. 1998; Nishimoto et al. 1999; Nishimoto et al. 2001). 
Functional binding sites for Oct-3/4 and Sox2 were identified within this enhancer 
region. In addition, a genetic element called M1 could be found within the enhancer 
and carries an octamer sequence important for Nanog expression (Rodda et al. 2005; 
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Tan et al. 2007). Besides these elements, it is likely that additional, yet unknown 
factors contribute to the regulation of UTF1. Experiments that demonstrate a fast 
down regulation of UTF1, which responds even faster to spontaneous and induced 
differentiation than Oct4 or Nanog, clearly point to a more complex regulation of the 
UTF1 expression (Nishimoto et al. 1999; Wei et al. 2005; Cai et al. 2006; Tan et al. 
2007). The fast response of the UTF1 expression upon induction of differentiation, 
which is probably supported by its low endogenous expression level, makes the UTF1 
promoter an interesting tool for the enrichment of high quality, homogenous 
pluripotent cell lines (Tan et al. 2007). In this context, it is important to note that 
reprogramming of human fibroblasts demonstrated that UTF1 over-expression and a 
p53 knockdown act synergistically to enhance reprogramming efficiency of Oct4, 
Klf4, Sox2 and c-Myc by 200-fold (Zhao et al. 2008). Knockdown of p53, which is 
believed to be suppressed by Klf4 or over-expression of UTF1 alone, had reduced 
supporting effects on reprogramming (Zhao et al. 2008). 
1.6  Direct reprogramming: Conversion of one somatic-cell 
type to another 
The fate of a cell can be altered by forced expression of single tissue-specific 
transcription factors. Gehring and colleagues (Schneuwly et al. 1987) were the first to 
show that in D. melanogaster larvae, ectopic over expression of a homeotic gene, 
Antennapedia, under the control of a heat-shock gene promoter led to a change in 
body plan, with an additional set of legs being formed instead of antennae. Even more 
striking was the finding by Gehring (Gehring 1996) almost a decade later that ectopic 
expression of eyeless (known as Pax6 in mice), a master controller of a cascade of 
2,500 genes, led to the development of functional eyes on the legs, wings and 
antennae of D. melanogaster. In mice, the first tissue-specific master regulatory 
transcription factor was identified by Weintraub and colleagues (Davis et al. 1987) in 
1987. They found that it was possible to induce a phenotypic conversion of fibroblasts 
to the myogenic lineage by expressing a single muscle helix–loop–helix protein 
MYOD. In addition, in 2004, the mouse C/EBP family of transcription factors was 
shown by Graf and colleagues to have a key role in the conversion of one blood cell 
type to another (from lymphocytes to macrophages) (Xie et al. 2004). In addition, 
when the gene encoding the transcription factor PAX5 was removed from B cells, 
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these cells reverted to less specialized progenitors (Cobaleda et al. 2007). It should be 
noted that, in mammals, altering the expression of single transcription factors 
generally results in the phenotype of somatic cells changing only to that of closely 
related cell types, so the effects of transcription factors are highly context dependent 
(Schafer et al. 1990; Farah et al. 2000). 
Direct reprogramming of mature cells from one lineage to another has emerged 
recently as an alternative strategy for generating cell types of interest. Basing on the 
studies of Weintraub and colleagues and on the information derived from the robust 
methodologies of generating iPS cells, it has been possible to directly reprogram 
mouse embryonic fibroblasts to neurons, CMs and to blood cell progenitors without 
an intermediate pluripotent state. 
Induced neurons (iNs) were formed by lentiviral transduction of a cocktail of 19 
neuronal specific transcription factors leading to neural specific expression of Tau in 
mouse embryonic fibroblasts(Vierbuchen et al. 2011). Later the cocktail was reduced 
to a minimum of four transcription factors Ascl1, Brn2, and Mytl1 or Zic1 required to 
form iNs which were convincingly demonstrated to function as typical neurons in 
vitro. In a similar study a cocktail of cardiac specific 14 transcription factors, related 
to heart development, were used to induce CMs (iCMs) from mouse tail tip fibroblasts 
and cardiac fibroblasts isolated from mice expressing EGFP/puromycin under a 
cardiac-specific alpha myosin heavy chain (αMHC) reporter (Ieda et al. 2011). Out of 
the initial pool of 14 factors, Gata4, Mef2c, and Tbx5 (T-box transcription factor) 
were found to optimally induce the αMHC-GFP reporter (25% of cells) and cardiac 
Troponin T (8% of cells). The iCMs exhibited spontaneous contractions and electrical 
activity in vitro. Another group used the 'Yamanaka factors'-OCT4 (also known as 
POU5F1), SOX2, KLF4 and c-MYC — to initiate reprogramming, but they blocked 
signaling through the JAK–STAT pathway, which is required for pluripotency in the 
mouse, and added the cardiogenic factor BMP4 (Efe et al. 2011). These modifications 
yielded minimal generation of iPS cells and instead activated the cardiac progenitor 
program and, within 2 weeks, generated substantial numbers of beating colonies. By 
18 days after induction, approximately 40% of the cells expressed cardiac troponin T. 
Later human dermal fibroblasts were reprogrammed into CD45+/CD34+ 
hematopoietic progenitor colonies by over expression of single factor (Oct4), in 
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combination with exposure to the cytokines SCF (stem cell factor) and FLT3LG 
(FMS-like tyrosine kinase 3 ligand). The resulting cells possess the potential to form 
both erythroid and myeloid cells when exposed to the appropriate cytokines (Szabo et 
al. 2011). Zabierowski et al have shown that only one factor, the active intracellular 
form of Notch1, is sufficient to convert mature pigmented epidermal-derived 
melanocytes into functional multipotent neural crest stem-like cells (Zabierowski et 
al. 2011). These induced neural crest stem cells (iNCSCs) proliferate as spheres under 
stem cell media conditions, re-express neural crest-related genes and differentiate into 
multiple neural crest derived mesenchymal and neuronal lineages. Moreover, iNCSCs 
are highly migratory and functional in vivo. 
Ambasudhan et al have reported that a combination of a microRNA (miR-124) and 
two transcription factors (MYT1L and BRN2) is sufficient to directly reprogram 
postnatal and adult human primary dermal fibroblasts (mesoderm) to functional 
neurons (ectoderm) under precisely defined conditions. These human induced neurons 
(hiNs) exhibit typical neuronal morphology and marker gene expression, fire action 
potentials, and produce functional synapses between each other. Success of direct 
reprogramming has opened new questions of efficiency, diversity, degree of 
developmental timing, resemblance of the characteristics of the reprogrammed cell to 
its target cell and the epigenetic of maintenance of the reprogrammed cell fate. Like 
the advent of the iPS cell field, it may soon be possible to induce reprogrammed cells 
from all the known cell types (Ambasudhan et al. 2011). 
It is also important to consider the advantages and disadvantages of direct 
reprogramming in comparison to iPS cell derived cell types. iPS cells offer great 
flexibility, scalability and multiple cell type derivation. When starting with pluripotent 
cells, current protocols yield differentiated cells that appear to correspond to fetal 
stages of human development. This is a considerable challenge in the context of 
modeling late-onset human diseases such as Alzheimer's or Parkinson's diseases (Saha 
and Jaenisch 2009). It may be only a matter of time before directed reprogramming 
can match the cell-type diversity currently accessible only through a pluripotent 
intermediate. One weakness of iPS that can be overcome by direct reprogramming is 
the age of the target tissue. Another potential advantage of direct reprogramming is 
the overall speed and simplicity of the differentiation conditions. In contrast, disease 
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modeling using iPS cells requires time to generate, expand, characterize, and 
differentiate pluripotent cells. 
1.7 Epigenetics of reprogrammed cells  
DNA methylation, acetylation and methylation of histone H3 and H4 amino terminal 
tail are crucial epigenetic modifications involved in regulating gene activity (Lachner 
et al. 2003). Embryonic stem cells carry several epigenetic characteristics that 
distinguish them from differentiated cells and that are thought to contribute to stem 
cell identity. For example, key pluripotency genes such as Oct4 and Nanog are free of 
DNA methylation in ES cells and can be actively transcribed, while lineage 
commitment results in silencing of these genes by de novo DNA methylation 
(Feldman et al. 2006). In addition to DNA methylation, histone modification patterns 
also differ between ES cells and differentiated cells. For example, the repression of 
developmental genes in ES cells is regulated in a remarkable way. Paradoxically, both 
activating H3K4me3 and repressive H3K27me3 histone modifications are found at 
these genes (Azuara et al. 2006; Bernstein et al. 2006). The H3K4me3 marks of these 
‘bivalent’ domains (chromatin regions bearing both activating and repressive histone 
modifications) allow transcription to be initiated at these genes, but transcription 
elongation is obstructed by proteins of the Polycomb group (PcG)—an evolutionarily 
conserved family of proteins that regulate expression of developmental genes through 
gene silencing that bind to the repressive H3K27me3 mark (Guenther et al. 2007). 
Intriguingly, most silenced developmental genes that are regulated by Oct4, Sox2 and 
Nanog in ES cells are also targeted by PcG proteins, indicating an important role for 
PcG proteins in ES cell pluripotency (Bernstein et al. 2006; Boyer et al. 2006). 
Bivalent domains are believed to be instrumental to the transcriptional flexibility of 
ES cells by allowing developmental genes to be stably repressed without irrevocably 
silencing them. Bivalent domains are virtually exclusive to ES cells and that they are 
an important characteristic of the pluripotent state. 
During nuclear reprogramming it is expected that the final structure of chromatin, 
which is believed to function in establishing cell-type-specific gene expression 
pattern, should be significantly modified by two major events of epigenetics, histone 
modification and DNA methylation. Following hybridization of ES cells with 
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thymocytes, the somatic cells undergo chromatin remodeling which is induced by 
reprogramming factors residing in ES cells (Kimura et al. 2002). Therefore, the 
erasure of somatic cell-specific histone modifications is a crucial step in the induction 
of successful nuclear reprogramming. DNA methylation is also a crucial remodeler of 
chromatin structure and gene expression regulation, which control differentiation, cell 
cycle progression, and early embryonic development However, tissue-specific genes 
of somatic cells become methylated and pluripotency-related genes become 
demethylated after being reprogrammed to the pluripotent state by fusion induced 
reprogramming. For example, the Oct4 promoter region of NSCs become 
demethylated during reprogramming; partially methylated patterns of the Oct4 
proximal enhancer (55.0%) and the promoter region (46.0%) in NSCs were 
completely demethylated just day 2 post-fusion with ES or EC cells (Do et al. 
2007).The reprogramming of the imprinted genes of somatic cells is dependent on the 
pluripotent fusion partners. Previous studies suggest that the resulting fusion hybrid 
cells display an identical potential to their respective pluripotent fusion partners. For 
example, the methylation pattern of the Igf2r region of thymocytes was not changed 
after fusion with ES cells (methylated on the maternal allele as in thymocytes), but 
was changed after fusion with EG cells (not methylated on both alleles) (Tada et al. 
2001). 
A key event in induced reprogramming may be the restoration of repressive bivalent 
domains at loci containing lineage-associated genes. In this way, lineage-associated 
genes that have been activated during differentiation and have lost repressive 
H3K27me3 marks may be re-silenced when these bivalent domains are restored. In 
contrast, chromatin of pluripotency genes must undergo different modifications, since 
these genes must be reactivated rather than silenced. It is thought that repressive 
H3K9me3 marks that were deposited in a G9a histone methyltransferase-dependent 
manner on Oct4 (but not Nanog and Sox2) upon lineage commitment (Feldman et al. 
2006), are removed from the Oct4 locus during reprogramming. Interestingly, it has 
been reported that the chromatin of fully reprogrammed iPS cells carries bivalent 
histone marks that are virtually identical to ES cells(Maherali et al. 2007; Takahashi 
et al. 2007; Wernig et al. 2007; Mikkelsen et al. 2008), indicating that the bivalent 
profile is indeed restored during reprogramming.  
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Induced reprogramming is associated with alterations in DNA methylation profiles as 
well. Pluripotency genes such as Oct4, Sox2 and Nanog are repressed by de novo 
DNA methylation upon differentiation, and these methylation marks are removed 
during the reprogramming process (Takahashi and Yamanaka 2006; Maherali et al. 
2007). In fact, the degree of demethylation at these loci may indicate the progression 
and faithfulness of reprogramming, as incompletely reprogrammed Fbx15-selected 
iPS cells display only partial demethylation of the Oct4 promoter (Takahashi and 
Yamanaka 2006).  
Recent reports indicate existence of epigenomic differences between ES cells and iPS 
cells and alterations in the differentiation potential of iPS cells compared to ES cells 
(Bourne et al. 2004; Mikkelsen et al. 2008). Lister et al demonstrated that although on 
a global scale ES cell and iPS cells methylomes are very similar, every iPS cell line 
shows significant reprogramming variability compared to both ES cells and other iPS 
cells, including both somatic ‘memory’ and iPS cell-specific differential DNA 
methylation (Lister et al. 2011). Further, all iPS cell lines share numerous non-
randomly distributed megabase-scale regions that are aberrantly methylated in the 
non-CG context, associated with alterations in CG methylation, histone modifications 
and gene expression. They also show that differentially methylated regions in iPS 
cells are transmitted to differentiated cells at a high frequency. 
1.8  Differences of iPS cells and ES cells  
Pluripotent stem cells can be derived by various reprogramming strategies as 
described above. Although reprogrammed cells have been shown to be similar to ES 
cells, their artificial nature of pluripotency raises the question of whether iPS cells, 
fusion hybrid cells and blastocyst-derived ES cells are molecularly and functionally 
equivalent. The initial reports on iPS cell derivation supported the morphological 
similarity with ES cells including expression of key pluripotency markers and cell 
surface markers. Analysis of genome-wide expression patterns and global histone 
modifications have shown a high degree of similarity between ES cells and iPS cells 
(Maherali et al. 2007; Okita et al. 2007; Wernig et al. 2007; Mikkelsen et al. 2008). 
However, substantial differences between the two cell types have been reported as 
well. For example, a reduced and more variable neuronal potential has been described 
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for a number of human iPS cell lines, regardless of whether they carried 
reprogramming transgenes in their genome or not (Hu et al. 2010). Likewise, an 
increased propensity of iPS cell-derived neural cells to form tumors after 
transplantation into the brains of immuno-compromised mice has been observed 
(Miura et al. 2009). In addition, human iPS cells-derived early blood progenitor cells 
appear to undergo premature senescence (Feng et al. 2010). At the molecular level, 
gene-specific and global differences in DNA methylation (Deng et al. 2009; Doi et al. 
2009; Pick et al. 2009) and in the expression of mRNAs and miRNAs (Chin et al. 
2009; Wilson et al. 2009) have been reported between both mouse and human ES 
cells and iPS cells.  
These findings indicate that subtle differences between ES and iPS cells exist. An 
additional study found gene expression differences indicative of a transcriptional 
memory in human iPS cells derived from fibroblasts, adipose tissue, and keratinocytes 
(Marchetto et al. 2009). While the cell lines analyzed in this study were derived in 
independent laboratories and with different technologies, which can confound gene 
expression analyses (Newman and Cooper 2010), another study confirmed and 
extended this finding by comparing genetically matched iPS cells derived from 
granulocytes, muscle progenitors, fibroblasts, and lymphocytes (Polo et al. 2010). iPS 
cells derived from these cell types exhibited discernible gene expression and DNA 
methylation patterns as well as differentiation biases into hematopoietic cells in vitro, 
some of which could be attributed to their cell type of origin. A parallel study 
corroborated these conclusions and further discovered that analysis of DNA 
methylation patterns in a given iPS cell clone could predict the somatic cell from 
which it was derived (Kim et al. 2011). Notably, continuous passaging of iPS cells 
(Polo et al. 2010) or the treatment of cells with chromatin-modifying drugs (Kim et 
al. 2009; Kim et al. 2011) attenuated these differences. Together, these results suggest 
that low-passage iPS cells retain a transient epigenetic memory of their cell type of 
origin that can influence their differentiation potential.  
1.9 Cardiac differentiation of pluripotent stem cells 
CMs are one of the first cell types induced from ES cells. Appearance of self-beating 
cells in EBs was first reported four years after the derivation of mouse ES cells 
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(Doetschman et al. 1985). It was shown that ES cell-derived Flk1+ cells can give rise 
to vascular cells as well as CMs (Yamashita et al. 2005). When Flk1+ cells were 
cultured on OP9 stroma cells, self-beating CMs appeared in 4 days. Flk1, Nkx2.5, 
and/or Isl1 were reported to mark multipotent cardiac progenitor population (Garry 
and Olson 2006). Though these markers mainly represent lateral plate mesoderm, 
primary heart field, and secondary heart field, respectively, these marker expressions 
overlap each other (Yan et al. 2009). The development of the cardiac lineage in ES 
cell differentiation cultures is easily detected by the appearance of areas of contracting 
cells that display characteristics of CMs. With continued differentiation, the number 
of spontaneously beating foci increases and all the EBs may contain localized beating 
cells. The rate of contraction within each beating area rapidly increases with 
differentiation, followed by a decrease in average beating rate with maturation. 
Depending on the number of cells in the initial aggregation step, the change in beating 
rate and the presence of spontaneous contractions continue from several days to >1 
month. Fully differentiated CMs often stop contracting but can be maintained in 
culture for many weeks. Thus, developmental changes of CMs can be correlated with 
the length of time in culture and can be readily divided into 3 stages of differentiation: 
early (pacemaker-like or primary myocardial–like cells), intermediate, and terminal 
(atrial-, ventricular-, nodal-, His-, and Purkinje-like cells).  
As observed with the hematopoietic and vascular systems, development of the 
cardiomyocyte lineage progresses through distinct stages that are similar to 
development of the lineage in vivo. An ordered pattern of expression of cardiac genes 
is observed in the differentiation cultures. CMs express cardiac gene products in a 
developmentally controlled manner. mRNAs encoding GATA-4 and Nkx2.5 
transcription factors GATANkx appear first. Transcripts encoding atrial natriuretic 
factor (ANF), myosin light chain (MLC)-2v, α-myosin heavy chain (α-MHC), β-
myosin heavy chain (β-MHC), Na+-Ca2+ exchanger, and phospholamban appear next. 
Sarcomeric proteins of ES cell–derived CMs are also established developmentally in 
the following order: titin (Z disk), α-actinin, myomesin, titin (M band), MHC, α-actin, 
cardiac troponin T, and M protein. CMs with characteristics of fetal/neonatal rodent 
CMs express slow skeletal muscle troponin I isoforms and a greater proportion of β-
MHC versus α-MHC, whereas CMs that more rapidly contract preferentially express 
cardiac troponin I and α-MHC. Thus, the appearance of cardiac-associated gene 
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products is a function of differentiation time, similar to that seen in normal 
myocardial development.  
Maturation of the lineage in the cultures is associated with changes in cell size and 
shape, progressing from small, round cells to elongated cells with well-developed 
myofibrils and sarcomeres (Boheler et al. 2002). Electrophysiological measurements 
of cells from different times in culture suggest that the cardiomyocyte population 
undergoes a change from early-stage cells with pacemaker-like activity to more 
terminally differentiated atrial- and ventricular-like cells (Maltsev et al. 1993; 
Hescheler et al. 1997; Banach et al. 2003). 
The identification and isolation of a cardiac precursor cell population is expected to 
provide a source of cells for tissue regeneration, while also providing valuable insight 
into cardiac development. Several recent studies focused on identifying these 
progenitor cells have reported that cardiac cells, including CMs, endothelial cells, and 
smooth muscle cells, may arise from cardiovascular progenitor populations with the 
expression of specific markers, such as Flk-1, c-kit, and Isl-1 (Yamashita et al. 2000; 
Yamashita et al. 2005; Kattman et al. 2006; Moretti et al. 2006; Yang et al. 2008; Bu 
et al. 2009).   
1.9.1 Purification of cardiomyocytes from differentiating pluripotent 
stem cell cultures 
While these studies clearly demonstrate the development of the cardiomyocyte 
lineage from differentiating ES cells, they are carried out in heterogeneous cultures in 
which these cells represent a minority of the entire population (Klug et al. 1996). A 
limitation for many studies is the identification of CMs, especially of the early stage. 
This appears particularly critical for molecular biological and biochemical studies, 
where a pure population of CMs is needed. This may help to address such critical 
questions as time point of differentiation into the cardiac lineage and regulation of 
gene expression. As there are relatively few antibodies available for the isolation of 
cardiac progenitors, investigators have genetically engineered ES cells to enable 
specific selection of cells representing different stages of development within the 
lineage. An ES cell line has be reported in which lacZ expression is under the control 
of the cardiac specific promoter human cardiac α-actin (Metzger et al. 1996). This 
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allows also a vital stain approach, in order to investigate early stage CMs functionally. 
This approach has been  further improvised by the establishment of stably transfected 
ES-cell lines, where in vivo reporter genes are under control of very early, cardiac 
specific promoters. ES cells have been generated to express either drug-resistance or 
fluorescent genes under the control of promoters that drive expression at specific 
stages of cardiac development. In the first of these approaches, (Klug et al. 1996) 
expressed the neomycin-resistance gene under the control of the cardiac α-myosin 
heavy chain (α-MHC) promoter. With G418 selection at appropriate stages of 
development, populations highly enriched (>99%) for CMs were isolated. When 
applied to large-scale cultures, this strategy enabled the generation of large numbers 
of CMs (Zandstra et al. 2003). Other strategies involve expressing the green 
fluorescent protein (GFP) from cardiac specific promoters including Nkx2.5 (Hidaka 
et al. 2003), cardiac α-actin (Kolossov et al. 1998), and myosin light chain-2v (Muller 
et al. 2000). Expression from myosin light chain-2v was designed to specifically 
select for ventricular cells from the ES cell differentiation cultures. Cells selected on 
this basis displayed electrophysiological properties of ventricular CMs, indicating that 
the strategy was successful. Recently, a FACS-based isolation of cardiac progenitors 
from murine iPS cells expressing green fluorescent protein (GFP) under the control of 
Nkx2.5 promoter has been reported (van Laake et al. 2010). Similarly Rust et al have 
used CD166 (ALCAM) specifically expressed in cardiac tissue during the cardiac 
crescent and heart tube stage, to select a population of differentiated cells that are 
enriched for CMs in hES cell cultures. However, scalable purification of 
differentiated iPS-CMs and their characterization has not yet been achieved. 
1.10  Potential application of research on cardiomyocytes 
derived from reprogrammed cells 
 
1.10.1 A model system for study of embryonic development 
The fully developed heart is composed of several diverse cell lineages including 
cardiomyocytes, endothelial cells, vascular smooth muscle and fibroblast cells that are 
derived from distinct subsets of mesoderm during the course of embryonic 
development. During cardiogenesis, the differentiation of these multiple heart 
lineages is under tight spatial and temporal control, resulting in the coordinated 
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formation of the distinct tissue components of the heart. Insight into the development 
of the heart can be acquired through the observation of differentiation of ES cells into 
CMs. Cardiac differentiation from ES cells closely mimics cardiac development in the 
embryo. In either case, the specification of the cardiovascular lineages involves a 
transition through a sequence of increasingly restricted progenitor cells, proceeding 
from a pluripotent state to mesoderm and then to cells committed to cardiovascular 
fates.  
Precursor cells in vertebrate mesoderm express the T-box transcription factor 
Brachyury T. Brachyury is considered a marker of mesodermal progenitors which 
defines the earliest induction of the lineage. However, as these cells progress into the 
precardiac mesodermal stage of development they begin to express mesoderm 
posterior 1 and 2 (Mesp1 and Mesp2 respectively). Cells expressing Mesp1 contribute 
to all four lineages in the heart. These factors are expressed transiently in the 
primitive streak and contribute to both primary and secondary heart fields, in addition 
to regulating the migration of cells to the anterior region of the embryo. Brachyury 
expression diminishes as newly formed mesodermal cells exit the primitive streak and 
migrate to varying sites in the developing embryo. Another gene associated with 
mesodermal differentiation is the fetal liver kinase-1 (flk1) gene encoding the vascular 
endothelial growth factors receptor 2 (VEGFR-2).  Mesp1, induced via T brachyury, 
acts as a key regulator of the cardiovascular transcriptional network by inducing 
directly and/or indirectly the expression of the majority of key cardiovascular 
transcription factors including Hand2, Myocardin, Nkx2-5, Gata4, Mef2c, Foxc1 and 
Foxc2. Primary heart field is derived from the anterior splanchnic mesoderm and from 
cardiac crescent. Primary heart field is positive for Nkx2.5, Tbx5, and Hand1, and 
gives rise to mainly the left ventricle. Secondary heart field originates from the 
pharyngeal mesoderm and is situated medially to the primary heart field. Secondary 
heart field is positive for Isl1, Tbx1, FGF8 and FGF10, and gives rise to mainly the 
right ventricle, outflow tract and inflow region. In addition to these two populations, 
proepicardial cells and neural crest cells also contribute to the heart 
structure(Gonzales and Pedrazzini 2009).  
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Figure 7: Cardiac cell types generated by in vitro differentiation of ES and iPS cells. 
Yamashita Experimental Cell Research, Volume 316, Issue 16, 1 Oct 2010, Pages 2555-
2559. 
The ability to access and manipulate populations representing early developmental 
stages in the ES cell differentiation cultures provides a new approach for addressing 
questions of embryonic development due to difficulty in isolating cells from the 
embryonic stages. Developmental studies of human CMs are now possible as a result 
of the recent availability of human ES/iPS cells. It is from these studies that we know 
today of the function of Cripto and Notch signaling in cardiac development of ES 
cells. Parisi and coworkers demonstrated that Cripto, known to be essential for 
cardiomyocyte development in vivo, plays a pivotal role in differentiation of ES cells 
to the cardiac lineage (Parisi et al. 2003). Cripto–/–ES cells display a deficiency in 
generating CMs in culture that could be restored by the addition of soluble Cripto to 
the differentiation cultures. Notch signaling also plays a role in cardiac development 
from ES cells (Schroeder et al. 2003).  
Cardiomyocyte induction from mouse iPS cells was first reported in 2008 (Mauritz et 
al. 2008; Narazaki et al. 2008; Schenke-Layland et al. 2008). CMs could be induced 
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from mouse iPS cells with similar methods as from mouse ES cells using EBs or 
stepwise methods. Various cardiovascular cells, such as CMs, arterial, venous, and 
lymphatic cells, and blood cells, were systematically induced from Flk1+ progenitor 
cells (Narazaki et al. 2008). Comparable levels of cardiovascular cells could be 
induced from iPS cells and ES cells (Fig. 7). As for human iPS cells, cardiomyocyte 
induction using EB methods was reported for the first time in 2009 (Zhang et al. 
2009). Though functional analyses of induced CMs suggest that human cardiac cell 
models could be established from human iPS cells, induction efficiency and stability 
are still not sufficient. Further improvements for more robust differentiation methods 
are still required. 
A critical area of investigation is the regulation of germ layer induction and tissue 
specification using the ES cell differentiation cultures. These issues are most easily 
addressed using lineage-specific markers that allow quantification of the response to 
the specific factor or sets of factors being tested. Given their role in the development 
of the early embryo, factors from the TGFβ, Wnt, and FGF families would be obvious 
candidates to be tested. The outcome of these experiments will establish a role for the 
different factors in these early developmental steps and ultimately lead to the 
establishment of defined conditions that will enable efficient and reproducible 
lineage-specific induction in both mouse and human ES cell differentiation cultures. It 
will be important to expand this approach to introduce different selectable markers 
into genes that define distinct developmental steps within a given lineage. These 
strategies will not only provide progenitors for cell-based therapy, they will also 
generate closely related populations that can be used for the identification of genes 
involved in the development and maturation of the lineage under investigation. Once 
genes have been identified, the ES cell system is an ideal model with which to study 
their role in lineage development.  
Furthermore, this cell model is valuable for more detailed studies on commitment and 
differentiation of CMs, on the role of growth factors, extracellular matrix components 
and connexins, on cardiac myogenesis, as well as on pharmacological and 
toxicological effects on morphology, gene expression, cardiac-specific ionic currents 
and action potentials. It may further provide a unique model to analyze the 
quantitative expression of ion channels and the corresponding structural changes 
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during the cardiac development which may reveal new insights into inborn heart 
diseases (Robbins 1993). A first attempt for studying the role of the extracellular 
matrix (β1-integrins) has been made already in 1996 (Fassler et al. 1996) by finding 
that the lack of integrins significantly influence cardiac development, in particular the 
expression of ion channels as well as myofibrillar proteins. The absence of integrins 
leads to a retarded differentiation of CMs.  
Simultaneous quantitative analysis of channel expression and ultra structure in ES 
cell-derived CMs as well as temporally and spatially controlled gene expression may 
offer for the first time the possibility to study pathophysiological phenomena. For 
example, an abnormal development of ion channels may lead to an electrical 
instability of the cardiomyocyte and consequently to arrhythmias.  
1.10.2 Regenerative medicine 
A variety of medical and surgical strategies have been developed for the treatment of 
heart failure. However, heart failure still remains a major cause of morbidity and 
mortality in developed countries. Therefore, a new strategy to improve the cardiac 
function and inhibit cardiac remodeling needs to be established. A number of 
strategies to regenerate heart tissue have been devised to resolve the shortage of 
available transplantation organs, including the transplantation of CMs or 
cardiomyogenic stem cells.  
The foremost aim of use of cell therapy to repair the heart is to introduce new CMs 
into the heart to replace those that are damaged or dead, for example after an infarct. 
ES cell can serve as new source of differentiated cell types for cell replacement 
therapy. hES-cell-derived CMs have been used in xenogeneic transplantation as 
“biologic pacemakers” for the treatment of bradycardia. Studies have shown that hES 
cell-CM introduced into mouse or rat hearts will survive and mature. However, the 
cells are often separated from the animal heart by fibrotic tissue, and these hearts have 
only shown short-term functional improvements. Whereas most studies have only 
been performed in small animals, studies in pigs showed improved cardiac function 
after intra-myocardial injection of hES cell-CM compared with the controls, but any 
long-term follow-up was not described. Despite these transient improvements in 
cardiac function following hES cell-CM transplantation in animals, there are a 
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number of other obstacles which need to be overcome before transfer to humans may 
even be considered. In vivo, human ES cell-CM triggers an immune response. 
Therefore all of the studies thus far have involved immune suppression or used 
immuno-compromised animals. The discovery of iPS cell may help overcome this by 
creating immune-matched cells for transplantation, but a large cell bank would still be 
necessary to match most of the population since human iPS cell lines for individual 
patients, at present, would not be economically available. Not only would cheaper 
reagents be necessary for scaling up the cell production, but the whole procedure 
would also have to be carried out under conditions of GMP (good manufacturing 
practice). These practices are by themselves costly and labor intensive. A second 
obstacle is the removal of all undifferentiated cells before the introduction into the 
body since undifferentiated pluripotent stem cells can give rise to teratomas when 
injected into a living organism, animal or human. The most important consideration 
though in human patients is the potential risk of arrhythmias, which can be caused by 
the introduction of immature CMs with intrinsic pacemaker-like activity into the 
human heart, as well as anisotropy and other scar-implanted cell interactions. 
iPS cells can be regarded as a renewable source of CMs. The major advantage of iPS 
derived CM over ES derived CM is that they can be derived from the same patient for 
whom disease treatment is being sought. Several elegant studies have already proven 
the potential of iPS cells to treat disorders. In a humanized sickle cell anemia model, 
mice have been rescued after transplantation of hematopoietic progenitors derived 
from autologous iPS cells with a genetically corrected β-globin locus (Hanna et al. 
2007). In a further report, iPS cells were differentiated into neurons that functionally 
integrated into the host brain upon transplantation into fetal mouse brain. In addition, 
such cells were able to improve behavior in a rat model of Parkinson’s disease 
(Wernig et al. 2007; Wernig et al. 2008). In another study, injection of 
undifferentiated iPS cells into diseased myocardium of mice led to multilineage repair 
(Nelson et al. 2009; Raya et al. 2009). Patient-specific iPS cells from Fanconi anemia 
patients have been generated that can, upon correction of the genetic defect, give rise 
to healthy hematopoietic progenitors (Raya et al. 2009). Furthermore, skin fibroblasts 
of a patient with homozygous β-thalassaemia have been reprogrammed into iPS cells, 
which could be differentiated into hematopoietic cells that synthesized hemoglobin 
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(Ye et al. 2009). There is no doubt that these studies demonstrate the enormous 
therapeutic potential of iPS cells, but there are still major hurdles to overcome. 
The best cell type in terms of safety and efficiency for reprogramming still has to be 
determined. Risk of pluripotent stem cells to cause teratomas after transplantation has 
to be eliminated by excluding them from in vitro-differentiated cultures. Those pure 
populations of disease-relevant cells then would have to be transplanted into patients 
by safe and effective methods that still have to be established. Reprogramming 
efficiency must be increased and generation of iPS cells must be scaled up and 
standardized to allow high-throughput drug screens and toxicity tests, as well as fast 
availability for an increasing number of patients. Finally, comprehensive pre-clinical 
trials are needed to evaluate safety and efficacy of ‘clinical grade’ iPS cells. 
1.10.3 Drug discovery 
Cell types such as CMs and hepatocytes generated from hES cells could provide ideal 
populations for predictive toxicology. These human cells could reveal the toxicity of 
certain drugs that might not be detected using conventional assays that rely on animal 
models. Other advantages of such ES-cell-based assays is the requirement of 
significantly less test compound than in vivo assays, enabling earlier use in the drug 
discovery phase, resulting in earlier prioritization between drug leads.  
ES cells offer many different strategies to develop drugs that can be used for 
regenerative medicine, that is, the therapeutic regrowth and/or repair of damaged 
cells. A unique strength of the ES cell system is the ability to engineer the ES cells to 
enable one to easily quantify the effect of drugs. This strategy could be used for drug 
discovery applications by introducing reporter molecules, such as GFP, into genes 
indicative of the development of specific progenitor populations or into genes 
associated with cell maturation and function. These customized assays could be used 
to identify those compounds that induce the growth and/or maturation of the cell types 
of interest. This capability offers a unique opportunity to develop clinically relevant 
commercial-grade pharmaceutical screening assays for certain human cell types that 
are not possible to produce by any other approach. hES cell lines with genotypes 
characteristic of various genetic diseases could not only provide novel insights into 
the mechanisms of the disease process, but also offer powerful screening systems for 
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developing drugs for treating those diseases. Such lines have already been established 
from embryos carrying genetic diseases, identified through pre-implantation diagnosis 
(Verlinsky et al. 2005). hiPS cell lines from patients suffering from a variety of 
different diseases can be generated (Park et al. 2008). The ability of human iPS cells 
to form various cardiac lineages, thus, makes them good candidates for some of the 
drug screening presently carried out using animals. 
Several exciting demonstrations of the disease modeling capability of hiPS cell-CMs 
have recently been published. In all studies to date, the resulting patient-specific hiPS 
cell-CMs have been found to at least partially exhibit the phenotype of the diseases 
under investigation: long-QT syndrome, Timothy syndrome, and LEOPARD 
syndrome. 
A seminal study evaluated the use of hiPS cells in modeling LEOPARD syndrome, an 
autosomal-dominant developmental disorder of multiple organ systems resulting from 
a missense mutation in the PTPN11 gene (Vergara et al. 2011). Compared with 
control hES cell-CMs, diseased hiPS cell-CMs were noted to have a higher mean cell 
surface area as well as nuclear translocation of the NFATC4 transcription factor, 
perhaps representing in vitro molecular surrogates of the disease's cardiac hypertrophy 
phenotype. Subsequently, evaluation of type 1 long-QT syndrome revealed that CMs 
derived from iPS cells containing  a  missense mutation in the KCNQ1 gene exhibit 
ventricular and atrial myocyte action potentials with significantly longer QT intervals 
and slower repolarization velocity as compared with wild-type CMs. Single-cell 
electrophysiological analysis on the ventricular patient-specific hiPS-CMs revealed a 
reduction in current, confirming that the KCNQ1 mutant interferes with the function 
of the wild-type subunit. Immunocytochemical tests of both populations of CMs 
suggested that the phenotype is the result of a trafficking defect, in which the mutated 
KCNQ1 protein fails to achieve membrane targeting. Last, stimulation of the 
ventricular patient-specific hiPS-CMs using isoproterenol had little to no effect on the 
patient-specific hiPS-CM repolarization and currents, whereas a significant reduction 
of both was produced in the wild-type cells. Additionally, the patient-specific hiPS-
CMs had reduced action potential duration: action potential interval ratios. These 
adrenergically stimulating tests cumulatively suggest that long-QT syndrome hiPS-
CMs are predisposed to arrhythmic events.  
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Another study has extended the above-mentioned findings by modeling type 2 long-
QT syndrome using similar methods (Itzhaki et al. 2011). These hiPS cells were 
derived from type 2 long-QT syndrome patients and contained a missense mutation in 
the KCNH2 gene. The resulting hiPS cell-CMs exhibited the electrophysiological 
hallmarks of the disease, including prolonged action potential duration and early after 
depolarizations in patch-clamping studies, as well as prolonged field potential 
duration in microelectrode array studies. Diseased hiPS cell-CMs displayed the 
expected defect in IKr (delayed-rectifier potassium current) as well as increased 
susceptibility to pharmacologically induced arrhythmogenesis. The authors also 
demonstrate an important proof-of-concept drug screening experiment to evaluate the 
effects of nifedipine, pinacidil, and ranolazine on the electrophysiological properties 
of the diseased hiPS cell-CMs.  
Yazawa et al (Yazawa et al. 2011) derived hiPS cells from patients with Timothy 
syndrome, a disorder in which patients have long-QT syndrome, autism, immune 
deficiency, and syndactyly caused by a mutation in the CACNA1C gene encoding the 
Cav1.2 L-type channel. Beating hiPS cell-derived EBs displayed irregular contraction 
rates, whereas single hiPS cells-CMs displayed increased action potential duration as 
well as reduced voltage-dependent inactivation of the L-type calcium channel current. 
Interestingly, ventricular CMs but not atrial CMs displayed the prolonged action 
potential phenotype indicative of long-QT syndrome, in contrast to the results of 
Moretti et al. (Moretti et al. 2010).  
1.10.4 Gene targeting to create reporter lines and disease models 
The modification of ES cells by introduction of ectopic reporters or by targeting 
developmentally important loci is becoming a very useful tool in understanding the 
differentiation of CMs. It is of significant interest in the study of heart disease, since it 
represents an opportunity to introduce different mutations against a single genetic 
background if using just one hES cell line. In this respect, genetic modification of hES 
cell lines can compliment studies with human iPS cells since deriving lines from 
different individual patients automatically implies a different genetic background. 
Genetic modifications can be introduced through non-homologous, homologous, site-
specific or transpositional recombination. The efficiency of these processes varies 
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between species and cells types. The efficiency of homologous recombination has 
been found to be extremely low. Zinc-finger nucleases have been used in targeting a 
number of human genes including VEGFA (vascular endothelial growth factor A), 
HoxB13 (homeobox B13) and CFTR (cystic fibrosis transmembrane conductance 
regulator). Site-specific recombination allows for more controlled introduction of 
exogenous DNA sequences. Another technique uses transposons to modify hES cell, 
employing three different systems, Sleeping Beauty (Wilber et al. 2007), PiggyBac 
(Lacoste et al. 2009)  and Mu (Paatero et al. 2008).  
 
 
Figure 8: Potential applications of research on reprogrammed cells.  
 
Thus research on cardiac derivatives of iPS cells will allow the development of novel, 
scalable screening platforms for compound discovery and toxicity testing which might 
help to develop more efficient and safer drugs (Fig.8). Moreover, the study of 
developmental and differentiation processes as well as stem cell malignancy and 
genetic disorders in vitro will become feasible. 
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2 AIM 
FH cells and iPS cells, which have been induced to pluripotency by reversing their 
biological clock, have undergone many epigenetic changes during the course of 
reprogramming and hence are more amenable to variable fates depending on the 
degree of epigenetic strain. When such cells undertake an in vitro differentiation 
process as that of ES cells, the following questions arise  
1. Are the cells generated by different reprogramming methods similar to ES 
cells? 
2. Will the cellular origin influence the in vitro differentiation potentials of 
reprogrammed cells? 
3. Can the distinct transcriptional and epigenetic patterns of reprogrammed cells 
dictate the altered differentiation capacity leading to aberrant cell fates? 
CMs can be readily generated by spontaneous differentiation of ES cells, FH cells, 
and iPS cells. Cardiac cells can be used as a model system to systematically decipher 
cardiogenesis, cardiac signaling processes, toxicological studies, and to understand 
disease mechanisms. Moreover many functional, molecular and physiological studies 
can be performed on CMs. In the present thesis work, I have chosen cardiomyocytes 
as a tool for understanding the effect of cell fate switching (brought about by 
reprogramming) on the developmental attributes of reprogrammed cells. CMs were 
derived by in vitro differentiation of ES cells and reprogrammed cells to asses the 
variability in their structural, molecular and functional characteristics. 
Specific Aims: 
a) To determine the pluripotent nature of reprogrammed cells.  
b) To evaluate the influence of altered genome on cardiac differentiation potential of 
reprogrammed cells. 
c) To obtain purified CMs from reprogrammed cells 
d) To compare the molecular, structural and functional properties of reprogrammed 
cell derived CM with those of ES derived CM. 
e) To analyze the transcriptional profile of ES and iPS cells at various developmental 
stages.
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3 MATERIALS AND METHODS 
 
3.1 Materials 
 
3.1.1 Cell culture reagents 
 
Name Manufacturer Catalogue Number 
ß-Mercaptoethanol Invitrogen 31350-010 
Dimethylsulfoxide DMSO Applichem 2045215 
Trypan Blue Stain,0.4% Invitrogen 15250-061 
PBS, Dulbecco's (1x) with Ca2+ and Mg2+ Invitrogen 14040174 
PBS, Dulbecco’s (1x) without Ca2+  and Mg2+ Invitrogen 14190169 
Dulbecco's modified eagle medium (DMEM) Invitrogen 41965039 
RPMI-1640 Invitrogen A1049-01 
Fibronectin from Bovine Plasma Sigma F1141-1Mg 
FBS heat inactivated Charge (Lot#)944855K Invitrogen 10500064 
Gelatin 2% Solution from Bovine Skin  Sigma G1393-100ml 
Iscove's Modified Dulbecco's Media(IMDM) Invitrogen 31980022 
L-glutamine 200mM Invitrogen 25030024 
Leukemia inhibitory factor (LIF-ESGRO) Millipore ESG1107 
Geneticin (G418) PAA P11-019 
MEM Non essential amino acids 100x Invitrogen 11140035 
Penicillin/Streptomycin 100x Invitrogen 15140122 
Puromycin PAA P15-019 
Trypsin/EDTA(1x), 0.25% Invitrogen 25300-054 
Propidium iodide Sigma P4864 
H.A.T. Supplement (50x) Invitrogen 21060017 
Polyethylene glycol 1500 Roche 10783641001 
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3.1.2 Consumables 
Material Specification Manufacturer 
Catalogue 
number 
96 Well Cell Culture 
Plate, flat, sterile 
Cell culture Applichem 655180 
Micro Amp 96 well plates Real time PCR 
Applied 
Biosystems 
4346906 
Bacteriological dishes  6 and 10cm  Cornig 430167,430166 
Cell culture pipettes 5, 10, 25 and 50 ml Greiner 606180 
Cell strainers 40 µm Becton Dickinson 352340 
Falcon tubes 15 a and 50 ml Becton Dickinson 358206,3582097
Cryotubes 1.8 µl Nunc 375418 
Electroporation cuvettes ES cells-0.4 cm Bio-Rad 165-2081 
 Bacteria-0.1 cm  165-2082 
FACS polystyrene round  
bottom tube 
5 ml, 12 x 75 mm Becton Dickinson 352052 
GeneChip mouse 
expression array set  
Mouse Genome 430 
Version 2 array 
Affymetrix 900495 
Microcentrifuge tube 0.5, 1.5 and 2.0 ml Eppendorf 0030 108.035 
Multi-well tissue culture 
plates 
6 wells and 96 wells Greiner 665180, 650180 
PCR tubes, thin-wall, 
sterile  
0.2 ml Eppendorf 0030 124.332 
Pipette tips 
With aerosol 
protection 
Axygen 
T-1000-B, T-
200-C, TF-20 
Acrodisc syringe filters 
GxF/0.2 µm AutoPack 
Tubes 
Pall Life sciences AP-4798 
Tissue culture dishes 3.5, 6 and 10 cm Becton Dickinson 356517 
Tissue culture Flask T-25, T-75 Becton Dickinson 353810 
µ-Dish 35mm low 
ibiTreat, sterile  
60x 35mm µ-dishes Ibidi 80136 
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3.1.3 Enzymes, Nucleotides and Markers 
 
Name Supplier 
Catalogue 
Number 
2x JumpStart™ Taq ReadyMix™ Sigma Aldrich P0982 
DNase I, Amplification Grade, 100U Invitrogen 18068-015 
SuperScript™ II Reverse 
Transcriptase,10,000U 
Invitrogen 18064-014 
Random primer, 1x Invitrogen 48190-011 
10 mM dNTP Mix Invitrogen 18427013 
100 bp DNA ladder Fermentas SM0242 
GeneRuler™ 1kb DNA Ladder Fermentas SM0311 
Agarsoe Invitrogen 16500-500 
Oligonucleotides / Primers * Sigma Aldrich  
TRIzol Invitrogen 
15596-026 
 
*See section 3.1.6 and 3.1.7 
  
 
3.1.4 Kits  
 
Kit Supplier 
Catalogue 
Number 
Qiagen Plasmid Maxi Kit  Qiagen 12163 
DNAeasy Blood and Tissue kit Qiagen 69504 
QIAquick Gel Extraction Kit (50) Qiagen 28704 
QIAprep Spin Miniprep Kit (50) Qiagen 27104 
QIAquick PCR purification Kit (50) Qiagen 28104 
Sybr Advantage qPCR Premix Clontech 639676 
DNeasy Blood & Tissue Kit (50) Qiagen 69504 
Mycoplasma Detection Kit for PCR Venor GeM 11-1050 
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3.1.5 Laboratory apparatus 
 
Apparatus Specifications Manufacturer 
Cell culture hood Clean Air Techniek  Thermo Scientific 
Incubator Direct  Heat CO2 Thermo Scientific 
ApoTome Flourescence microscope Carl Zeiss 
Electrophoresis chamber Long horizontal Starlab 
FACScan Calibur Becton Dickinson 
Microscope Brightfield Carl Zeiss 
Mastercycler Personal 25x0.2ml PCR tubes Eppendorf 
Real time PCR machine 7500 Fast Applied biosytems 
Spectrophotometer Nanodrop100 Peqlab 
pH meter Seven Easy Mettler Toledo 
Micro liter Pipettes P10, p20,P200,P1000 Gilson 
Pipetmann 
Liquid handling with 
sterile filter 
Thermoscientific 
Thermomixer Comfort 24x0.5ml,24x2.0ml Eppendorf 
 
3.1.6 PCR primers used for SNP genotyping 
 
Name ref seq Primer 
Product  
size 
Annealing 
temp., °C 
SNPa1 rs3722007 F: GGCTTCTGGCTCTGTTTTTG 
R: GGAAACAGCCAATCTTCAGG 
483 58 
SNPb2 rs13476485 F: AGGCAAGGTGCTTGTGATCT 
R: TGGTATTCACATGCCACAGG 
323 54 
SNPa3 rs31512068 F: TCGGGCATAGTCTCTGGTTC 
R: GCCAGGGAACTACAACTCCA 
445 58 
SNPa4 rs13459075 F: TGAAGAGTCAGGCAGAAGCA 
R: CTAAGGAGCAGACCCAGCAC 
330 58 
SNPb5 rs3664494 F: GAGCTTGGAAGGGGAAGG 
R: AAATGAAGGGAGGCGACATA 
330 54 
SNPa6 rs13472545 F: CCAGCCCACAGTGAGTTGTA 
R: GGGAAACCACAAAGACAGGA 
492 58 
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Name ref seq Primer 
Product  
size 
Annealing 
temp., °C 
SNPb8 rs13479805 F: ATAACCAGCTGAGGGTGTGC 
R: ATGAGAGCCACATGGAGGAG 
310 54 
SNPa9 rs13480095 F: GACAGGCACAGCAAGGTACA 
R: CCTGTGGATCTCACCTGTCA 
377 58 
SNPa10 rs13480662 F: CCCTGCTGTCTTTCTCTGCT 
R: TGTGGGGGACATCTTCATCT 
365 58 
SNPb11 rs26891750 F: ATGAAGGCTGCAGGAAAAGA 
R: CCAAAGAAGGACCCTGTTCA 
346 54 
SNPa12 rs29196570 F: ACACAGAACGGTCAGGTGGT 
R: CGGAGAGGGGCATACATAAG 
352 58 
SNPa13 rs13481715 F: CCAGGAGTGTGTCTGCTCAA 
R: GCAGAGTTGCCTGAGAATCC 
423 58 
SNPa14 rs30707092 F: GTTGCCACTTCTTCCTCTGC 
R: CACATTTCGTGGGTCACAAG 
412 58 
SNPa15 rs13482486 F: ACTTAGTCATGGGCGGGTTT 
R: TTGCCCTGACACTTGACATC 
431 58 
SNPa16 rs4163196 F: ACGGAGGTGTGTTCTGGTGT 
R: GAGATGGGCAGAGGAGAGTG 
377 58 
SNPa17 rs3023450 F: CCATCCCTTTTATGCCTCCT 
R: CACCTCCTTCTTGCTCACCT 
349 58 
SNPa18 rs29882799 F: ACCGGGAAGAACTGGAAACT 
R: AGCCACACAGAGGAACAACA 
300 58 
SNPa19 rs4223757 F: TGCAAGACTGTCAGGAGGTG 
R: CTGCCCACACTGGTTACCTT 
352 58 
SNPbX rs13483822 F: CCGACTGTTCCCAAAACACT 
R: GCATTTGCTACTGGGATGCT 
382 54 
SNPb14 rs6262654 F: CGAACCCACACAGCAGATAA 
R: CACATCTTCCCAGGCTTGAT 
364 54 
* temp.,-temperature 
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3.1.7 PCR primers used for gene expression analyses 
 
Gene* NCBI  Accession Sequence (5
’ to 3’) Product size (nt) 
Annealing 
temp., °C 
Oct3/4 NM_013633 F: AGCCGACAACAATGAGAACC R: TGATTGGCGATGTGAGTGAT 168 61 
Sox2 NM_011443 F: TACCTCTTCCTCCCACTCCA R: TCTCCAGTTCGCAGTCCAG 212 61 
Klf4 NM_010637 F: CCCACCAGGACTACCCCTAC R: GTGTGGGTGGCTGTTCTTTT 218 61 
c-Myc NM_010849 F: ACACGGAGGAAAACGACAAG R: CTTGTGCTCGTCTGCTTGAA 295 61 
rv-Oct3/4 NM_013633 F: AGAAGGCGAAGTCTGAAGCC R: ATCCTCCCTTTATCCAGCCC 200 61 
rv-Sox2 NM_011443 F: TACACCCTAAGCCTCCGCCT R: TCAGCTCCGTCTCCATCATG 220 61 
rv-Klf4 NM_010637 F: TCTCTAGGCGCCGGAATTC R: CCATGTCAGACTCGCCAGGT 190 61 
rv-c-Myc NM_010849 F: CTTCTCTAGGCGCCGGAATT R:TGGTGAAGTTCACGTTGAGGG 160 61 
Nkx2.5 NM_008700.2 F: CCACTCTCTGCTACCCACCT R: CCAGGTTCAGGATGTCTTTGA 107 60 
MLC2v NM_010861.2 F: AAAGAGGCTCCAGGTCCAAT R: TCAGCCTTCAGTGACCCTTT 140 60 
Troponin 
T NM_011618.1 
F: GAGGAGGTGGTGGAGGAGTA 
R: GGCTTCTTCATCAGGACCAA 150 60 
CD31 NM_008816.2 F: CAGGTGTGCGAAATGCTCT R: ATGGGTGCAGTTCCATTTTC 113 60 
 
Troponin 
C 
NM_009393.2 F: CAGCAAAGGGAAGTCTGAGG R: CGTAATGGTCTCACCTGTGG 124 60 
Sox17 NM_011441 F: TAAAGGTGAAAGGCGAGGTG R: GCTTCTCTGCCAAGGTCAAC 219 60 
AFP NM_007423.3 
F: CCTATGCCCCTCCCCCATTC 
R:CTCACACCAAAGCGTCAACACAT
T 
324 60 
GAPDH NM_008084.2 F: GGTGCTGAGTATGTCGTGGA R: CGGAGATGATGACCCTTTTG 97 60 
 
*Abbreviations: rv – denotes the sequence expressed from the retroviral vector, MLC2v - ; AFP - 
; GAPDH - Glycerinaldehyd-3-phosphat-Dehydrogenase; temp.,-temperature 
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3.1.8 Primary and secondary antibodies 
 
 
Antibody 
 
Supplier  and 
Catalogue No. 
 
Final  
concentration 
 
 
Use in 
Mouse monoclonal antimouse α-
sarcomeric actinin 
Sigma 
A7732 
1.2 µg/ml 
 
IHC 
Mouse monoclonal Antimouse 
SSEA1 
Santa Cruz 
sc-21702 
 
8µg/ml 
1µg/ml 
 
FACS 
IHC 
Troponin T monoclonal  antibody Thermoscientific 
ms-295 
4 µg/ml 
 
IHC 
FITC conjugated anti-mouse H-2Kb BD Pharmingen 
553456 
10  µg/ml 
 
FACS 
PE-conjugated anti-mouse H-2Kd BD Pharmingen 
562004 10  µg/ml 
FACS 
Normal mouse IgG2a-PE Santa Cruz 
Sc-2867 8  µg/ml 
FACS 
Normal mouse IgG2a-FITC Santa Cruz 
Sc-2010 8  µg/ml 
FACS 
Anti-mouse Oct3/4 Santa Cruz 
Sc-5279 1  µg/ml 
IHC 
Mouse monoclonal anti-mouse α-
myosin heavy chain 
Santa Cruz 
Sc-168676 1  µg/ml 
IHC 
IgG1 Isotype Control, purified, 
unlabelled 
Molecular Probes 
A105538 10  µg/ml 
IHC 
Goat Anti-mouse IgG1, AlexaFluor 
555 conjugate 
Santa cruz 
Sc-3890 1  µg/ml 
IHC 
Goat anti-mouse IgM, FITC 
conjugate 
Sigma-Aldrich 
F-9259 1  µg/ml 
IHC 
Hoechst 33324 Molecular Probes 
H-21492 1  µg/ml 
IHC 
*IHC-immunohistochemistry 
*FACS-Florescence activated cell sorting 
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3.1.9  Buffers and Solutions 
 
0.1% DEPC-treated water 
Diethyl Pyrocarbonate (DEPC) was dissolved in tridistilled water (500 μl DEPC in 
500 ml tdH2O). Incubated overnight at 37°C with constant shaking and sterilized by 
autoclaving. 
 
0.5 M EDTA, pH 8.0 
93.05g Ethylenediaminetetraaceticacid (EDTA) disodium salt dihydrate (Sigma, 
catalogue no. E-5134) was dissolved in 500 ml of tdH2O. It was heated and NaOH 
(Applichem, catalogue no. A1551.0500) was added to aid the salt in dissolving. pH was 
adjusted to 8.0 and the solution was sterilized by autoclaving. 
 
10x TBE 
108 g Tris-Base (0.89 M, Promega, catalogue No. H513a), 55 g Boric Acid (0.89 M, 
Sigma, catalogue no. B-6768) and 7.44 g EDTA-Na2-salt (0.02 M) were dissolved in 
800 ml tdH2O and finally made to 1 liter. 
 
10x TAE 
48.46 g Tris-Base (0.4 M), 11.4 ml Glacial Acetic Acid (Sigma, catalogue no. A-6283) 
and 3.72 g EDTA-Na2-salt (0.01 M) were dissolved in 800 ml tdH2O and finally made 
to 1 liter. 
 
4% Para-formaldehyde fixative 
16% Para-formaldehyde (Roth, catalogue no. 335.2) was diluted to a final 
concentration of 4% before being used for fixing live cells for immunocytochemistry. 
 
LB medium and agar plates 
10 g tryptone (Scharlau, catalogue no. 07-119), 5 g yeast extract (Scharlau, catalogue 
no. 07-079) and 10 g sodium chloride (Roth, catalogue no. 3957.1) were dissolved in 
500 ml distilled water, mixed well and made to 1 liter. The solution was sterilized by 
autoclaving. For preparing agar plates, 15 g agar (Roth, catalogue no. 5210.2) was 
added to 1 liter LB medium and autoclaved. LB agar was cooled down to 50°C and the 
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appropriate antibiotic was added and poured into 10 cm bacteriological dishes. Prepared 
plates were stored at 4°C and used within two weeks. 
 
TSS buffer (Transformation and Storage Solution) 
20ml of 50% PEG4000 solution is added to 70 ml sterile LB medium and mixed 
thoroughly. Then 5ml of dimethyl sulfoxide (DMSO; Sigma, catalogue no. C6295) and 
5ml of 1M MgCl2 (pH6.5, sterile filtered) is then mixed with the LB medium 10% PEG 
solution to obtain TSS buffer which can be used for freezing bacterial competent cells. 
 
Alkaline phosphatase staining solution 
Solution A: Napthol AS-MX phosphate (Sigma, catalogue no. 4875) is dissolved to a 
concentration of 2mg/ml in 0.1M Tris/HCl (pH 9.2).Solution B: Fast Red TR salt TM 
(Sigma, catalogue no. F2768) is dissolved to a concentration of 1mg/ml in 0.1M Tris/ 
HCl pH 9.2.Solution A is then mixed with solution B to obtain a final concentration of 
Napthol at 200µg/ml (1:10 dilution). The resulting solution is mixed well and used 
immediately for staining methanol fixed and dried cells. The solution works only when 
used fresh. 
 
Crystal violet staining solution 
3% solution of crystal-violet (Fluka, catalogue no. 61135) in Methanol 
 
3.1.10  Sterilization of Solutions and Equipments 
All solutions (heat insensitive) and plastic ware was sterilized at 121°C, 105 Pa for 60 
min in an autoclave. Heat sensitive solutions were sterile-filtered through a disposable 
sterile filter (0.2 to 0.45 µm pore size). Glassware were sterilized overnight in an oven 
at 220°C. The solutions for RNA preparations were handled with DEPC-treated water 
and the equipment for RNA analyses was cleansed using RNase Zap (Ambion, 
catalogue no. AM9780) to inactivate any RNase contamination. 
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3.2 Methods 
 
3.2.1 Molecular Biology Methods 
 
3.2.1.1 Preparation of E. coli competent cells 
Competent cells were prepared according to the protocol described (Chung and Miller, 
1988). 5 ml of LB medium containing ampicillin at final concentration of 100µg/ml was 
inoculated with a single bacterial colony (DH5α) and incubated overnight at 37°C with 
constant shaking. Next day, 1 ml of the overnight culture was added to 100 ml of LB medium 
and incubated at 37°C with vigorous shaking until the optical density at 600 nm reached 
0.4 (between 0.40 and 0.45). The culture was quickly chilled on ice for 5 min and the 
cells were pelleted down by spinning at 3000g for 5-8 min at 4°C. The supernatant was 
discarded and the pellet was resuspended in ice cold TSS buffer using 1/10 volume of 
initial culture (e.g. 10 ml TSS for 100 ml culture). The suspension was aliquoted in 
desired amounts (typically in 100 µl/vial), snaps frozen in liquid nitrogen and stored at -
80°C. 
3.2.1.2 Transformation of competent bacterial cells  
200 µl of competent E. coli cells (DH5α) were thawed on ice (10 min) mixed with 10 µl 
of plasmid (10-100 ng) and placed on ice for 30 min with occasional mixing. The 
transformation reaction mixture was heat shocked at 42°C for 90 sec and immediately 
placed on ice for 2 min. In order to accelerate the bacterial growth, 800 µl of LB 
medium was added to the reaction mixture and incubated at 37°C with shaking for 1h. 
Cells were collected by centrifugation in a table-top centrifuge (provide model and the 
manufacturer) at 8,000 rpm (6000xg) for 30 sec at RT and plated on LB-agar plate 
containing appropriate antibiotic. The plate was incubated overnight at 37°C in the 
upside-down position. 
3.2.1.3 Plasmid DNA preparation 
Transformed E. coli cells were cultivated for at least 12 hrs in LB medium containing 
appropriate antibiotics at 37°C. Plasmid DNA (10 µg) was isolated from 5 ml bacterial 
cultures using the Mini-prep kit (Qiagen) according to manufacturer’s 
recommendations. For larger amounts up to 100 µg of plasmid DNA, the Midi-Prep Kit 
(Qiagen) was used. 
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3.2.1.4 RNA isolation 
 
 500µl of TRIzol reagent (Invitrogen) is added to the cell sample. The sample is 
homogenized by pipetting 4x up/down with 27G ¾ Nr. 20 needle. The homogenized 
samples are then incubated for 5 min at room temperature (RT) to permit the complete 
dissociation of nucleoprotein complexes.100µl of chloroform is add to the sample and 
tubes are capped securely and vigorously shaken by hand for 15 sec. and later incubated 
at RT for 2-3 min. The samples are then centrifuged at 10,500 rpm for 15 min at 4°C. 
The resulting aqueous phase is then transferred to a fresh tube. RNA is then precipitated 
from the aqueous phase by mixing with 500µl isopropanol per tube. After 10 min 
incubation at room temperature, the tubes are centrifuged at 10,500 rpm for 10 min at 
4°C. The supernatant is then discarded and the RNA pellet is washed once with 1ml of 
75% ethanol per tube. The pellet is then mixed by vortexing and then the tube is 
centrifuged at 8,500 rpm for 5 min at 4°C.At the end of the procedure, the RNA pellet is 
briefly dried on air. RNA is then dissolved in sterile, RNase-free water.1µl of RNA is 
used to determine the concentration by Nanodrop. RNA samples are aliquoted 2x and 
stored until use at –80°C.  
3.2.1.5 Quantification of nucleic acids 
Nucleic acid concentrations were determined by spectrophotometric measurement of the 
amount of ultraviolet radiation absorbed by the bases. The readings were taken at 260 nm 
and 280 nm. The reading at 260 nm allows calculation of the concentration of nucleic 
acid in the sample. An optical density (OD) of 1 corresponds to approximately 50 µg 
/ml for double-stranded DNA and 40 µg /ml for single-stranded DNA and RNA. The 
ratio between the readings at 260 nm and 280 nm (OD260/OD280) provides an estimate 
of the purity of the nucleic acid. Pure preparations of DNA and RNA have 
OD260/OD280 values of 1.8 and 2.0, respectively. Alternatively the nucleic acids were 
quantified using Nanodrop ND-1000 spectrophotometer which uses a patented sample 
retention system that holds 1 μl of sample without any need for traditional containment 
devices like cuvettes and capillaries. Using fiber optic technology and surface tension, 
the sample is held between two optical surfaces that define the path length in vertical 
orientation. 
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3.2.1.6 Restriction digestion of DNA 
The restriction analysis was performed with 1 µg DNA in a total volume of 20 µl. The 
DNA sample was digested with restriction enzyme in the prescribed buffer at the 
recommended temperature for 1-2 h for double digestion, in most cases Tango buffer was 
used according to the manufacturer's (Fermentas) instruction. At the end of incubation, 
the single and/or double digested DNA samples and undigested controls were analyzed by 
agarose gel electrophoresis (100 ng /lane) and purified if necessary. 
3.2.1.7 Semi quantitative RT-PCR analysis 
 
1 µg of total RNA was treated with DNAseI (amplification grade, Invitrogen) in the 
presence of 10xBuffer at 37°C for 15 min. DNAse treated RNA was used for reverse 
transcription. cDNA synthesis was performed with Superscript II Reverse transcriptase 
(Invitrogen) after priming using random hexamers. Generation of cDNA was performed 
in a total reaction volume of 30 µl. Finally the cDNA was dilute 1:4 (filled up to 120 µl) 
with nuclease free water. cDNA samples were frozen at –20°c until used for PCR 
amplifications of gene of interest. 
3.2.1.8 PCR (Polymerase Chain Reaction) amplification 
In order to amplify the double stranded genomic DNA or single stranded cDNA, 
polymerase chain reaction (PCR) was performed. For PCR amplification, cDNAs were 
amplified using JumpStart REDTaq ReadyMix and 0.25 µM of each primer. All 
amplifications were performed using Eppendorf PCR Cycler under optimized 
conditions for each target sequence. PCR reactions were performed in sterile 0.2 ml thin-
wall tubes as described below. 
 
PCR component                                      Volume                      Final concentration 
2x JumpStart Taq ReadyMix                   10 μl                     1x 
Forward primer (5 μM)                         1.2. μ l                 0.25 μM 
Reverse primer (5 μM)                          1.2. μ l                 0.25 μM 
cDNA*                                                                      2.0 μ l 
H2O                                                                      4.6 μ l 
-------------------------------------------------------------------- 
Total volume                                                20 μl 
Materials and Methods 
- 64 - 
PCR conditions 
1. Denaturation 2 min 94°C 
2. Denaturation 35 sec 94°C 
3. Annealing 45 sec 60°C 
4. Elongation (1 min/1Kb fragment) 72°C 
5. Repeat step 2- 4 for 29-35 cycles 
6. Extension 10 min 72°C 
7. Hold 4°C 
After amplification the products were confirmed by electrophoresis on ethidium bromide 
stained (final concentration of (10µg/µl) agarose gels. 
3.2.1.9 Quantitative real-time PCR 
Total RNA isolation and cDNA synthesis were performed as described above. For PCR 
amplification, 2 μl of cDNAs (1:30 dilution of cDNA as in 3.2.1.7) were amplified 
using 1x QuantiTect SYBR Green PCR Master Mix (Clontech) and 0.3 µM of each 
primer pair in final volume of 20 μl/well. Amplification was performed in MicroAmp 
96-well plates (Applied Biosystems) starting with an initial step for 2.0 min at 50 °C, 10 
min template denaturation/hot start step at 95 °C, followed by 40 cycles (95°C for 15 
sec, 58°C for 30 sec and 60°C for 45 sec). Quantitative PCR analysis for each sample 
was performed in triplicates. GAPDH was used as an internal control. Relative gene 
expression values were obtained by normalizing CT (threshold cycle) values of the target 
genes in comparison with CT values of the housekeeping gene (GAPDH) using the ∆CT 
method. 
3.2.1.10 DNA Electrophoresis in agarose gels 
To analyze the PCR products, samples were electrophoretically separated according to 
their molecular size in (0.6%-2%). agarose gels The agarose was boiled in a microwave 
for 2-3 min in 0.5x TBE or 0.5x TAE buffer and after cooling down (~ 60°C) 2-3 µl of 
ethidium bromide solution (10 mg/ml) per 100 ml gel was added and poured in a gel 
caster. The amount of DNA loaded was as follows on a gel: 10µl of PCR reaction 
volume/well, for plasmid after purification 100 ng/well, for the restriction digest 
100ng/well. Migration of the DNA in the gel can be judged by visually monitoring the 
migration of the tracking dyes, that is Bromophenol blue and Xylene cyanol present in 
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the DNA loading buffer. After adequate migration, DNA fragments are visualized on an 
ultraviolet transilluminator (due to the intercalation of the fluorescent dye ethidium 
bromide into the double strand of DNA, DNA becomes fluorescent) and photographed 
by a camera attached to a gel documentation system. In order to define the size of the 
DNA fragments, DNA size marker was also loaded on the gel. 
3.2.1.11 Isolation of DNA fragments from agarose gels 
For the isolation of DNA fragments from agarose gels, the appropriate DNA band was 
excised from the gel with a sterile scalpel, transferred into 500µl eppendorf tubes and 
extracted using QIAquick Gel Extraction Kit (Quiagen) according to manufacturer’s 
recommendations. The isolated DNA was eluted/ redissolved in elution buffer and the 
purity and integrity of the isolated DNA fragment determined electrophoretically. 
3.2.1.12 Microarray expression analysis 
Three independent total RNA samples of each cell type were prepared using TRIzol. 
Samples used in this study are summarized in the Table 2. Biotin-labeled cRNAs were 
prepared using the Ambion® Illumina RNA amplification kit (Ambion Europe), 1.5 μg 
was hybridized to Sentrix® whole genome bead chips (Mouse WG-6 v2.0, Illumina) 
carrying 45281 probe sets and scanned on the Illumina® BeadStation 500x.  
Raw data extraction of mRNA microarrays was performed with  Beadstudio 3.1.1.0 
software using the Beadstudio Gene Expression Analysis Module 3.1.8. All further 
analysis was performed in R (http://www.r-project.org, version 2.8.0) using 
Bioconductor packages. For further analysis we used quantile normalization 
implemented in the affy package. Variable genes were defined by a coefficient of 
variation (SD/mean) between 0.5 - 10. Determination of present calls was based on the 
detection p-value assessed by Beadstudio software; a gene was called present if the 
detection p-value was < 0.05. Otherwise the mRNA transcript was called absent. 
Differentially expressed genes were selected using a fold change/P value filter with the 
following criteria: Only p-values smaller than 0.05 and an expression change higher 
than 2 fold and a difference between mean intensity signals greater 100 were considered 
statistically significant for further analysis. The Benjamini-Hochberg method was used 
to adjust the raw p-values to control the false discovery rate. The fold-change was 
calculated by dividing the mean intensity of the genes in one group by that in the other 
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group. If this number was less than one, the negative reciprocal was used. Hierarchic 
cluster analysis was performed using the hcluster method in R. Before clustering, the 
data were log2 transformed. Distances of the samples were calculated using Pearson 
correlation and clusters were formed by taking the average of each cluster. PCA 
analysis was performed using the p-curve package in R. When visualizing PCA results, 
the first 3 principal components (coordinates) were z-transformed (mean= 0, standard 
deviation = 1) and subsequently plotted in 3D. 
3.2.1.13 Selection of SNPs and design of primers for their detection 
A single-nucleotide polymorphism (SNP) is a DNA sequence variation occurring when 
a single nucleotide in the genome differs between members of a biological species or 
paired chromosomes in an individual. We use SNP sequencing as stool to confirm the 
presence of variant alleles in fusion cell hybrids each originating from a genome of 
different mouse strain - 129S2 (source of HM-1 ES cells) and F1 generation of DBA/2J 
x C57BL/6 (source of bone marrow cells and spleenocytes). The SNPs were identified 
by a genome-wide screen of the SNP variation between these two strains of mice to 
identify single nucleotide variations on each of chromosome The database for Mouse 
Genome Informatics was used. 
(http://www.informatics.jax.org/javawi2/servlet/WIFetch?page=snpQF). SNP sites 
located on  each chromosome were randomly selected and primers were designed in 
order that 200 bases spanning 3’ and 5’ ends of the variant nucleotide could be 
amplified and recognize two sequences harboring one nucleotide variation on a single 
chromosome. In this way 21 primer pairs were designed to recognize a single sequence 
with one allelic variation for each of the 21 chromosomes of the mouse genome. 
Genomic DNA was isolated from HM-1 ES cells, spleenocytes and FH cells (clones1.2, 
2.1 3.1 and 4.2) using DNeasy Blood and Tissue kit and PCR was performed with 100 
ng of DNA to amplify the sequence encompassing the specific SNP using primers listed 
in chapter 3.1.6 at final concentration of 0.15μM. PCR products pooled from 4-5 PCR 
reactions were purified using QIAquick PCR Purification kit and then sequenced using 
the Big Dye Terminator kit  and primers listed in chapter 3.1.6 to determine the allelic 
variation at one position of each chromosomes. The sequencing was performed in the 
sequencing facility of Institute for Biochemistry, Cologne, Germany. Sequences were 
analyzed using Chromas Pro1.5 software.  
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3.2.1.14 Preparation of vector constructs 
The UTF-Neo vector was kindly provided by Prof. Peter Dröge and is described in the 
publication by Tan et al. 2007. Full-length UTF1 was cloned into phagemid pTZ-18R 
yielding pTZ-UTF1. Its coding region was subsequently replaced with neomycin (Neo), 
yielding  pTZ-UTF1-Neo (Fig. 9a) 
The α-MHC–PAC–IRES–eGFP (αPIG) vector was generated previously by Eugen 
Kolossov (Kolossov et al. 1998). The pIRES2-EGFP vector (CLONTECH Laboratories, 
Inc.) was truncated via excision of the CMV-IE promoter by AseI-NheI and re-ligated. 
The α-MHC promoter (5.5-kb BamHI–Sal I fragment) of the α-MHC–pBK plasmid 
(provided by J. Robbins, University of Cincinnati, Cincinnati, OH) and the PuromycinR 
cassette (HindIII-ClaI fragment) of the pCre-Pac vector were inserted into the multiple 
cloning site of the truncated pIRES2-EGFP vector. The resulting vector was named 
αPIG vector henceforth (Fig. 9b). 
 
 
A. 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
Figure 9. Schematic drawing of vectors. αPIG vector. (A) pTZ-UTF1-Neo  vector in which 
the coding region of UTF1 is replaced with neomycin resistance gene. (B)pIRES2-EGFP 
vector truncated with puromycin resistance, IRES and eGFP under the control of cardiospecific 
α-MHC promoter. 
Materials and Methods 
- 68 - 
3.2.1.15 Establishment of transgenic cell lines 
The αPIG vector was verified by sequencing and 14 µg of the vector was digested using 
the enzyme SacI (1U per 10µg plasmid) at 37°C overnight. After overnight digestion, 
the enzyme was inactivated by heating the reaction mix at 65°C for 20 minutes and then 
stored at -20°C until used for transfection. An aliquot of the restriction digest was 
verified for the completeness of plasmid linearization by agarose gel electrophoresis. A 
confluent dish of murine iPS cells (TiB7.4, provided by Prof. Rudolf Jaenisch and Prof. 
Alexander Meissner, MIT, Cambridge, USA) was trypsinized and cell number was 
determined. Approximately 5x106 cells were resuspended in 700 μl PBS (without 
Ca/Mg). 20 μg of the linearized plasmid vector was diluted in 100 μl of PBS and mixed 
with the cell suspension. The mixture was transferred into a GenePulser cuvette (0.4 cm 
electrode, gap 50). The cell and plasmid mix was incubated on ice for 20 minutes. 
Electroporation was then performed using GenePulser Electroporator (BioRad) at 260 V 
and 500 μF. Immediately after electroporation the cell suspension was transferred to 10 
cm dish containing 10 ml of iPS medium with LIF and layered with irradiated MEFs 
prepared one day earlier. Selection of resistant colonies was started 48 hours later by 
addition of neomycin at a concentration of 500 μg/ml. Approximately 10 days later 
resistant colonies were obtained. 40 colonies were picked and sub cultured as separate 
clones. All clones were expanded and frozen in multiple vials. At least ten clones were 
chosen for the initial round of screening for cardiac differentiation. Three clones-clone 
25, clone 15 and clone 11 were routinely used for cardiac differentiation. All data 
described in this thesis were generated with αPIG-iPS clone 25. The transgenic murine 
D3 ES cell line αPIG-ES (clone 44) was generated with the same αPIG vector 
previously and was used for comparative analyses. 
To enrich pluripotent cells from the non-homogenous population of TiB7-4 cells, 
UTF1-Neo was used as selection vector. TiB7-4 cells were electroporated with circular 
UTF1-Neo plasmid and selected with G418 24 hours after the transfection, which 
ultimately resulted in several colonies. Three were isolated two weeks after 
electroporation and expanded as subclones UTF-1, UTF-2 and UTF-3. No further 
selection with G418 was applied. UTF-1, -2 and –3 were sub-cultured for 40 passages. 
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3.2.2 Cell Culture Techniques 
 
 
3.2.2.1 Culture conditions for murine ES, iPS and fusion hybrid cells 
The murine iPS cell line TiB7.4 was kindly provided by Rudolf Jaenisch and Alexander 
Meissner. The transgenic ES cell line αPIG44 derived from a parental ES cell line D3 
was described previously (Kolossov et al. 2006). The ES cell line HM-1 was obtained 
from ATCC. Fusion hybrid cells were providedby  Bernd Fleishcmann and Hans 
Schöler. The ES , iPS and FH cells were cultured in ES/iPS cell medium composed of 
Dulbecco’s modified minimal essential medium (DMEM) supplemented with 15% fetal 
bovine serum (FBS), 100 μM β-mercaptoethanol, 1x non-essential amino acids and 
1000 U/ml leukemia inhibitory factor (LIF). The cells were grown on monolayer of 
mitotically inactivated murine embryonic fibroblasts (MEFs). Pluripotent ES and iPS 
cells grow in the form of compact colonies with clearly defined borders. Cells were 
passaged every 2-3 days by trypsinization and seeding onto irradiated MEFs. 
3.2.2.2.      Inactivation of MEFs and preparation of feeder plates 
ES cells are usually grown on a layer of mitotically inactivated primary MEFs in the 
presence of LIF to promote growth and prevent differentiation. These cells stop dividing 
after a couple of passages, so embryonic fibroblasts need to be isolated freshly from 
time to time. This requires pregnant female mice at day 13 post coitum (p.c., assuming 
day one is the first day the plug is observed). F1 hybrid or outbred mice are favored 
because of increased litter size. Murine embryonic fibroblasts (MEFs) were isolated 
from 12.5 to 13.5 p.c. mouse embryos. The head is discarded and the body parts 
including the limbs are collected and dissociated by trypsinization to produce single-cell 
suspensions. After expansion, aliquots can be frozen and stored in liquid nitrogen 
indefinitely. Alternatively, MEFs suitable for ES cell culture may be obtained from 
commercial sources. MEFs must be inactivated prior to use as a feeder layer for mouse 
ES cells. Mitotic inactivation prevents the dilution of ES cell lines with dividing 
fibroblasts. MEFs can be inactivated using γ-irradiation, or mitomycin C treatment .We 
routinely used irradiated MEFs for ES cell maintenance. 
A frozen vial MEFs is thawed and plated in a 75-cm2 tissue culture flask or 100-mm 
plate in MEF medium (DMEM supplemented with 10% FBS and 1x non-essential 
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amino acids). The cells are allowed to grow until confluent (3 to 5 days). Medium is 
changed after the first day and every other day thereafter. The cells are then passaged by 
trypsinizing and resuspending the cell pellet in 10 to 50 ml MEF medium without 
penicillin/streptomycin, and plating at a 1:10 dilution. Medium is added to a final 
volume of 10 to 15 ml per 75-cm2 flask or100-mm plate. The cells are allowed to grow 
until confluent (3 to 5 days), and passage at a 1:5 to 1:10 dilution, using twenty-five to 
fifty 150-cm2 flasks. Medium from confluent flasks is removed and the cells are rinsed 
with 15 ml Ca2+ and Mg2+  free PBS, and trypsinized again. MEFs from ten to fifteen 
150-cm2 flasks can be processed together. The pellet is resuspended in 10 ml MEF 
medium without penicillin/streptomycin and transferred in suspension to a 50 ml Falcon 
tube. The cells are then exposed 2 times to 4000 rads of γ-radiation. The cells 
suspension is then immediately diluted to 50 ml with MEF medium without 
penicillin/streptomycin. The number of cells is counted and either used freshly for ES 
cell culture by plating (0.8x106 cell/6cm dish) or frozen (10x106 cells/ vial) for later use. 
3.2.2.2 Passaging of ES, iPS cells and fusion hybrid cells 
Before passaging, murine ES or iPS cells were dissociated using 0.25% Trypsin/EDTA. 
Medium was aspirated from the 6 cm cell culture plate and washed once with 5 ml pre-
warmed PBS. Cells were then incubated with 1 ml of trypsin for 2-3 minutes at 37°C. 
Cells were uniformly dispersed into single cells by gentle trituration. Trypsin was 
inactivated by the addition of four volumes of ES/iPS cell medium. Cells were collected 
by centrifugation at 1000 rpm (300xg) for 5 minutes at RT in table top centrifuge. 
Supernatant was discarded and the pellet was resuspended in the fresh ES/iPS cell 
medium. The cells were counted using Neubauer counting chamber and the viability of 
cells was determined by Trypan blue dye exclusion method. The cells were seeded at a 
density of 0.3-0.5 x 10
6 cells per 6 cm plate containing irradiated MEFs. 
3.2.2.3 Freezing and thawing of cells 
ES or iPS cells, fusion hybrid cells and MEFs were trypsinized, washed, centrifuged and 
resuspended in ES/iPS cell medium. The cell concentration was adjusted to 1-2x106 
cells per ml and 0.9 ml of this suspension was mixed with the 0.9 ml of ice-cold cell 
freezing medium containing 80% FBS and 20% DMSO. Aliquots of cells (1-2 x 106 
cells/vial/1.8 ml) were frozen at -80°C overnight and for long-term storage transferred 
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to liquid nitrogen. For thawing, frozen cells were quickly transferred from liquid 
nitrogen into a 37°C water bath, thawed, washed with 10 ml of pre-warmed medium and 
seeded on a dish coated with 0.1% gelatin or seeded with irradiated MEFs (see above) 
depending on the requirements of the experiment. 
 
3.2.2.3. Mycoplasma assay 
Supernatant from a 24 hour culture of the various cell lines was withdrawn and was 
routinely checked for mycoplasma contamination by a PCR based protocol using Venor 
GeM Mycoplasma Detection Kit.  
 
3.2.2.4. Isolation of murine bone marrow cells and spleenocytes  
The animals were sacrificed according to standard method of sacrifice and then 
dissected under sterile conditions. The spleen was then collected in a dish containing 1x 
PBS. A 70um filter is placed at the mouth of a 50 ml falcon tube and rinsed with 10% 
RPMI. The spleen is then transferred on the filter. With the help of the piston of 5ml 
syringe the spleen is pressed against the filter to dissociate the cells and continuously 
rinsed with medium. This collects all the cells after dissociating from spleen in the 
falcon. 
Femoral bone was also collected by dissection of the thigh region to isolate bone 
marrow cells. With the help of 24G needle, a small hole is punctured into the head of 
the bone. Another hole is punched through the other end of the bone. Sterile medium 
(10% RPMI) is taken into the syringe, a 24G needle is fixed to the syringe which is then 
inserted into one of the holes made. The other end of the bone is directed toward the 
mouth of a sterile falcon. The medium is then flushed through the bone in a way that the 
bone marrow cells get collected in the falcon tube. 
3.2.2.4 Reprogramming by fusion 
5x106 HM-1 ES cells were mixed with 5x106 of either murine bone marrow cells or 
spleenocytes (ratio of 1:1) from DBA/2JxBL6 mice and washed in PBS. The mixture 
was centrifuged in 50 ml conical tubes at 130xg for 5 minutes. After removal of the 
supernatant, 1 ml of a prewar med 50% polyethylene glycol (PEG 1500) was added to 
the cell pellet drop by drop. 24 ml of complete medium (DMEM supplemented with 
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15% FBS, 1x non essential amino acids, and 50µM beta mercaptoethanol) was added up 
to the final volume of 25 ml over 5 minutes time, with constant stirring at 37°C and 300 
rpm in a Thermomixer  (Eppendorf) equipped with a 50 ml tube adapter. The cells were 
centrifuged at 130xg for 10 minutes at RT in swing-out rotor, washed gently with 
DMEM, resuspended in a cell culture medium containing 1000 U/ml LIF and seeded 
onto inactivated MEFs. Selection for fused cells was started 48 hours later by addition 
of 50x HAT supplement (Invitrogen) into the medium to a final concentration of 1x 
(0.1mM hypoxanthine, 0.4μM aminopterin 0.016mM thymidine). The ES cell colonies 
rescued by fusion with wild-type somatic cells were detected 5-7 days after fusion and 
subcloned by culturing in the presence of HAT in ES/iPS cell medium. 
3.2.2.5 In vitro cardiac differentiation of ES, iPS or fusion hybrid cells 
Cardiac differentiation of transgenic iPS and ES cells was performed in spinner flasks. 
A confluent culture of ES/iPS cells was trypsinized and cell number was determined. 
1x106 cells were suspended in a total of 14 ml differentiation medium 
(IMDM/Glutamax supplemented with 20% FBS, 100 μM β-mercaptoethanol and 1x 
non-essential amino acids) to a final concentration of 7x104 cells/ml and cultured for 
two days in non-adherent plates (10 cm in diameter) under continuous agitation (50 
agitations per minute) on a horizontal shaker. Embryoid bodies (EBs) were formed in 
two days after beginning of differentiation. At day 2, EBs were counted in 30 μl drops 
and 28000 EBs were transferred into a spinner flask (Cell Spin 250, IBS Integra 
Biosciences) containing 200 ml of the differentiation medium. The spinner flask was 
equipped with stirrers and cells were agitated at 40 rpm. Medium was not changed until 
day 9 of differentiation when a sample of approximately 10 ml was withdrawn from the 
spinner flask and checked for appearance of beating or GFP-positive areas within the 
EBs. With the help of a florescence microscope the occurrence of GFP-positive areas in 
EBs arising as a result of cardiac differentiation of transgenic ES/iPS cell lines was also 
checked. At the sight of beating and green florescence in EBs, drug selection was 
initiated by adding puromycin (8 μg/ ml). This led to death of non cardiac cells and 
enrichment of cardiac cell types. On day 11, the surviving cardiac clusters (CCs) were 
transferred into 10 cm non-adherent culture dishes for further purification leading to 
highly purified cardiac clusters. Medium was changed with fresh puromycin every 
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second day. Analyses were performed with cardiac clusters that were collected on day 
16 of differentiation after 7 days of puromycin treatment. 
Differentiation of FH cells and HM-1 ES cells was performed using a hanging drop 
method. The cells were suspended in Iscove´s modified Dulbecco´s medium (IMDM), 
supplemented with 20% fetal calf serum, 100 units/ml penicillin, 100µg/ml 
streptomycin, 1% non-essential amino acids, and 100 μM β-mercaptoethanol. Then, 
20µl drops containing 500 cells each were placed on the lids of cell culture dishes. The 
drops were made to hang by inverting the lid on the base of the dish. After 2 days of 
cultivation in hanging drops, the embryoid bodies (EB) were transferred into 20% 
IMDM and cultivated for further 5 days in suspension. On day 7, EB were plated onto 
0.1% gelatine-coated adherent dishes. Fresh medium was replaced. The EBs attaches in 
24hours to the surface and starts growing horizontally and undergoes multilineage 
differentiation. Appearance of cardiac cells (usually from day 8 onwards) is marked by 
beating areas within EBs.  
3.2.2.6 Detection of contaminating undifferentiated ES or iPS cells in 
purified cardiomyocytes 
In order to detect rare contaminating ES or iPS cells within the puromycin-selected cardiac 
clusters, 0.1-0.3x106 dissociated single cells were seeded on irradiated MEFs and cultured 
for 7-14 days in complete ES/iPS cell medium. During this period of time any surviving ES 
or iPS cells, which resisted puromycin in cardiac clusters, will appear. When colonies of 
undifferentiated cells were formed in plates, crystal violet staining was performed to 
visualize and count the number of colonies indicative of the number of contaminating 
ES/iPS cell in purified CMs. Crystal violet staining was performed by washing the cells two 
times with PBS-/- and then adding a 3% solution of crystal-violet (prepared in Methanol) 
to the plate and incubating for 10 min at Room temperature. The stained plates were 
then washed with tap water 4-5 times until the background was colorless. The plates 
were air dried and the number of blue stained colonies was determined. 
Contaminating pluripotent cells in preparations of puromycin-selected CMs were also 
detected by monitoring teratoma formation. After 7 day of puromycin selection, day 16 
cardiac clusters were dissociated into single cells by Trypsin/EDTA treatment and 0.5-
2.0x106 CMs were injected subcutaneously into immunodeficient 6-8 weeks old Rag2-/-γc-/- 
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mice and monitored for a period of 3 months. Experimental animals were obtained from Dr. 
Mamoru Ito (Central Institute for Experimental Animals, Japan). Studies with experimental 
animals were approved by the regional government authority of the state North Rhine-
Westphalia. Animals was sacrificed by cervical dislocation when teratomas reached 
appropriate size, tumors were explanted, measured and fixed using 4% buffered 
paraformaldehyde (pH 7.5) for 12 hrs at 4°C for H&E staining and histological analysis.  
3.2.2.7 Alkaline phosphatase staining 
ES, iPS or fusion hybrid cells were plated at a clonal density of 0.5-1 x 104 cells per 6 
cm dish and cultured for 5-7 days. Cells on the dish were washed twice with PBS, fixed 
in 100% methanol for 10 min at RT and air-dried. Cells expressing alkaline phosphatase 
(ALP), a pluripotency marker, were determined by staining for 15-30 min at RT with 
1:10 dilution of Napthol AS-MX phosphate (200 g/ml, Sigma) in Fast Red TR salt TM 
(1 mg/ml, Sigma) that was prepared in Tris/HCl (pH9.2) as described in section 
above3.1.10. The reaction was stopped by rinsing the cells with distilled water and air-
drying. Alkaline phosphatase positive colonies were stained red and photographed using 
the phase-contrast microscope equipped with 4x and 10x lens (Zeiss). 
3.2.2.8 Ploidy determination 
To measure the content of DNA in fusion hybrid cells and to determine their ploidy, 
pluripotent cells were trypsinized and counted.1x106 cells were washed with PBS and 
then fixed overnight in 70% ethanol prepared with tdH2O at -20°C. Next day cells were 
centrifuged at 130xg, resuspended in 1ml PBS and treated with RNAse (exact type, 
manufacturer) at the final concentration of 100 μg/ml for 15-20 minutes at 37°C. The 
suspension was then equally distributed into two 1.5 ml micro centrifuge tubes. One 
tube received propidium iodide (PI) at a final concentration of 50 μg/ml and the other 
was maintained as a control without PI. The samples are incubated on ice for 15 
minutes. The DNA content of cells was measured using a flow cytometer FACScan. 
Tetraploid fusion hybrid clones and diploid parental ES cells (HM-1) and somatic cell 
(spleenocytes) were included in the analysis. HM-1 ES cells and spleenocytes were used 
as a diploid and dividing cell control. On the first dot plot FSC Vs SSC was acquired. A 
gate was drawn on the most dense population thereby eliminating cell debris. On the 
second dot plot FL3-A on X axis and FL-3W on the Y axis were set along with gate of 
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the first plot. During acquisition the cell aggregates would be seen on the extreme right 
of the FL3-AVs FL3-W plot. The cell aggregates were gated out for acquisition of a 
histogram with FL-3A as Y-axis. 
3.2.2.9 Coating of cell culture plates 
0.1% gelatin prepared in sterile PBS was layered over adherent tissue culture dishes of 
the required size and place in incubator at 370C for a minimum of 1 hour. 
Fibronectin was diluted in sterile PBS to reach a final concentration of 2.5µg/ml This 
solution was coated on either ibidi plates (for immunostaining) or on coverslips placed 
in 3.5cm adherent dishes (for electrophysiology) and stored in incubator at 370C for 4-
12 hours These plates were then ready for growing CMs. If not used immediately they 
could be stored at 40C until use. Care was taken to prevent drying. 
 
3.2.3 Immunoassaying, microscopy and flow cytometry 
3.2.3.1 Immunofluorescence staining  
Immunostainings were performed on undifferentiated ES or iPS cells as well as 
differentiated cells. Undifferentiated ES/iPS cells were cultured on MEFs and after 2-3 
days of culture they were fixed in 4% buffered paraformaldehyde (pH 7.5) for 15 min at 
RT for immunostaining. Single ES or iPS cell-derived cardiac muscle cells (CMs) were 
plated on fibronectin-coated μ-dishes (Ibidi) at 0.3x106 cells /plate in differentiation 
medium containing 8μg/ml puromycin. After 2-3 days adherent CMs were fixed in 4% 
buffered paraformaldehyde (pH 7.5), permeabilized by Triton X-100 and then blocked 
against unspecific antibody binding with 10% fat free milk powder dissolved in PBS 
(blocking solution) for 1 h at RT. After blocking, cells were washed with PBS and 
incubated with primary antibody diluted in blocking solution overnight at 4°C. Cells 
were rinsed with 0.01% TritonX-100 in PBS and incubated with species-specific 
secondary antibodies diluted in blocking solution for 1 h at RT. Nuclei were 
counterstained with Hoechst 33342 (2µg/ml) at 37°C for 20-30 minutes. Finally cells 
were washed and imaged on an Axiovert 200M fluorescence microscope (Zeiss).  
3.2.3.2 Flow cytometric analysis 
Single cells were prepared by Trypsin/EDTA treatment as described above. The 
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dissociated cells were centrifuged, washed and filtered through a 40 μm cell strainer 
(BD Pharmingen). Cell count was then determined and cells were resuspended in 
appropriate volume of staining buffer (PBS supplemented with 0.1% FBS) to obtain a 
cell density of 0.5 x106 cell/ 50 μl. Cells were then dispensed into 1.5 ml micro 
centrifuge tubes (50 μl/tube) and stained either with isotype control or antigen-specific 
antibodies diluted in the staining buffer. Cell-surface antigen expression was detected 
using fluorescently conjugated antigen-specific antibodies (direct staining) or labeling 
the cells with unconjugated primary antibody followed by fluorescently-tagged 
secondary antibody (indirect staining) by incubating at 4°C for 30 minutes. The cells 
were washed 2-times with and 1 ml of Cell Wash. Unstained samples were used as a 
negative control. The cell suspension was transferred into the FACS tubes and data was 
acquired on flow cytometer (FACScan, BD Pharmingen). Cells were gated on forward 
and side scatter dot plots. 10,000 events per sample were acquired and the data were 
analyzed with CellQuest Pro software (Beckton Dickinson). To assess the percentage of 
GFP-positive cells in the purified cardiac clusters, single cell suspension of puromycin-
selected cardiac clusters was prepared by dissociation with 0.05% Trypsin/EDTA and 
analyzed by flow cytometry. Propidium iodide was used for dead cell staining.  
3.2.3.3 Electrophysiology 
Puromycin-purified cardiac clusters from aPIG-ES and aPIG-iPS and beating areas from 
derived from FH clones were dissociated into single CMs by treating with collagenase 
B (1mg/ml) for 20-30 minutes. CMs were plated on fibronectin-coated glass cover slips 
(22x22 mm square glass cover slips in 3.5 cm dishes) and cultured for 24-48 hours 
before measurements were performed. The cover slips were placed into a recording 
chamber at RT and cells perfused continuously with extracellular solution. Cell 
membrane capacitance was determined on-line PULSE software (HEKA Elektronik). 
Action Potential (AP) of spontaneously beating CMs were recorded by the whole-cell 
current-clamp technique using an EPC-9 amplifier and the PULSE program. Response 
of CMs to hormonal regulation was assessed by administering isoproterenol (Iso) and 
carbachol (CCh). The standard whole-cell patch-clamp recording technique in the 
voltage-clamp mode was used for recording voltage-gated Na+-, L-type Ca2+-, and 
depolarization-activated outward K+-channel currents. Data are presented as the mean ± 
standard error of the mean (SEM). Student’s t test was applied for statistical evaluation.  
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4 RESULTS 
 
4.1 Reprogramming by fusion 
 
4.1.1 Generation of fusion hybrid clones 
In order to test the reprogramming ability of ES cells and to determine the cell fate 
change brought about by fusion based reprogramming, we induced fusion between 
mouse ES cells and somatic cells like spleenocytes and bone marrow cells.  
HM-1 ES cells were derived from 129/ola and are HPRT1-deficient. Hypoxanthine-
guanine phosphoribosyltransferase (HGPRT) encoded by HPRT1 gene plays a central 
role in the generation of purine nucleotides through the purine salvage pathway. As a 
result, these cells are sensitive to medium containing the HAT (hypoxanthine, 
aminopterin, and thymidines) supplement. HAT inhibits the enzyme dihydrofolate 
reductase (DHFR), which is necessary in the de novo synthesis of nucleic acids. Thus, 
the cell is left with no other option but to use the alternate purine salvage pathway, 
which utilizes HGPRT. But due to the lack of HPRT in HM-1 cells, nucleic acids 
cannot be synthesized and this leads to cell death. When HM-1 cells are fused with 
HGPRT+ bone marrow cells or spleenocytes, the resulting fused cells can be selected 
based on their resistance to HAT. In the HAT medium HGPRT- HM-1 cells will die and 
only the HGPRT+ fused cells will survive. The bone marrow cells or spleenocytes 
eventually die under the ES cell culture conditions, thus only hybrid cells with ES cell-
like morphology are left surviving.  
HM-1 ES cells (haplotype b) were fused using polyethylene glycol (PEG) with either 
adult mouse bone marrow or spleen cells derived from DBA2J mice (haplotype d). 
After fusion the cell mixture was plated on MEFs and grown in ES culture conditions in 
the presence of HAT. After a few days of selection with HAT, the ES cells like colonies 
were obtained. The emerging colonies were indicative of successful reprogramming of 
somatic cells by fusion with ES cells. Each colony was picked up, individually 
expanded and termed as a fusion hybrid (FH) clone. These clones were routinely 
maintained under ES cell conditions in the presence of HAT. Four FH clones (FH1.2; 
FH2.1; FH3.1 and FH4.2 have been used in the present study (Fig. 10A-C). FH1.2 and 
FH2.1 resulted by reprogramming of bone marrow cells and FH3.1 and FH4.2 were the 
result of reprogramming of spleenocytes by fusion with HM-1 cells. The FH clones 
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obtained resembled very closely in their morphology to ES cells and therefore presumed 
to be pluripotent.  
The pluripotent nature of the FH clones was demonstrated by in vitro differentiation of 
FH cells. When differentiation was started, FH2.1 and FH4.2 formed embryoid bodies 
(EBs) similar to but comparatively smaller than those formed by HM-1 ES cells (Fig. 
10D-F). EBs when allowed to spread on gelatin surface formed multicelluar structures 
similar to those formed by conventional HM-1 ES cells representing differentiation into 
multiple lineages (Fig. 10G-I). 
 
 
 
 
 
 
 
 
 
 
Figure 10. Pluripotency of HM-1 ES and FH cells. (A-C) Pluripotent colonies of HM-1ES 
(A) FHclone 2.1(B) and FH clone 4.1(C).Scale=100um. EBs at day 2 and day 8 of 
differentiation of HM-1 (D and G) FH clone2.1 (E, H) and FH 4.2(F, I).Scale bar=200µm. The 
fusion clones were provided by our collaborators Martin Breitbach (AG Bernd Fleshcmann) and 
Tobias Cantz (AG Hans R.Schöler). 
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4.1.2 Ploidy of fusion hybrid cells  
The fusion between the two diploid cells leads to formation of a tetraploid cell. In order 
to confirm that the resulting fusion-derived pluripotent cell lines contain double amount 
of DNA, the DNA content of undifferentiated FH cells and HM-1 ES cells was 
determined by propidium iodide staining. Dead cells and  aggregates were gated out 
based on FL3-A and FL3-W parameters Flow cytometric analysis of stained cells 
revealed that the cells of the fusion clones carry a tetraploid genome (Fig. 11). This was 
demonstrated by the predominant 4n peak and 8n peak in a histogram plot of the cells 
after uptake of propidium iodide. HM-1 ES cells showed only the expected 2n (cells in 
G0/G1 phase of the cell cycle) and 4n peaks (cells in the G2/M phase of the cell cycle). 
These results demonstrate that FH cells maintain tetraploid genome and do not loose 
their hybrid character during prolonged culture.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Cell cycle analysis of spleenocytes and undifferentiated cells of HM-1 ES and 
FH clones. Single cells were fixed and stained with Propidium iodide before analyzing on a 
flow cytometer 10,000 events were acquired for each sample on a histogram with FL3-A on Y-
axis. 
 
To test whether the tetraploid chromosome set in FH cells remains stable when the cells 
undergo differentiation, the ploidy of FH cells was determined at various time points of 
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spontaneous differentiation (day 4, 6, 8 and 10). FH2.1 EBs at all days of differentiation 
retained a DNA cotent similar to that of their undifferentiated counterparts with a high 
4n and 8n peaks. Thus it seems that the tetraploid state of the FH cells was stably 
maintained in the course of prolonged passaging of undifferentiated FH cells as well as 
during the course of their differentiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Fusion hybrid cells maintain tetraploidy in the course of differentiation. Ploidy 
state of fusion hybrid clone 2.1 in EB cells obtained at day 4, (A), day 6 (B), day 8 (C) and day 
10 (D) of differentiation. EBs were dissociated by Trypsin/EDTA, stained with propidium 
iodide and analyzed by flow cytometry as described in the methods section.  
4.1.3 Confirmation of tetraploid character of fusion hybrid clones by 
SNP genotyping  
To enable the tracing of chromosomes from both fusing cells, we had chosen fusing 
partners from different strains of mouse that can be distinguished by their single 
nucleotide polymorphisms (HM-1 ES cells were from 129sv and somatic cells from 
DBA/2JxBL6 mouse). These strains also differ in their MHC class I haplotypes, 
enabling further confirmation of the hybrid character of fusion derived cells by flow 
cytometric assessment of MHC class I expression (see below chapter 4.1.4). A genome-
wide screen of the SNP variation between these two strains of mice was performed to 
identify single nucleotide variations on each of chromosome. The reference variant 
alleles of the SNPs chosen for each chromosome are tabulated in Table 1. The presence 
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of both parental chromosomes in the fusion hybrid cell would be elucidated by the 
presence of two alleles at chosen SNP locus on a given chromosome.  
Validation of the technique of identification of the variant alleles was performed by 
sequencing of HM-1 ES cell and somatic cell (spleenocytes) DNA mixed at 
predetermined ratios of 1:1 imitating the expected situation in fusion hybrid cells. 
Figure 13 shows the result of sequencing of the SNP on chromosome 3 of this control 
setup demonstrating the presence of dual peak (nucleotides C and T) at position 170 in 
1:1 mixed DNA. The pure DNA from HM-1 ES cells and somatic cells presents only 
the single nucleotide peak expected at this SNP position for each cell line (C for HM-1 
ES cells and T for somatic cells). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.  Validation of sequencing as a method for SNP genotyping. Identification of SNP 
on chromosome 3 with SNPa3 primer by sequencing of DNA isolated from HM-1 ES cells (A, 
expected variant allele: C) and spleenocytes (B, expected variant allele: T). The sequencing of 
DNA sample from both cell types mixed at ratio 1:1 revealed the presence of double peak for 
C/T variation at this SNP position. 
 
Genomic DNA from parental cells and all four fusion hybrid clones (FH1.2; FH2.1; 
FH3.1 and FH4.2) was sequenced using the primers to identify one arbitrarily selected 
SNP variation on each of 21 murine chromosomes (19 autosomes and 2 sex 
chromosomes). These analyses confirmed that all fusion hybrid clones contained the 
variant alleles of their parental cell lines on all chromosomes tested (Fig. 14 and Table 
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1). These findings were confirmed in at least two independent experiments. Only clone 
1.2 did not show two alleles on chromosomes 5 and 10 (Table 1). The presence of both 
alleles in all fusion clones demonstrated that the fusion clones retained both parental 
nuclei and at least one of each pair of parental autosomes, which were not lost during 
cell division and differentiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. A representative example of identification of both parental SNPs in fusion 
hybrid clones. Sequencing of selected SNP on chromosome 7 with SNPa7 primer shows the 
presence of only one polymorphic allele in HM-1 ES cells (adenine) and somatic cells 
(cytosine). All four fusion hybrid cell lines contain both alleles (C/T, arrows) at this SNP 
position, suggesting the existence of both parental genomes in these cells. 
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Table 1. The results of SNP genotyping of parental HM-1 ES and cells (129sv strain) 
somatic cells (DBA2J strain) and fusion hybrid cells. 
 
Presence of both alleles in fusion 
hybrids 
Chromosome 
number 
SNP 
name 
129 SV DBA/2J 
Clone 
1.2 
Clone 
2.1 
Clone 
3.1 
Clone 
4.2 
1 SNPa1 C T CT CT CT CT 
2 SNPb2 C T CT CT CT CT 
3 SNPa3 C T CT CT CT CT 
4 SNPa4 G T GT GT GT GT 
5 SNPb5 A G A AG AG AG 
6 SNPa6 A C AC AC AC AC 
7 SNPa7 A C AC AC AC AC 
8 SNPb8 C T CT CT CT CT 
9 SNPa9 A C AC AC AC AC 
10 SNPa10 G T G GT GT GT 
11 SNPa11 C T CT CT CT CT 
12 SNPa12 A G AG AG AG AG 
13 SNPa13 C T CT CT CT CT 
14 SNPa14 A T AT AT AT AT 
15 SNPa15 C T CT CT CT CT 
16 SNPa16 A G AG AG AG AG 
17 SNPa17 C T CT CT CT CT 
18 SNPa18 C T CT CT CT CT 
19 SNPa19 A G AG AG AG AG 
 
4.1.4 Expression of both parental MHC class I haplotypes on fusion 
hybrid cells 
The SNP genotyping allows for accurate determination of the hybrid character of fusion 
hybrid cells. However, this method is time consuming and can not be used for a quick 
monitoring of cells. To enable easy monitoring of a fusion cell character, fusion cell 
partners were chosen from mouse strains expressing different MHC class I haplotypes, 
the expression of which can be easily determined by cell surface staining and flow 
cytometry. Reports from our and other groups have demonstrated that ES cells in their 
undifferentiated state do not express detectable levels of MHC class I molecules on their 
surface and their expression can not be enhanced by interferon γ (IFNγ) treatment 
(Abdullah et al. 2007; Frenzel et al. 2008). In contrast, differentiated cells derived from 
ES cells express MHC class I molecules at low but detectable levels and this expression 
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can be increased with IFNγ. We have postulated that somatic cells (such as 
spleenocytes) reprogrammed to pluripotency by fusion with ES cells would down 
regulate their normally very high MHC class I expression on the cell surface once their 
genomes in FH cells are successfully reprogrammed to a pluripotent state. To assess 
whether this is true we first assessed the expression of MHC class I molecules on fusion 
hybrid cells. As expected, fusion hybrid cells in their undifferentiated state expressed 
very low levels (1.5-1.7%) of MHC class I molecule of both haplotypes (Fig. 15). IFNγ 
treatment also could not enhance the expression of MHC class I molecules on FH cells 
in their undifferentiated state (Fig. 15A). However, when their progeny at day 4 of 
differentiation were analyzed, these cells expressed both MHC class I haplotypes. 2.6 % 
of FH 2.1derived day4 EBs expressed H-2Kb which was enhanced upto 43% after IFNγ 
induction. 11.9% of the same cells expressed H-2Kd antigen the expression of which 
was enhanced upto 70% upon IFNγ induction. (Fig. 15B left panels). 3% of FH clone 
4.2 derived EBs, at day 4, expressed H-2Kb which was enhanced upto 30% after IFNγ 
induction. 21% of the same cells expressed H-2Kd antigen whose expression was 
enhanced upto 60% upon IFNγ induction. (Fig. 15B, right panels). This response of 
day4 EB derived from fusion hybrid cells is similar to that of conventional murine ES 
cells and their differentiated derivatives. Day 11 EBs derived from  fusion hybrid cells 
had relatively low expression of MHC class I molecules but still could be induced with 
IFNγ (28 %  and 16% induction of H-2Kb and H-2Kd respectively in FH clone 2.1 
derived day11EBs (Fig. 15C left panels); 17% and 40% induction of H-2Kb and H-2Kd 
respectively in FH4.2 derived day11EBs (Fig. 15C, right panels), this also in 
agreement with the expression of these molecules on conventional ES cell derivatives at 
this stage of differentiation (Abdullah et al. 2007). HM-1 ES cells did not express H-
2Kb and H-2Kd antigens in the undifferentiated state but when induced with IFNγ, day 4 
EBs and day 11 EBs derived from HM-1 ES cells expressed H-2Kb antigen but not H-
2Kd according to their origin from the 129sv mouse strain. The expression of both MHC 
class I haplotypes on fusion hybrid clones suggest that these cells contain chromosome 
17 encoding for MHC class I heavy chain from both parental cell types. In addition, the 
ES cell-like expression pattern of MHC class I molecules on the surface of fusion 
hybrid cells further confirms that somatic cells, normally expressing high levels of these 
molecules, were successfully reprogrammed to a pluripotent state by fusion with ES 
cells.  
Results 
- 85 - 
IgG2a
-IFNg
+IFNg
IgG2a
-IFNg +IFNg
IgG2a
-IFNg
+IFNg
Day 0 Day 4 Day 10
PE
C
ou
nt
s
HM-1 cells
Spleenocytes
H
-2
K
d
H
-2
K
b
A.
IgG2a
-IFNg
+IFNg
IgG2a
-IFNg
+IFNg
IgG2a
-IFNg
+IFNg
IgG2a
-IFNg
IgG2a
-IFNg
B.
H-2Kb H-2Kd
IgG2a
FH 2.1
-IFNg
+IFNg
IgG2a
-IFNg
+IFNg
IgG2a
-IFNg
+IFNg
IgG2a
IgG2a IgG2a
-IFNg
+IFNg
-IFNg -IFNg
+IFNg
+IFNg
H-2Kb H-2Kd
FH 4.2
IgG2a IgG2a
IgG2a IgG2a
IgG2a IgG2a
-IFNg -IFNg
-IFNg -IFNg
-IFNg -IFNg
+IFNg
+IFNg
+IFNg +IFNg
+IFNg +IFNg
C.
D
ay
 0
D
ay
4
D
ay
11
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Expression of MHC class I molecule on the surface of fusion hybrid clones with 
and without induction. (A) HM-1 ES cells and their derivatives at day 4 and day10 and (C) 
Undifferentiated FH cells and their derivatives at day 4 and day11with and without IFNγ 
induction were dissociated into single cells, stained with antibodies specific for H-2Kb and H-
2Kd molecules and the percentage of positive cells was determined by flow cytometry (B) 
Spleenocytes derived from DBA/2JxBL6 mice were checked for expression of H-2Kb and H-
2Kd molecules.  
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The above results suggested that although a fraction of cell expresses one of the MHC 
class I haplotypes but still it was unclear if these molecules are expressed on a single 
cell. To rule out the possibility that two populations of cells (one H-2Kb expressing and 
the other H-2Kd) exist in these cultures, it was necessary to confirm that both types of 
molecules are expressed on one single cell. Therefore double staining was performed to 
provide a final proof for their fusion character. 
Co-staining of H-2Kb and H-2Kd antigens was performed on FH 4.2 derived day 4 EBs 
after induction with IFNγ. Single stained cells were first analyzed for both haplotypes. 
73% of FH4.2 derived day4 EBs were induced to express H2-Kd molecule whereas only 
26% of the same cells expressed H-2Kb haplotype (Fig. 16A). In control experiments, 
90% of HM-1 ES derived day4 EBs were induced for H-2Kb but H-Kd could not be 
induced in these cells (Fig. 16B). 
Analysis of double stained cells revealed that out of the 73% cells that expressed H-2Kd. 
only upto 28% of cells were also positive for H-2Kb. Therefore only 28% of the cells 
expressed both H-2Kb and H-2Kd.  48% of the cells expressed only H-2Kd. All cells 
(26%) that expressed H-2Kb also expressed H-2Kd but not vice versa. 
This lack of expression could be attributed to loss of one sister chromosome but this 
possibility is ruled out due to the fact that both alleles of chromosome 17 were detected 
in SNP analysis. We are unable to explain this result but it is likely that technical 
difficulties of low staining intensity of FITC conjugated H-2Kb antibody could not 
detect weaker signals. The presence of at least 28% of dual positive cells expressing 
both H-2Kb and H-2Kd  molecules demonstrates the co-existence and stable transcription 
of two genomes in single fusion hybrid cell. 
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Figure 16. Dual staining of HM-1 ES and FH cell derived day 4EBs to perform 
simultaneous check for expression of H-2Kb and H-2Kd MHC-I haplotypes.  A) HM-1 ES 
derived day 4 EBs stained with either H-2Kb FITC or H-2Kd PE antibody or both antibodies 
together. B) FH clone 4.2 derived day 4 EBs stained with either H-2Kb FITC or H-2Kd PE 
antibody or both antibodies together. 
 
4.1.5 Expression of somatic CD markers on fusion hybrid cells 
Upon reprogramming somatic cell is expected to loose its somatic marker as a result of 
unidirectional reprogramming towards pluripotency depending on the extent of 
reprogramming that has occurred in fusion hybrid cells. To elucidate this, we checked 
the expression of markers of the lymphoid lineage that are usually expressed on 
spleenocytes and bone marrow cells (somatic fusing partners). Using spleenocytes as 
positive control cells, we found that 97%, 35%, 57% and 39% f these cells expressed 
antigens specific for leukocytes (CD45), monocytes/macrophages (CD11b), B 
lymphocytes (CD19) and T lymphocytes (CD3a), respectively (Fig. 17A). 
Undifferentiated HM-1 ES cells did not express any of these markers (Fig. 17B). The 
fusion hybrid cells in undifferentiated state also did not express significant levels of 
CD45, CD11b and CD19 antigens, but low levels of T cell antigen CD3a was expressed 
on 2.4% of cells (Fig. 17C). This could be attributed to the actively transcribing somatic 
genome coexisting with ES cell genome within the small fraction of fusion hybrid cells 
due to incomplete epigenetic reprogramming of specific regions of the somatic genome. 
These results demonstrate that the somatic genome has been dominated by chromatin 
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modifying factors expressed by the ES cell genome leading to silencing of the somatic 
cell genes in the FH cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Expression of markers somatic cell markers (lymphoid lineage) on fusion 
hybrid cells in undifferentiated state. Flow cytometric analysis of the expression of surface 
antigens CD45, CD11b, CD19 and CD3a on spleenocytes (A) undifferentiated HM-1 ES cells 
(B) and undifferentiated fusion clone 4.2 cells (C) . 
 
4.1.6 Cardiac differentiation of fusion hybrid clones 
Mouse ES cells can bring about reprogramming of somatic cells and thus lead to the 
generation of hybrid cells that harbour a dominating ES nucleus in the tetraploid 
genome. These reprogrammed ES like FH cells could now be used as model systems to 
study the developmental processes in line with those on conventional ES cells.  
First question that is addressed here is can the tetraploid cells differentiate into cardiac 
lineage as normal ES cells do. Secondly what are the physiological characteristics of the 
cardiac cells derived from tetraploid cells and will they exhibit any altered physiology. 
What will be the maturation state of the myocytes.  
The cardiac differentiation potential of the FH cell was tested by subjecting the FH cells 
to spontaneous differentiation using hanging drop method. We routinely differentiated 
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clone 2.1 and clone 4.2 and used these clones in our study. The cardiac cells derived 
form fusion cells expressed cardiac specific genes αMHC, Mlc2v and cardiac troponin 
T (cTnT), which were strongly enriched in EBs on day 16 of differentiation (Fig. 18A). 
Immunocytochemical stainings for cardiac specific proteins α-actinin and cTnT 
revealed the cross striation pattern typical for CM derived from conventional ES cells 
(Fig. 18B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Cardiac differentiation of fusion hybrid cells. RT-PCR analysis for expression of 
cardiac genes and a house keeping gene GAPDH in FH clones 2.1 and 4.2 (A). 
Immunostainings for α-actinin and cardiac troponin T in HM-1 ES cell- and fusion hybrid 
derived-CMs at day 16 of differentiation. Scale bars=100 μm.  
 
 
4.1.7 Electrophysiological properties of fusion hybrid-derived 
cardiomyocytes 
Characteristics of spontaneous action potential (AP) in FH derived CM 
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In order to understand the physiology of CMs derived from FH cells, Action potential 
(AP) recording on single cardiac cells (obtained by dissociation of beating and plating 
on fibronectin coated dishes) was performed. Two stages of differentiation were 
assessed, early differentiation stage (EDS- between day 16 and day 20 of 
differentiation.) and late differentiation stage (LDS- between day 30 and day 40). 
Fusion-derived CM and ES-CM were characterized into different phenotypes, by 
analyzing of spontaneous action potentials (AP) at EDS and LDS (Fig. 19). In all CM 
types, all AP types were found at EDS and LDS (Fig. 19) their distribution, however, 
changed during the differentiation. At EDS, most CM of all types displayed pacemaker-
like AP, the amount was 77% of ES-CM, 66% of 2.1-CM, and 67% of 4.2-CM (Table 
1). Minor differences in AP parameters observed between EDS and LDS reflect these 
changes in AP distribution (Table 1). AP parameters were similar between fusion-
derived CM and ES-CM, when corresponding AP types are compared. 
 
Effect of muscarinic and β-adrenergic receptor agonists on AP frequency. 
Carbachol (CCh), a synthetic acetylcholine analog, was applied to investigate the 
muscarinic signaling. CCh evoked a significant reduction of AP frequency by 53±12% 
in ES-CM (n=9, p<0.01), by 61±9% in FH2.1-CM (n=10, p<0.001), and by 44±7% in 
FH4.2-CM in EDS (n=10, p<0.05; Fig. 20 A). In ES-CM and FH 4.2-CM and FH2.1 
CM CCh impact was similar at EDS. Negative chronotropic effects of CCh were 
reversible upon washout (Fig. 20A right panels). 
We also examined the CM response to β-adrenergic regulation with isoproterenol (Iso). 
When 1 μM Iso was administered to EDS (Fig. 20B), an increase of AP frequency was 
observed. At EDS, Iso increased the AP frequency by 69±22% in ES-CM (n=9, 
p<0.01), by 111±28% in FH 2.1-CM (n=14, p<0.001), and by 39±19% in FH 4.2-CM 
(n=18, p>0.05; Fig. 20B). At LDS, Iso increased the AP frequency by 60±20% in ES-
CM (n=12, p>0.05), by 181±77% in FH 2.1-CM (n=7, p<0.05), and by 52±13% in FH 
4.2-CM (n=13, p<0.01). Positive chronotropic effects of Iso were reversible upon 
washout (Fig. 20, right panels). 
The action potentials recordings suggest that FH cell differentiate and form all three 
cardiac subtypes, atrial ventricular and pacemaker type in similar way like ES cells. 
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Response to β-adrenergic and muscarinic agonists suggests the presence of intact 
receptors as in fully functional cardiac cells. The response observed in FH derived CM 
was the same as observed for ES-CM. These observations suggests that FH derived CM 
have normal physiology despite originating from chromosomally abnormal cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Cardiac subtypes derived form in vitro differentiation of HM-1, F2.1 and 
FH4.2. Three cardiac subtypes–atrial like, pacemaker like and ventricular like cells could be 
obtained at day16 of differentiation.  
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Figure 20. Chronotropic response of HM-1-ES and FH clone 2.1 and 4.2 derived EDS CM. 
(A) Negative chronotropic response to carbachol (B) Positive chronotropic response to 
isoproterenol. 
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The results of my studies on FH cells and the CMs derived from them suggest that: 
  
1. Fusion between somatic cells and ES cells leads to a reprogrammed pluripotent 
state in the FH cells. 
2. The FH cells carry a tetraploid genome through many passages but retain the 
same cardiac developmental potential as that of ES cells. 
3. The FH derived EBs also maintain a tetraploid state during differentiation. 
4. Expression of MHC class-I molecules corresponding to both fusing partners 
elaborated on the fusion nature of FH cells. 
5. FH cells failed to express somatic markers relative to their somatic fusion 
partner demonstrating the dominance of ES cell genome in the FH cells. 
6. The CMs derived from FH cells demonstrated normal cardiac structure and 
mature into three functional cardiac subtypes of atrial, ventricular and pace 
maker like cells as demonstrated by their AP parameters. 
7. The CMs demonstrated intact β-adrenergic and muscarinic signaling thus 
suggesting normal function of CMs. 
8. The ploidy state of the cardiac cell genome could not be determined due to 
heterogeneous cell population obtained in spontaneous differentiation by EB 
formation. 
In the light of developments taking place in the filed of stem cells during 2006, another 
source of cardiac cells emerged from a very efficient way of reprogramming. The iPS 
cells were fast proving to be developmentally similar to ES cells. Cardiac cells derived 
from fully reprogrammed cells like iPS present a platform to study the stability of the 
differentiated state of cells during a developmental process. iPS cells have advantage 
over pluripotent FH cells, as iPS cells meet all the criteria for pluripotency, including 
germline transmission and live pups after tetraploid complementation (Meissner et al. 
2007; Okita et al. 2007; Wernig et al. 2007). Fusion hybrid cells, however, may not 
develop into the germ cells after blastocyst injection, due to the tetraploidy of the cells. 
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4.2   Advancement of methods for iPS cell generation  
 
4.2.1 Instability of the genetically unmodified iPS cell line TiB7-4 
The iPS cell lines TiB7-4 were generated by Alexander Meissner and Marius Wernig at 
the laboratory of Rudolf Jaenisch at the Whitehead Institute of Technology, MA, USA. 
Retroviral transduction of wild type murine tail tip fibroblasts with Oct4, Sox2, cMyc 
and Klf4 was performed to generate genetically unmodified iPS cell line TiB7-4 
(Meissner et al. 2007; Wernig et al. 2007). This cell line more closely fulfilled the 
criteria requirement of no genetic modification as our intention was to study the impact 
of reprogramming imposed on the properties of differentiated derivatives like cardiac 
cells. 
TiB7-4 iPS cells were cultivated on MEFs in the presence of LIF. Interestingly, 
observations on the morphology of the colonies at various passages showed that this iPS 
cell line was not stably maintaining its morphology and thus its pluripotency. In early 
passages (p7) some colonies resembled an elliptical, sharp-bordered morphology typical 
for undifferentiated murine ES cells, but there were few colonies that lost this typical 
colony shape and appeared as loose colonies breaking into single cells. With increase in 
passage number this morphology turned more heterogeneous and all compact colonies 
disappeared. (Fig.  21A). The visual observation was confirmed by determining the 
percentage of cells that express pluripotency marker SSEA1. Flow cytometric analysis 
was performed on cells stained with SSEA1 at passages 7, 9 and 14 (Fig. 21B). 54% of 
the cells expressed SSEA1 at passage 7. A strong reduction in this percentage was 
noticed in later passages with only 38% positive cells at passage 9 and 41% at passage 
14. This implies that the cells lost pluripotency with each passage and therefore TiB7.4 
cells were unstable pluripotent cells. 
4.2.2 UTF1-Neo selection of pluripotent iPS cell sub clones from 
TiB7.4  
To enrich for pluripotent cells from the non-homogenous population of TiB7-4 cells, we 
hypothesized the insertion of pluripotency marker driving antibiotic selection into the 
iPS cells (Tan et al. 2007). Hence UTF1-Neo was used as a selection vector. In this 
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vector, the neomycin resistance gene is under the control of the promoter of the UTF1 
gene, which is specifically expressed in pluripotent ES cells and is rapidly down 
regulated upon ESC differentiation). Hence, iPS cells stably expressing the neomycin 
resistance gene only in pluripotent state should be stabilized in an undifferentiated state 
in the presence of Neomycin (also known as G418). To test this hypothesis, TiB7-4 
cells were electroporated with circular UTF1-Neo plasmid and selected with G418 
beginning 24 hours after the transfection. During the G418 selection several colonies 
arose. Out of these colonies three were isolated two weeks after the electroporation and 
expanded as sub clones UTF-1, UTF-2 and UTF-3. No further selection with G418 was 
applied. UTF-1, -2 and –3 were subculture for 40 passages and displayed homogenous 
colonies with elliptical shape and sharp borders (Fig. 22A). The expression of Stage 
Specific Embryonic Antigen 1 (SSEA1) was checked as a marker of pluripotency. At passage 
4 and above, the SSEA1 surface antigen was expressed on 91%, 95% and 87% of UTF-
1, UTF-2 and UTF-3 cells, respectively and remained so at later passages (Fig.  21B). 
For example, at passage 11, the fraction of SSEA1 positive cells for UTF-1, UTF-2 and 
UTF-3 clones was 95%, 94% and 98%, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Morphology and SSEA 1 expression of wild type TiB7-4 iPS cells. (A) 
Morphology of TiB7-4 iPS cells at different passages in cell culture. (B) Expression of SSEA1 
at different passages as determined by flow cytometry. M1 and M2 is the percentage of cells 
stained negative and positive respectively for SSEA1. Figures taken from own publication No. 2 
(Pfannkuche et al. 2010). 
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These data suggest that UTF1 selection generates pluripotent clones of TiB7-4 iPS cells 
that could be maintained stably for up to 40 passages even in the absence of drug 
selection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Characterization of three individual, UTF1-Neo selected iPS cell clones UTF-1, 
-2 and -3 derived from TiB7-4 cells. (A) Morphology of UTF-Neo selected iPS cells six and 
forty passages after transfection. Selection with G418 was performed only until initial isolation 
of colonies. (B) Expression of SSEA1 of UTF-1, -2 and –3 as indicated by flow cytometry four 
and eleven passages after transfection. (D) Alkaline phosphatase staining of UTF-1, -2 and –3 
iPS cells sub clones at passage 4, 11 and 9. M1 and M2 is the percentage of cells stained 
negative and positive respectively for SSEA1. Figures taken from own publication No. 2 
(Pfannkuche et al. 2010).   
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4.2.3  Analysis of TiB7-4 sub clones derived from TiB7-4 with 
SV40-Neo selection  
To rule out effects generated by electroporation or by selection for highly proliferative 
sub clones, a control SV40-Neo vector was transfected into TiB7-4 parental iPS cells. 
The SV40-Neo vector expresses resistance against G418 and is driven by the 
ubiquitously active early SV40 promoter. G418 selection then resulted in a variety of 
clones. In a first experiment, ten clones of the SV40-Neo transfected TiB7-4 were 
randomly selected and isolated. Morphology of these clones varied, ranging from ES 
cell-like to differentiated colonies. Flow cytometric analysis of these clones at passage 3 
resulted in different fractions of cells that were positive for the pluripotency marker 
SSEA1. In a second experiment, TiB7-4 cells were again transfected with SV40-Neo 
and subsequently selected with G418. Six clones with a typical morphology for murine 
ES cells were isolated and expanded. Stable integration of the SV40-Neo selection 
marker was confirmed by PCR amplification using genomic DNA of sub clones and 
primers for the SV40 promoter and the Neomycin resistance gene. The morphology of 
the colonies was analyzed at passages 3, 7 and 12 after transfection (Fig.23A, B). At 
early passage, all six clones formed colonies that resembled the typical shape of mouse 
ES cells but spontaneous differentiation set in after further passaging and resulted in a 
fragmentation of the colonies at passage 8 in the SV40-Neo transfected clone 1 (Fig. 
23A) and clones 2, 3 and 6. The observed loss of regular colony morphology was even 
more pronounced at passage 12. Remarkably, there was no such change in colony 
morphology seen in clone 4 (Fig. 23B). 
To determine whether the loss of typical ESC-like colony morphology in majority of 
stable SV40-Neo transfectants was related to loss of pluripotency marker SSEA1, the 
expression of this marker was analyzed at different passages using six different sub 
clones (Fig. 23C-H). All six clones show similar SSEA1 expression ranging from 80% 
to 89% at passage 3. At passage 7 even higher fraction of cells expressed SSEA1. 
However, at passage 12 only clones 4 and 5 retained high fraction of SSEA1 positive 
cells (88% and 87%, respectively), while the remaining four clones had almost lost 
SSEA1 expression. These data indicate that UTF-1 Neo selection allows for enrichment 
of pluripotent cells in a specific manner and it is not a result of random effect of 
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electroporation procedure or selection of highly proliferative sub clones as the clones 
generated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23.  Morphology and SSEA 1 expression of SV40-Neo transfected control clones. 
(a-b) Colony morphology of SV40-Neo selected clone 1 and 4 at passage 3, 7 and 12 after 
transfection. (c-h) SSEA1 expression of SV40-Neo selected clones 1-6 at the three different 
passages after transfection as determined by flow cytometry. M1 and M2 is the percentage of 
cells stained negative and positive respectively for SSEA1. Figures taken from own publication 
No. 2 (Pfannkuche et al. 2010). 
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Thus, selection of iPS cells based on colony morphology is not sufficient to prove the 
fully reprogrammed state of the cells and a stable pluripotent phenotype.Thus, the 
morphological observation of the iPS cell line TiB7.4 led to the improvisation in the 
method to effectively isolate fully reprogrammed clones of iPS cells based on UTF-1 
Neo selection. 
4.3  Generation of transgenic iPS cells that will allow purification of 
cardiomyocytes 
In depth analysis of the differentiated progeny from iPS cells is crucial before 
concluding on the similarity of ES and iPS cells. Research on iPS cells promises major 
application including in vitro developmental studies, for understanding disease 
pathologies and physiological pathways, toxicological testing, and for epigenetic 
studies. For such application of iPS cells, CMs as a differentiated derivative of iPS cells 
can serve as a model system. This study was aimed at performing high throughput 
molecular, phenotypic, physiologic and genomic characterization of cardiac cells 
derived by invitro differentiation of iPS cells as a pure population. To implement all the 
applications of iPS cells, there is requirement for robust supply of differentiated 
derivatives of iPS cells in a pure and homogenous form. Homogenous cell population 
enables a controlled analysis on various physiological and transcriptional processes. 
 iPS cells exhibit pluripotency and can differentiate in vitro into multiple lineages 
including CMs. When iPS cells are allowed to differentiate in vitro, they form cells of 
all three lineages, the ectoderm, mesoderm and endoderm. CMs can be easily identified 
during the differentiation of iPS cells as spontaneously beating areas within spherical 
embryoid bodies (EBs). But these beating EBs also contain cells of other lineages and 
thus make it difficult to obtain CMs in high purity. Therefore, we aimed at generating a 
transgenic iPS cell line to be able to purify CMs. We used the αPIG vector, in which 
cardiac α-myosin heavy chain (αMHC) promoter drives the expression of puromycin 
N- acetyltransferase (PAC) and the internal ribosomal entry site (IRES) flanked 
enhanced green fluorescent protein (eGFP), to genetically modify murine iPS cells to 
stably express PAC and eGFP specifically in CMs.  
TiB7-4 iPS cells were electroporated with αPiG vector as described in the Methods 
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section. Resistant colonies were selected by addition of neomycin at a concentration of 
500µg/ml. About 30 colonies were picked and sub cultured as separate clones. 8 clones 
were randomly chosen for cardiac differentiation and the others were frozen in multiple 
batches. Five clones could reproducibly differentiate into EBs containing spontaneously 
beating, green fluorescing areas, which first appeared on day 8-9 of differentiation. Three 
clones, αPIG-iPS clone 25, αPIG-iPS clone 15 and αPIG-iPS clone 11 were routinely 
used for cardiac differentiation. All data described here was generated with αPIG-iPS 
clone 25. The transgenic murine D3 ES cell line αPIG-ES (clone 44) was generated with 
the same αPIG vector previously (Kolossov et al. 1998) and was used for comparative 
analyses. 
4.3.1 Transgenic iPS cells retain their pluripotential characteristics 
When cultured on MEFs, undifferentiated murine iPS cells formed colonies very similar 
to murine ES cells (Fig. 24A). Undifferentiated ES and iPS cells appeared as tightly 
packed colonies with high nucleus/cytoplasm ratios. Within the colonies, iPS and ES 
cells had distinct margins and were positive for Oct4 (Fig. 24B) and ALP (Fig. 24C), and 
more than 90% of cells expressed SSEA1 on their surface (Fig. 24D). 
 
  
  
 
 
 
 
 
 
 
 
Figure 24. Expression of pluripotency markers on undifferentiated transgenic murine iPS 
and ES cells. A) Undifferentiated colonies on mitotically inactivated MEFs. Colonies were 
immuno-positive for Oct4 (B) and ALP (C). D) Flow cytometric analysis of expression of 
SSEA1 on ES and iPS undifferentiated cells. Scale bars=100 µm. 
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4.3.2 Transgenic iPS cells efficiently form EBs with a kinetic similar 
to that of ES cells 
The iPS cells when differentiated by withdrawal of LIF and cultured in non-adherent 
bacterial dishes on an orbital shaker readily formed EBs. At day 2 of differentiation, 
these EBs were transferred to a 200 ml spinner flask where they differentiated further to 
cells of different lineages. The kinetics of the growth of EBs was monitored by 
withdrawing a small number of EBs from the spinner flask at various intervals (day 2-
16) and acquiring images through a light microscope and determining their diameter 
using the Axiovision Software. These analyses revealed that iPS cells differentiated to 
multi-cellular EBs with kinetics similar to that of ES cells (Fig. 25).  
 
A.                                                                B.  
 
 
 
 
 
 
 
 
 
Figure 25. Kinetics of differentiation of 
αPIG-iPS and αPIG-ES. (A) Phase contrast 
images of EBs at different days of 
differentiation. (B) Kinetics of growth of EBs 
derived form ES and iPS cells during 
differentiation. The data are expressed as mean 
± s.e.m. and were derived from at least 3 
independent differentiations. 
Scale bar =500μm. 
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4.3.3 Drug selection yields highly purified iPS-CMs 
During the course of spinner flask differentiation of ES and iPS cells, multiple lineages 
are formed within the EBs. At day 9, the formation of cardiac lineage was identified by 
appearance of contracting areas within EBs. When visualized under a florescence 
microscope the contracting areas showed GFP florescence (Fig. 26A). Purification of 
the cardiac cells was initiated by addition of puromycin at day 9. After 7 days of 
puromycin treatment, all non-cardiac cells in EBs were eliminated and the resistant cells 
survived as GFP-positive clusters exhibiting vigorous spontaneous contractile activity 
(Fig. 26B, C).  
 
 
 
 
 
 
 
 
 
 
 
      
Figure 26. Embryoid bodies formed from transgenic ES and iPS cells and purification of 
cardiac clusters. (A) Phase contrast images of day 16 EBs derived from ES and iPS cells 
without puromycin treatment. (B) Phase contrast images of day 16 cardiac clusters derived from 
ES and iPS cells after puromycin treatment. (C) Florescence images of GFP fluorescing purified 
cardiac clusters. Scale bars=100 μm. 
 
To assess the purity, after 7 days of puromycin treatment cardiac clusters were 
dissociated to single cells. Flow cytometric analysis revealed that cardiac clusters 
consisted almost exclusively of CMs (>97%, Fig. 27A, B). After drug selection, αPIG-
iPS and αPIG-ES cells yielded comparable number of CMs (2.7±1.4 vs 2.0±1.6 CMs 
per each ES or iPS cell initially taken for differentiation, Fig. 27C).  
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Figure 27. Purity of iPS-CMs and ES-CMs. (A) Flow cytometric estimation of the purity of 
cardiac clusters at day 16 of differentiation. Left panels show percentage of GFP positive cells 
in EBs before purification and right panels show percentage of GFP positive cells after 
purification with 8 μg/ml puromycin for 7 days. (B) Florescence image of plated purified CMs 
after dissociation into single cells. Scale bars=100 μm. (C) The yield of purified CMs obtained 
after differentiation of ES/iPS cells. (D) Pluripotent stem cell colonies obtained after plating of 
purified CMs derived from ES and iPS cells on MEFs. 
 
To further determine the presence of any contaminating undifferentiated cells that had 
survived the selection procedure, purified cardiac clusters were also subjected to 
teratoma formation assay. Purified iPS-CMs and ES-CMs obtained after 7 days of 
puromycin treatment were injected subcutaneously into immunodeficient Rag2-/-γc-/- 
mice and teratoma formation was monitored over a period of three months. The 
experiments were controlled by injecting undifferentiated iPS and ES cells in parallel 
animals. No teratomas were detected in animals injected with iPS-CMs, suggesting that 
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these cells were highly pure. However, teratoma was formed in animals that received 
ES-CMs, which is indicative of their significant contamination with ES cells. 
 
Table 2. Assessment of purity of iPS cell- and ES cell-derived cardiomyocytes by 
teratoma induction assay in vivo  
Cell type* # of cells injected s.c. # of animals injected # of tumours detected 
iPS 0.4x10E6 1 1 
iPS 1.0x10E6 4 4 
iPS 2.0x10E6 3 3 
    
ES 1.0x10E6 2 2 
ES 1.0x10E6 2 2 
ES 2.0x10E6 1 1 
    
iPS-CM 0.4x10E6 2 0 
iPS-CM 1.0x10E6 3 0 
iPS-CM 2.0x10E6 3 0 
    
ES-CM 0.4x10E6 1 1 
    
 
* The indicated number of undifferentiated αPIG-iPS or αPIG-ES cells or puromycin-selected day 16 
αPIG-iPS-CMs or αPIG-ES-CMs was injected subcutaneously in Rag2-/-γc-/- immunodeficient animals 
and teratoma occurrence was monitored over the period of three months. 
In order to quantify the number of contaminating pluripotent stem cells in CM 
preparations, single cardiac cells were plated on irradiated MEFs in ES cell medium 
containing LIF but no puromycin. This culture facilitates the growth of remnant 
undifferentiated cells. Presence of one contaminating ES cell leads to the formation of 
one colony. The number of ES cell colonies was monitored after 2 weeks of culture 
using crystal violet staining. The results of this colony forming assay are tabulated in 
Table 2. iPS-CMs were found to be highly pure and devoid of any contamination form 
undifferentiated cells. In contrast, the purity of ES-CMs differed between batches 
sometimes with no colonies and sometimes with as high as 30 colonies per one million 
of seeded CMs. 
 To further assess the purity of iPS-CMs, dissociated CMs were cultured on MEFs for 
14 days under ES cell culture conditions to detect rare contaminating pluripotent stem 
cells. In seven independent experiments no pluripotent stem cell colonies were detected 
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after seeding 0.1-0.5x106 drug-selected iPS-CMs/ plate (Fig. 27D, right panel). 
However, ES cell-derived CMs still contained some undifferentiated ES cells, although 
the contamination level was very low (20ES cells per 1x106 CMs) (Fig. 27D, left 
panel). Thus, puromycin selection allows for generation of highly purified αPIG-iPS-
CMs. 
Table 3. iPS or ES cell colony forming assay 
Differentiation* Cell type # of cells plated # of iPS cell colonies detected Observation time 
1 iPS-CM 0.1x106 0 2 weeks 
  0.1x106 0 2 weeks 
2 iPS-CM 0.5x106 0 2 weeks 
  0.5x106 0 2 weeks 
3 iPS-CM 0.3x106 0 2 weeks 
  0.3x106 0 2 weeks 
4 iPS-CM 0.3x106 0 2 weeks 
  0.3x106 0 2 weeks 
5 iPS-CM 0.8x106 0 2 weeks 
6 iPS-CM 0.5x106 0 2 weeks 
7 iPS-CM 0.5x106 0 2 weeks 
  
# of colonies: 0±0 per 1x106 CMs, 
n=11  
Differentiation* Cell type # of cells plated
# of ES cell 
colonies detected 
per plate 
Observation time
1 ES-CM 0.2x106 6 2 weeks 
 ES-CM 0.2x106 1 2 weeks 
 ES-CM 0.2x106 3 2 weeks 
 ES-CM 0.1x106 2 2 weeks 
 ES-CM 0.1x106 2 2 weeks 
2 ES-CM 0.2x106 0 2 weeks 
 ES-CM 0.1x106 0 2 weeks 
3 ES-CM 0.2x106 2 2 weeks 
4 ES-CM 0.3x106 0 2 weeks 
5 ES-CM 0.3x106 9 2 weeks 
 ES-CM 0.3x106 6 2 weeks 
  
# of colonies: 19±9 per 1x106 
CMs, n=8  
 
Finally, we have also determined the purity of CMs by highly sensitive RT-PCR assay. 
We found that the transcript levels for cardiac genes Mef2c, GATA4, NKx2.5, troponin T 
and C and RyR2 were highly enriched in both the ES and iPS cell-derived puromycin-
selected clusters as compared to intact EBs (Fig. 28). In contrast, the transcripts for 
endodermal (AFP) and ectodermal markers (Sox17, CD31) were not detected (Fig. 28) 
in purified CMs. These data indicate that drug selection yields highly pure populations 
of molecularly indistinguishable CMs from both transgenic iPS and ES cell lines. 
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Figure 28. RT-PCR analysis of the genes expressed in αPIG-ES and αPIG-iPS. Expression 
of cardiac genes (A) and non cardiac genes (B) in undifferentiated state (UD), embryoid bodies 
(EB) and in purified CMs (CM) derived from ES and iPS cells.  
 
4.3.4 Virally-encoded Oct4 is incompletely silenced in iPS-CMs 
Since the iPS cells used in this study contain stably integrated retroviral expression 
cassettes, we asked whether any residual expression of viral transgenes can be detected 
in purified cardiac clusters. To distinguish between endogenous and viral transcripts, we 
used primers specific for virally encoded sequences to determine the viral transcripts 
and primers in the 5’ untranslated region to determine the endogenous gene expression. 
The endogenous Oct4, Sox2, Klf4 and c-Myc transcripts were strongly expressed in 
undifferentiated ES and iPS cells and EBs (Fig. 29A). The transcripts for endogenous 
Klf4 and c-Myc were also expressed in iPS- and ES-CMs but the endogenous Sox2 was 
only barely detectable in CMs. The endogenous Oct4 mRNA was weakly expressed 
only in iPS-CMs but not in ES-CMs. As expected, virally encoded transcripts were not 
detectable in ES cells. However, they were expressed at low levels in undifferentiated 
iPS cells and iPS-EBs with exception of Sox2, which was not detected in any of the 
samples. In purified iPS-CMs the viral Klf4 and c-Myc were detectable at very low 
levels. However, viral Oct4 was expressed in iPS-CMs at levels similar to those in 
undifferentiated iPS cells. Hence, retrovirally encoded Oct4 appears to be incompletely 
silenced in iPS-CMs. To firmly exclude the possibility that endogenous Oct4 and Nanog 
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were expressed in purified CMs, we determined the methylation status of Oct4 and 
Nanog promoters in undifferentiated cells and in CMs. We found that Oct4 and Nanog 
promoters were highly methylated in iPS- and ES-CMs and strongly hypo ethylated in 
their undifferentiated counterparts (Fig. 29B). This data support the conclusion that the 
expression of Oct4 in iPS-CMs is purely due to incomplete silencing of viral Oct4 and 
not due to endogenous Oct4 activation or undifferentiated cell impurity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Expression of viral transcripts in αPIG-ES and αPIG-iPS.  (A) Expression of 
viral and endogenous transcripts of the four reprogramming genes Oct4, Sox2, Klf4 and cMyc 
in undifferentiated (UD) ES and iPS cells, and in purified CMs  derived from ES and iPS cells 
(clones 1 and 2). The expression levels are compared with that of housekeeping gene GAPDH 
(right panel). (B)% methylation of endogenous promoters of Nanog and Oct4 loci. 
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4.3.5 Structure of cardiomyocytes derived from iPS and ES cells 
When plated CM cultures were immuno-stained with cardiac specific antibodies, both 
iPS and ES derived CMs demonstrated well-organized cross-striations of sarcomeric α-
actinin, cardiac troponin T, and stained positive for MLC2v (Fig. 30). This proves the 
structural integrity of the CMs derived from both transgenic ES and iPS cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Immunocytochemistry of ES and iPS derived cardiomyocytes. (A) GFP-positive 
ES-CMs and iPS-CMs immunoassayed for (A) Troponin T (B) α-MHC and (C, D) α-actinin. 
Nuclei are stained with Hoechst 33342 (blue). Expression of cardiac genes in ES and iPS 
derived CMs. Scale Bar=50µm (A-C) and 30µm (D). 
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4.3.6 Cardiomyocytes derived from iPS cells are not fully mature 
We compared the structural organization of iPS derived CMs with that of the mouse 
embryonic heart and adult heart. Scanning electron microscopy reveals that the 
organization of microfilaments and contractile apparatus in iPS derived CMs is highly 
disintegrated and less organized in comparison to highly ordered and dense pattern of 
the actin myosin filaments in adult heart. The murine heart at embryonic stage E11.5 
and E16.5 also showed similar disorganized pattern. Therefore the structural pattern 
reveals that the day 20 CMs derived from iPS cells resembles an immature state. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. Ultra structural analysis of iPS-CMs. Scanning electron microscopic images of 
fetal heart at embryonic stage day 11.5 (A), 16.5 (B), adult heart (C) and iPS derived CMs (D). 
The electron microscopy was perfomed by Nadine Lange and Petra Muller in the lab of 
Wolfram Friedrich Neiss. 
 
4.3.7 Intact β-adrenergic and muscarinic signalling in drug-selected 
iPS-CMs 
To characterize the hormonal regulation of iPS-CMs compared to ES-CMs, β-
adrenergic receptor agonist isoproterenol (Iso) and muscarinic receptor agonist 
carbachol (CCh) were applied (Fig. 32A). In both cell types, Iso (1 µM) significantly 
increased the spontaneous AP frequency whereas CCh (10 µM) caused a decrease (Fig. 
32B, left panel). Additionally AP duration at 90% of repolarization (APD90) was 
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shortened and prolonged in the presence of Iso and CCh, respectively (Fig. 32B, right 
panel). Small differences observed between iPS- and ES-CMs were not significant, 
suggesting the existence of intact β-adrenergic and muscarinic signaling cascades in 
lineage-selected αPIG-iPS-CMs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Current-clamp characterization of murine αPiG-ES and αPiG-iPS cell-derived 
cardiomyocytes. (A) Representative action potential (AP) traces showing the effect of Iso 
(1µM) and CCh (1µM) on ES cell- (top panel) and iPS (bottom panel) cell-derived CMs. (B) 
Statistical analysis of the effect of Iso and CCh on the spontaneous AP frequency (left) and on 
the AP duration at 90% of repolarization (APD90).  
 
4.3.8 Functional voltage-gated ion channels in iPS-CMs  
To quantify the expression of functional ion channels in the plasma membrane of iPS-
CMs and ES-CMs, we used the whole-cell voltage-clamp and determined current 
densities by normalizing the maximal current amplitude to the cell size (Fig. 33A). 
There was no significant difference in Na+- and L-type Ca2+-current density between 
iPS-CMs and ES-CMs  Potassium currents in our experiments represent the sum of all 
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depolarization-activated outward components comprised of the transient-outward (Kto) 
and delayed-rectifier K+-currents (ultra-rapidly activating, Kur, rapidly activating, Kr, 
and slowly activating, Ks) as well as leak K+-channels. We measured peak currents 
(Ipeak), and late currents (Isus) at the end of the 500-ms depolarizing pulses and found no 
significant difference in Ipeak and Isus densities between iPS- and ES-CMs. These data 
suggest that K+-channels in iPS-CMs are functional and that the contribution of 
different K+-channels to the net depolarization-activated outward K+-current in drug-
selected iPS-CMs and ES-CMs is comparable. We also determined the current-voltage 
relationships of the Na+-, L-type Ca2+-, and K+-currents, and found that these parameters 
were also indistinguishable between iPS-CMs and ES-CMs for all channels tested (Fig. 
33B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. Functional expression of voltage-gated ion channels in αPIG-ES-CM  and 
αPIG-iPS-CM. (A) Density values of Na+, L-type Ca2+ , and K+ Ipeak  and Isus currents in ES-
CMs and iPS-CMs. (B) Current-voltage relationships of Na+, L-type Ca2+, Ipeak, and Isus K+ 
currents in ES-CM and iPS-CM.  
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4.4 Global transcriptional profiling of iPS and ES cell-derived 
cardiomyocytes 
 
4.4.1   iPS-CMs and ES-CMs are transcriptionally highly similar 
Functional analyses presented above indicate that iPS-CMs are electrophysiologically 
highly similar to those of their ES cell counterparts. Gene expression profiling is one 
important technology to take a global view on gene expression and it might be suited to 
check novel iPS cell lines with respect of their similarity to ES cells. To establish 
whether this functional similarity is mirrored at the molecular level, we compared the 
global gene expression pattern of iPS cells with that of ES cells at various 
developmental stages. 
For global gene expression profiling, cRNAs from undifferentiated ES and iPS cells, 
EBs derived from day 16 ES and iPS cells, puromycin-selected cardiac clusters (CCs) 
derived from ES and iPS cells at day 16 of differentiation and tail tip fibroblasts (TTF) 
of adult mice were hybridized to mouse whole genome Illumina bead chips. 
Experimental samples are summarized in Table 4. Three biological replicates from 
independent experiments were used. All data have been deposited in NCBI's Gene 
Expression Omnibus and are accessible through GEO Series accession number 
GSE18514. 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=nhqtfgmousswodu&acc=GSE18
514  
 
In these analyses, 18339±1358 (40.5±3.0%) probe sets received intensity signals above 
background and among expressed transcripts 5689 (31.0%) were identified as variable 
among samples (coefficient of variation: 0.5-10). We classified all the above samples 
into four distinct developmental stages - undifferentiated stem cells, differentiated cells 
(mixture of different cell types in unselected EBs), pure CMs at early maturation stage 
and adult somatic cells (TTFs). Hierarchical clustering of all variable genes revealed 
that CMs derived from iPS and ES cells cluster closely together and are distinct from 
undifferentiated cells, EBs and fibroblasts (Fig. 34A). Likewise, principal component 
analysis (PCA) with this gene set showed that iPS-CMs and ES-CMs cluster together. 
Distinct clusters were also formed by undifferentiated ES and iPS cells, iPS-EBs and 
ES-EBs, and by TTFs (Fig. 34B). In addition, scatter-plot analysis further emphasized a 
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close correlation of gene expression levels between iPS and ES cells (r²=0.98±0.005, 
n=9), iPS-EBs and ES-EBs (r²=0.97±0.009, n=9), iPS-CMs and ES-CMs 
(r²=0.97±0.003, n=9) but not between iPS cells and fibroblasts (r²=0.82±0.014, n=9), 
(Fig.  34C).  
Table 4. List of samples used for global gene expression profiling on Illumina platform. 
No. Sample name Description Cell line Passage # 
1 D3αPIG-ES _undiff_rep1 murine ES cells (D3αPIG-ES), 
undifferentiated 
D3αPIG-ES 7 
2 D3αPIG-ES _undiff_rep2 murine ES cells (D3αPIG ES), 
undifferentiated 
D3αPIG-ES 9 
3 D3αPIG-ES _undiff_rep3 murine ES cells (D3αPIG ES), 
undifferentiated 
D3αPIG-ES 10 
4 D3αPIG-d16- EB_rep1 mESC-derived embryoid bodies, day 16 of in 
vitro differentiation 
D3αPIG-ES 5 
5 D3αPIG-d16 -EB_rep2 mESC-derived embryoid bodies, day 16 of in 
vitro differentiation 
D3αPIG-ES 15 
6 D3αPIG-d16 -EB_rep3 mESC-derived embryoid bodies, day 16 of in 
vitro differentiation 
D3αPIG-ES 21 
7 D3αPIG-d16- CM_rep1 mESC-derived cardiac clusters, day 16 of in 
vitro differentiation 
D3αPIG-ES 5 
8 D3αPIG-d16 -CM_rep2 mESC-derived cardiac clusters, day 16 of in 
vitro differentiation 
D3αPIG-ES 15 
9 D3αPIG-d16 -CM_rep3 mESC-derived cardiac clusters, day 16 of in 
vitro differentiation 
D3αPIG-ES 21 
10 αPIG-TIB-iPS_undiff_rep1 murine iPS cells (αPIG-TIB-iPS), 
undifferentiated 
iPS clone 25 5 
11 αPIG-TIB-iPS_undiff_rep2 murine iPS cells (αPIG-TIB-iPS), 
undifferentiated 
iPS clone 25 7 
12 αPIG-TIB-iPS_undiff_rep3 murine iPS cells (αPIG-TIB-iPS), 
undifferentiated 
iPS clone 25 8 
13 αPIG-TIB-iPS-d16 EB_rep1 iPS-derived embryoid bodies, day 16 of in 
vitro differentiation 
iPS clone 25 39 
14 αPIG-TIB-iPS-d16 EB_rep2 iPS-derived embryoid bodies, day 16 of in 
vitro differentiation 
iPS clone 25 20 
15 αPIG-TIB-iPS-d16 EB_rep3 iPS-derived embryoid bodies, day 16 of in 
vitro differentiation 
iPS clone 25 21 
16 αPIG-TIB-iPS-d16 
CM_rep1 
iPS-derived cardiac clusters, day 16 of in vitro 
differentiation 
iPS clone 25 39 
17 αPIG-TIB-iPS-d16 
CM_rep2 
iPS-derived cardiac clusters, day 16 of in vitro 
differentiation 
iPS clone 25 20 
18 αPIG-TIB-iPS-d16 
CM_rep3 
iPS-derived cardiac clusters, day 16 of in vitro 
differentiation 
iPS clone 25 21 
19 Adult 129/B6 TTF1_rep1 Tail Tip fibroblasts derived from tail of adult 
mice of strain 129xB6 
Primary cells  2 
20 Adult 129/B6 TTF1_rep2 Tail Tip fibroblasts derived from tail of adult 
mice of strain 129xB6 
Primary cells  3 
21 Adult 129/B6 TTF1_rep3 Tail Tip fibroblasts derived from tail of adult 
mice of strain 129xB6 
Primary cells  4 
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These data demonstrate the close similarity at the global transcriptional level between 
the various developmental stages of iPS and ES cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Global Transcriptional profile of αPIG-iPS cells and αPIG-ES cells. A) 
Hierarchical cluster analysis of variable genes. (B) Principal component analysis. (C) Scatter 
plots showing comparison of global gene expression between αPIG-ES and αPIG-iPS cells; 
αPIGES-EBs and αPIGiPS-EBs; and αPIGES-CMs and αPIGiPS-CMs. Comparison was also 
made with TTF against αPIG-iPS cells.  
Although globally similar, small groups of genes comprising 1.4-2.8% of present 
transcripts were differentially expressed between iPS and ES cell groups at each 
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developmental stage (264 transcripts between undifferentiated iPS and ES cells, 508 
between iPS-EBs and ES-EBs and 400 between iPS-CMs and ES-CMs) (Fig. 35). 
However, these differences were not significantly greater than the difference between 
undifferentiated iPS and ES cells or between different ES cell or different iPS cell lines 
as reported by others (Chin et al. 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  35. Differential gene expression chart of different developmental stages of ES and 
iPS cells.  
 
4.4.2  Enriched functional categories in purified cardiac clusters 
In order to determine which biological terms are enriched in iPS-CMs compared to ES-
CMs. About 3000 probe sets were found to be differentially expressed (p-value adjusted 
for multiple testing using Benjamini-Hochberg correction smaller than 0.05 and fold 
change above ±2) between CMs and EBs and between CMs and fibroblasts.  A total of 
1478 genes were upregulated in iPS-CMs compared to iPS-EBs. In addition, 
comparison of iPS-CMs and TTFs revealed 1666 upregulated genes in iPS-CMs. In 
order to identify the most important biological processes, molecular functions, cellular 
components and pathways that are significantly enriched in drug-selected CMs, we 
performed the functional annotation clustering analysis using DAVID (Huang et al. 
2009). Using the enrichment score of >3 as a threshold for significantly enriched 
categories we obtained 16 overrepresented annotation clusters that belonged into two 
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major groups (Table 5). The first group consists of 10 clusters containing GO terms of 
biological processes such as mitochondrion, oxidative phosphorylation, tricarboxylic 
acid cycle, and mitochondrial electron transport chain and glucose metabolism. The 
second group contained clusters with GO terms contractile fiber, myofibril assembly, 
sarcomere, heart development and cardiac cell differentiation. All these categories are 
known essential components of the functional cardiac phenotype and were similarly 
enriched in both iPS- and ES-CMs.  
 
Thus, by generating highly purified CMs from transgenic murine iPS and (ES) cell 
lines, we derive the following information: 
 
1. iPS and ES cells differentiated into CMs at comparable efficiencies yielding 
highly purified CMs after drug selection. 
2.  Purified iPS- and ES-CMs exhibited indistinguishable structural properties, 
similarly responded to pharmacological agents, expressed functional voltage-
gated sodium, calcium and potassium channels and possessed comparable 
current densities.  
3. Global transcriptional profile and gene ontology signature of transgenic iPS-
CMs were very similar to that of ES-CMs but clearly distinct from fibroblasts 
used to generate iPS cells and differentiated cells in iPS or ES cell-derived 
embryoid bodies.  
4. After 7 days of puromycin selection, iPS-CMs did not contain any residual 
pluripotent cells nor formed teratoma in vivo, while ES-CMs still showed 
contamination with undifferentiated cells and occasionally gave rise to teratoma 
after transplantation. 
Thus, drug selection allows for production of large quantities of iPS-CMs that are 
functionally and molecularly indistinguishable from their ES cell counterparts. The 
availability of pure iPS-CMs will permit assessment of their utility for myocardial repair 
in vivo, development of improved protocols for cardiac differentiation of iPS cells, and 
validation of their applicability for pharmacological and toxicological applications. 
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Table 5. Functional annotation clustering performed in DAVID of genes upregulated in 
cardiomyocytes in iPS-CM vs. iPS-EB, ES-CM vs ES-EB and iPS-CM vs TTF 
comparisons. 
 
  Enrichment score 
Annotation 
cluster Descriptor functional categories 
iPS-
CM 
vs 
iPS-
EB 
ES-
CM  
vs 
ES-
EB 
iPS-
CM 
vs 
TTF 
1 
Mitochondrion, oxidative phosphorylation, respiratory 
chain 43,41 32,24 49,93
2 Cytoplasm, intracellular organelle 28,91 25,59 n.d. 
3 Tricarboxylic acid (TCA) cycle, cellular respiration, catabolic process 14,12 8,54 13,46
4 Contractile fiber, myofibril, sarcomere, I band, Z band 13,77 14,61 11,05
5 
Transmembrane transporter-, oxidoreductase-, 
cytochrome c oxidase- and hydrogen ion transmembrane 
transport-activity 
12,97 11,83 14,63
6 NADH dehydrogenase (ubiquinon) activity 10,24 6,35 12,44
7 Cardiomyopathy 7,71 6,42 n.d. 
8 
Glucose/hexose metabolic process, monosaccharide 
catabolic process 6,77 5,81 4,55 
9 Mitochondrial matrix and lumen, mitochondrial ribosome 6,41 4,98 5,85 
10 Heart development and morphogenesis, myofibril assembly, actomyosin structure organisation,  4,66 4,65 5,43 
11 Proton transporting ATP-synthase complex, energy coupled proton transport 4,31 3,59 5,88 
12 Cellular polysaccharide-, energy reserve- and glucan-metabolic process 4,27 n.d. n.d. 
13 Mitochondrial respiratory chain, NADH dehydrogenase complex 3,87 n.d. 4,03 
14 M band, A band 3,29 3,11 n.d. 
15 Iron-sulfur- and metal-cluster binding 3,03 n.d. 4,35 
16 Sarcoplasmic reticulum, sarcoplasm n.d. n.d. 3,12 
n.d. – not detected; TTF – adult tail tip fibroblasts 
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5 D ISCUSSION 
Although reprogrammed cells are seemingly similar to ES cells, an in depth comparison 
of the pluripotent cell types is obviously essential. Accordingly CMs derived from 
diverse pluripotent cells. CMs can serve as a model system to understand the 
developmental process of the heart. Elucidating the role of structural proteins, 
understanding the signaling process of the maturation of the cardiac cells, functional 
regulation of proteins in the heart are important biological studies that can be 
undertaken when there is robust supply of CMs at hand. The rapid in vitro 
differentiation of mouse pluripotent cells into functional CMs provides a renewable 
source of CMs for such studies. 
5.1 Reprogramming by fusion 
In the present study, we have shown that somatic cells (bone marrow cells and 
spleenocytes) could be successfully reprogrammed by fusion with HGPRT-/- HM-1 ES 
cells. We have shown that PEG could efficiently induce the fusion of ES cells with 
somatic cells and that the resulting hybrid cells could be selected based on resistance to 
HAT. Hybrid lines expressed characteristics of normal ES cells, including apparent 
immortality in culture, ES cell-like colony morphology, and pluripotency by formation 
of differentiated cells derived from the three embryonic germ layers in vitro. The 
resulting hybrids carried a near tetraploid genome, suggesting existence of genome from 
both parental cells together. We confirmed the existence of both parental genomes by 
comprehensive analysis of the SNP variations in the genome of the hybrid cells. The 
presence of two individual alleles on each chromosome indicated the presence of two 
genomes in the hybrid cells. In 3 out of four clones tested, 19 SNP sites consisted of two 
alleles of parental types. Only one clone (clone 1.2) carried only one allele of SNP5 and 
SNP10 on chromosome 5 and 10 respectively. This could be due to loss of sister 
chromatid in FH clone 1.2 as represented by near tetraploid genome. The lack of 
expression of tissue specific surface markers on FH cells in their undifferentiated state 
and the fact that the hybrid cells exhibit the phenotype of ES cells and not that of the 
spleenocytes or bone marrow cells illustrates the dominance of the ES genome over the 
differentiated cell genome. Therefore pluripotency seems to behave as a dominant trait 
in the hybrid cell genome. These findings show the remarkable capability of ES cells to 
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override the adult somatic cell program, as seen after SCNT (Campbell et al. 1996). Our 
results are similar to prior findings by Ying et al. who also detected tetraploid cells after 
cell fusion with ES cells (Ying et al. 2002). 
The coexistence of both parental genomes was confirmed in FH cells by detecting the 
MHC class I molecules specific for each parental cell type. As shown in Fig. 15 and 16, 
the EBs derived from FH cells at day 4 of differentiation, when induced with IFNγ, 
expressed MHC class I molecules of both haplotypes H-2Kb and H-2Kd on the surface 
of positive cells. Only 28% of the cells expressed both MHC class I molecules whereas 
48% cells expressed only H-2Kd. All cells that expressed H-2Kb also expressed H-2Kd 
but not vice versa. The expression of somatic genes in differentiated derivatives of FH 
cells clearly suggests ‘somatic memory’ of the reprogrammed genome in a fraction of 
the cells. Speculation of the lack of expression of somatic genes in a majority of the 
cells can be based on dominance of fully reprogrammed genome but before we make 
any conclusions the technical difficulties of staining two surface antigens together on a 
single cell need to be resolved.  
In this study we addressed the question of characteristics and functionality of CMs 
derived from FH cells which have been demonstrated to be near tetraploid. Tetraploid 
FH cells have been shown to contribute to chimeras after blastocyst injection (Matveeva 
et al. 1998), but only limited data exists on their differentiation ability in vitro. In our 
experiments, sspontaneous differentiation of hybrid cells in hanging drops lead to the 
appearance of beating areas in plated EBs. The onset of beating in hybrid cells was 
relatively delayed compared to what is routinely observed in conventional ES cells. This 
could be attributed to the ploidy state or strain of reprogramming imposed on FH cells. 
Late onset of beating has also been reported for certain iPS cell lines (Pfannkuche et al. 
2009). Although cardiac differentiation is delayed in fusion hybrid cells, they can 
efficiently differentiate to form functional CMs. CMs derived from FH clone 2.1 and 
4.2 demonstrated typical molecular and structural characteristics of CMs. FH derived 
CM demonstrated intact β-adrenergic and muscarinic regulation and exhibited action 
potential parameters resembling that of three subtypes of CMs including ventricular, 
atrial and nodal phenotype. The atrial phenotype was the predominant one in fusion 
derived CMs whereas HM-1 ES derived CM mostly consisted of ventricular-like 
phenotype. There is also a difference between CM derived from the fusion-generated 
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clones and iPS-derived CM, as latter mostly reveals AP of ventricular phenotype 
(Kuzmenkin et al. 2009). This different cell fate might result from different 
reprogramming approaches and might reflect a different manifestation of somatic 
memory in FH derived CM reflecting the origin of cell. 
 ES cell-derived factors are capable of reverting the somatic cell genome into a 
pluripotent state in FH cells containing a near tetraploid genome but demonstrating an 
equivalent cardiac differentiation potential as that of ES cells. EBs derived from FH 
cells maintain tetraploid and contain CMs. But ploidy of CMs could not be determined 
in this study because of the heterogenous nature of spontaneous in vitro differentiation 
of FH cells. Thus, reprogramming does not affect the cardiac differentiation potential of 
hybrid cells and does not lead to any aberration in the molecular structural and 
functional characteristics of cardiac derivatives. The cell fusion approach is useful as a 
tool for investigating the mechanism of cellular plasticity and reprogramming. This 
method has also proven to be very powerful for investigating factors required for 
reprogramming of somatic nucleus into a pluripotent state (Lluis et al. 2008; Wong et 
al. 2008). 
5.2 Advancement of the method for iPS cell generation 
 
The establishment of homogenous cell populations is of importance for a variety of 
purposes. Lines of ES as well as iPS cells that contain a mixture of pluripotent and pre-
differentiated cells might be less suited to perform in vitro differentiations to study 
aspects of differentiation or to form specific derivatives for detailed analysis. This is 
particularly true for human ES cell cultures that usually contain a subset of less 
pluripotent and pre-differentiated cells (Amit et al. 2000; Eiges et al. 2001). 
Reprogramming of somatic cells to pluripotency leads to generation of heterogeneous 
mix of iPS cells which have achieved varying levels of pluripotency. It is therefore 
highly desired to generate homogeneous populations of iPS cells since heterogeneous 
cultures will potentiate obscure findings.  
It was demonstrated that an UTF1 promoter-driven Neomycin-gene is a sensitive 
selection marker in human ES cells to enrich pluripotent cells and to eliminate pre-
differentiated cell types from the culture (Tan et al. 2007). In addition, UTF1 is down-
regulated faster than other pluripotency markers upon differentiation of ES cells (Tan et 
al. 2007). For this reason, we hypothesized that UTF1-Neo selection might help to 
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select for high-quality pluripotent cells that exists within heterogenous TiB7-4 iPS cell 
population.  
We established three sub clones of TiB7-4 after transfection of TiB7-4 with UTF1-Neo 
and selection for two weeks with Neomycin. These clones displayed homogenous 
morphologies without signs of spontaneous differentiation for up to 40 passages 
indicating the presence of high-quality pluripotent cells within the TiB7-4 population. 
Flow cytometric analysis for SSEA1 clearly indicated a substantial improvement of the 
culture after selection for UTF1-Neo with 97% to 98% SSEA1 positive cells in all three 
clones. With respect to the fact that the residual 2% of cells might represent feeder 
fibroblasts one can assume that all iPS cells in this culture are positive for SSEA1. 
Remarkably, this effect could be observed without continuous selection. We speculate 
that the complete removal of pre-differentiated cells leads to a terminal stabilization of 
the UTF1-Neo selected clones. While pre-differentiated cells might influence the cell 
signalling and induce differentiation of neighbouring cells, populations that are depleted 
of pre-differentiated cells might exhibit a more stable pluripotent phenotype. The 
described selection, however, does not influence the ability of the UTF1-Neo selected 
cells to form EBs and to undergo differentiation within these spheroids giving rise to all 
three germ layers, which was also demonstrated earlier for UTF1-selected human ES 
cell lines.  
Control transfections with a Neomycin resistance under the control of the ubiquitous 
active SV40 early promoter led to the identification of cell clones that partially 
resembled a perfect ES cell-like elliptical colony shape with sharp borders. Closer 
analysis of six control clones resulted in the surprising finding that four out of these six 
clones spontaneously underwent differentiation after some passages what was first 
obvious by disturbed colony formation and down regulation of UTF1 and Nanog and up 
regulation of Oct4, and later by a loss of SSEA1 surface antigen. The remaining two 
clones, however, seemed to be stably pluripotent at least during the observation period 
of 12 passages. The reason for the instability is not clear and it might be speculated that 
it results from incomplete reprogramming or reactivation of the reprogramming virus.  
The discussed findings underline that a UTF1-based selection is more efficient in 
deriving fully reprogrammed cells and a stable pluripotent phenotype. Fully 
reprogrammed cells within an iPS colony can be effectively isolated by selection with 
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UTF1-Neo. However, a selection based on the colony morphology may also give rise to 
stable pluripotent sub clones but requires the culture of the cells over a prolonged period 
of time and the surveillance of the pluripotency markers Nanog and UTF1 by real time 
PCR. Further studies will address the duration of UTF1-Neo based selection needed to 
achieve homogenous pluripotent cells. It can be speculated that shorter selection 
intervals than the two weeks employed here might be sufficient to obtain UTF1 selected 
cultures, perhaps even without stable integration of the selection cassette into the iPS 
genome. The application of methods like transient nucleofection, adenoviral or 
baculoviral transduction to transiently introduce the UTF1-Neo vector into the iPS cell 
population might ultimately combine the benefit of selection with the advantage of 
transient transgene delivery.  
Alternative selection approaches utilized reactivation of the endogenous Nanog or Oct4 
locus to indicate induction of pluripotency. While selection of reprogrammed 
fibroblasts, in which neomycin resistance is driven by endogenous Nanog promoter, 
was reported to result in a higher number of colonies compared to Oct4-Neo selection, 
only 11.5% of the resistant colonies with ES-like appearance revealed pluripotency and 
22% of the Oct4-selected clones with ES-like appearance were found to be pluripotent 
(Wernig et al. 2007). Based on these report it can be assumed that the Nanog-driven 
selection is less suitable to generate high quality iPS cells. A detailed characterization of 
a Oct4-Neo selected as well as a Nanog-Neo selected iPS cell line indicated a delay in 
the in vitro differentiation of both cell lines when compared to the ES lines R1 and D3 
(Pfannkuche et al. 2009).  
5.3 Functional cardiomyocytes derived from iPS cells  
The importance of derivation of homogenous cell population is not limited to 
pluripotent state but also to the mature cells types like CMs. Purification of CMs from 
the differentiating cultures of pluripotent stem cells is especially important to study 
cardiac specific developmental, functional and transcriptional process. 
Genetic enrichment strategies using drug selection markers expressed under the control 
of cardiac specific promoters have been successfully applied for purification of murine 
and human ES-CMs (Kolossov et al. 2006; Anderson et al. 2007; Doss et al. 2007; Xu 
et al. 2008; Kita-Matsuo et al. 2009). These approaches permitted genetic and 
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physiological studies of pure CMs without the potentially confounding influence of 
other cells present in differentiating EBs. These cell lines represent excellent tools for 
identification of new agents that direct differentiation of pluripotent stem cells to CMs 
and for optimization of scalable production of pure CMs in controlled bioreactors. In 
addition, the ability to produce high numbers of well characterized CMs that will 
facilitate progress in basic research leading to cell based therapy, disease modeling, 
drug screening and drug discovery.  
The transgenic αPIG-iPS cell line generated in this study is the first that enables 
selection of contractile iPS-CMs free of other cell lineages and allows for detailed 
comparison of their functional and molecular properties with their ES cell-derived 
counterparts. A FACS-based isolation of cardiac progenitors from murine iPS cells 
expressing GFP under the control of Nkx2.5 promoter has been reported (van Laake et 
al. 2010; van Laake et al. 2010). In this study, the genome-wide transcriptional profiles 
of undifferentiated iPS and ES cells as well as isolated cardiac progenitors have been 
analyzed and shown that the gene expression profiles of iPS and ES cell-derived cardiac 
progenitors were even more similar than those seen between corresponding 
undifferentiated iPS and ES cell lines. In culture, these progenitors could be induced to 
form beating CMs and, upon transplantation, the progenitors engrafted into the infarcted 
mouse myocardium without formation of teratomas. Our analyses with iPS-CMs are in 
agreement with these findings, although we are unable to conclude, due to comparison 
of only single iPS and ES cell lines, whether the gene expression variance between iPS-
CMs and ES-CMs is significantly smaller than that found between undifferentiated iPS 
and ES cells. Studies with additional transgenic cell lines will be necessary to provide 
clear answer to this question.  
Our data show that the difference in transcriptome between iPS-CMs and ES-CMs is 
not significantly greater than the difference shown here by us and previously by others 
to exist between undifferentiated iPS and ES cells (Chin et al. 2009). This small 
difference in gene expression profile does not seem to affect the functional properties of 
iPS-CMs, which were undistinguishable from those of ES-CMs. Analysis of 
spontaneous APs of single cells revealed that the iPS-CMs and ES-CMs were similar 
with respect to their maturity. The difference observed in AP-frequencies of intact drug-
selected cardiac clusters derived from iPS and ES cells may not necessarily be 
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attributed to the normal biological variability of the lines used in this study. In our 
previous functional assessment of micro dissected beating areas derived from two 
different iPS cell lines (lines N10 and O9) we also observed significantly slower beating 
frequencies in iPS-CMs compared to ES-CMs (Pfannkuche et al. 2009). These 
differences may have been caused by different proportions of different cardiac muscle 
cell types (ventricular, atrial, pacemaker) in multicellular iPS cell- and ES cell-derived 
beating areas. It is also possible that small difference in purity of iPS and ES cardiac 
clusters in the present study may have affected the AP-frequency of a cardiac tissue. 
Indeed, we have observed no contaminating pluripotent cells in iPS-cardiac clusters but 
found that rare ES cells (19 ES cells per 1x106 ES-CMs) still contaminate ES-cardiac 
clusters after seven days of puromycin selection and occasionally lead to teratoma 
formation in animals injected with these cells. Here also, additional transgenic iPS and 
ES cell clones must be compared to accurately assess the differences between these cell 
types and implications for their functional performance in 3D tissue in vivo and long-
term safety. 
Although free of contaminating undifferentiated iPS cells, iPS-CMs potentially carry 
the risk of tumor formation due to residual expression of virally encoded Oct4 
transcripts. It is unclear whether this incomplete silencing of Oct4 may have caused 
some of the differences in gene expression profiles detected between ES- and iPS-CMs. 
However, the comparable efficiencies of cardiac differentiation of iPS and ES cells and 
their similar functional properties demonstrate that the incomplete silencing of 
transgenes did not interfere with these processes. This is in accordance with the finding 
that ectopic Oct4 expression in the heart of adult mice did not lead to any detectable 
alterations of cell phenotype (Hochedlinger et al. 2005). However, iPS cells generated 
by non-integrating reprogramming methods were shown to be transcriptionally more 
similar to ES cells than those generated with stably integrating viral vectors (Wang et 
al. 2010). Therefore, it can not be excluded that minor transcriptional differences 
observed in our study were due to use of virally reprogrammed iPS cells.  
Our study demonstrates the generation of highly purified populations of iPS-CMs using 
drug selection in a mass culture system and confirms that the cardiac derivatives of iPS 
and ES cells are highly similar in their structural, morphological and 
electrophysiological properties as well as global gene expression patterns. The ability to 
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produce homogenous population of CMs will facilitate further comparative analyses of 
iPS- and ES-CMs, assessment of the therapeutic potency of pure iPS-CMs in animal 
disease models, optimization of cardiac differentiation protocols and search for 
cardioactive drugs and toxic substances. 
In conclusion, functional, structural and transcriptional assessment of the cardiac cells 
obtained as a result of invitro differentiation of ES cells and reprogrammed cells 
suggests that switching of cell fate from a differentiated state to pluripotent state and 
then again into cells of cardiac lineage does not have a major influence on the functional 
characteristics of the cardiac cells. This work proves reprogrammed cells as a renewable 
source of cardiac cell thus demonstrating potential of the reprogramming technology 
which holds great promise for scientific research and medicine in the years to come. 
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